HRP20030466A2 - Urea substituted imidazoquinoline ethers - Google Patents
Urea substituted imidazoquinoline ethers Download PDFInfo
- Publication number
- HRP20030466A2 HRP20030466A2 HR20030466A HRP20030466A HRP20030466A2 HR P20030466 A2 HRP20030466 A2 HR P20030466A2 HR 20030466 A HR20030466 A HR 20030466A HR P20030466 A HRP20030466 A HR P20030466A HR P20030466 A2 HRP20030466 A2 HR P20030466A2
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- alkenyl
- aryl
- compound
- 10alkyl
- Prior art date
Links
- -1 imidazoquinoline ethers Chemical class 0.000 title claims description 28
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 title description 14
- 239000004202 carbamide Substances 0.000 title description 6
- 229940124669 imidazoquinoline Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 119
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 40
- 102000004127 Cytokines Human genes 0.000 claims description 28
- 108090000695 Cytokines Proteins 0.000 claims description 28
- 241001465754 Metazoa Species 0.000 claims description 28
- 125000000217 alkyl group Chemical group 0.000 claims description 27
- 125000003342 alkenyl group Chemical group 0.000 claims description 26
- 229910052739 hydrogen Inorganic materials 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 23
- 229910052736 halogen Inorganic materials 0.000 claims description 17
- 230000015572 biosynthetic process Effects 0.000 claims description 16
- 125000001424 substituent group Chemical group 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 13
- 239000001257 hydrogen Substances 0.000 claims description 13
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 12
- 150000002367 halogens Chemical class 0.000 claims description 11
- 125000005842 heteroatom Chemical group 0.000 claims description 10
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 10
- 102000006992 Interferon-alpha Human genes 0.000 claims description 9
- 108010047761 Interferon-alpha Proteins 0.000 claims description 9
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims description 8
- 208000036142 Viral infection Diseases 0.000 claims description 7
- 230000009385 viral infection Effects 0.000 claims description 7
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical group CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims description 6
- 230000001613 neoplastic effect Effects 0.000 claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 4
- WSACGZUDEZAEBA-UHFFFAOYSA-N 1-[2-[2-[4-amino-2-(2-methoxyethyl)-6,7,8,9-tetrahydroimidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]-3-phenylurea Chemical compound COCCC1=NC2=C(N)N=C3CCCCC3=C2N1CCOCCNC(=O)NC1=CC=CC=C1 WSACGZUDEZAEBA-UHFFFAOYSA-N 0.000 claims description 3
- ZLZKHTRPQRBTHF-UHFFFAOYSA-N 1-[2-[2-[4-amino-2-(2-methoxyethyl)imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]-3-phenylurea Chemical compound COCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCOCCNC(=O)NC1=CC=CC=C1 ZLZKHTRPQRBTHF-UHFFFAOYSA-N 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- JLEIUQMCUDLUEJ-UHFFFAOYSA-N n-[2-[2-[4-amino-2-(2-methoxyethyl)imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]-n-methylmorpholine-4-carboxamide Chemical compound COCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCOCCN(C)C(=O)N1CCOCC1 JLEIUQMCUDLUEJ-UHFFFAOYSA-N 0.000 claims description 3
- LUBJCRLGQSPQNN-UHFFFAOYSA-N Z-phenylurea Natural products NC(=O)NC1=CC=CC=C1 LUBJCRLGQSPQNN-UHFFFAOYSA-N 0.000 claims description 2
- FPSFQWQURORCDK-UHFFFAOYSA-N n-[2-[2-[4-amino-2-(2-methoxyethyl)imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]morpholine-4-carboxamide Chemical compound COCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCOCCNC(=O)N1CCOCC1 FPSFQWQURORCDK-UHFFFAOYSA-N 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 107
- 239000000243 solution Substances 0.000 description 94
- 238000006243 chemical reaction Methods 0.000 description 85
- 239000011541 reaction mixture Substances 0.000 description 44
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 37
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 36
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
- 238000003756 stirring Methods 0.000 description 30
- 239000007787 solid Substances 0.000 description 28
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 26
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 26
- 229910052938 sodium sulfate Inorganic materials 0.000 description 26
- 235000011152 sodium sulphate Nutrition 0.000 description 26
- 239000003921 oil Substances 0.000 description 25
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 24
- 239000007832 Na2SO4 Substances 0.000 description 23
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 20
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 239000000203 mixture Substances 0.000 description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 17
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 16
- 229910052757 nitrogen Inorganic materials 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 15
- 235000011114 ammonium hydroxide Nutrition 0.000 description 15
- 238000011282 treatment Methods 0.000 description 15
- 238000005160 1H NMR spectroscopy Methods 0.000 description 14
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 14
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
- 229910052799 carbon Inorganic materials 0.000 description 12
- 239000012299 nitrogen atmosphere Substances 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 11
- 230000028993 immune response Effects 0.000 description 11
- 230000006698 induction Effects 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 10
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 10
- 239000012267 brine Substances 0.000 description 10
- 239000006260 foam Substances 0.000 description 10
- 239000012044 organic layer Substances 0.000 description 10
- 238000010992 reflux Methods 0.000 description 10
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 9
- ITIRVXDSMXFTPW-UHFFFAOYSA-N 1H-imidazo[4,5-c]quinoline Chemical group C1=CC=CC2=C(NC=N3)C3=CN=C21 ITIRVXDSMXFTPW-UHFFFAOYSA-N 0.000 description 8
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 125000003118 aryl group Chemical group 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 239000012266 salt solution Substances 0.000 description 8
- 230000003612 virological effect Effects 0.000 description 8
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 7
- HQBUPOAKJGJGCD-UHFFFAOYSA-N 3h-imidazo[4,5-c]quinolin-4-amine Chemical class NC1=NC2=CC=CC=C2C2=C1N=CN2 HQBUPOAKJGJGCD-UHFFFAOYSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000012458 free base Substances 0.000 description 7
- 125000001072 heteroaryl group Chemical group 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 238000010189 synthetic method Methods 0.000 description 7
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 6
- 150000001414 amino alcohols Chemical class 0.000 description 6
- 239000012298 atmosphere Substances 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 125000004122 cyclic group Chemical group 0.000 description 6
- 125000000623 heterocyclic group Chemical group 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 239000012948 isocyanate Substances 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000012312 sodium hydride Substances 0.000 description 6
- 229910000104 sodium hydride Inorganic materials 0.000 description 6
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 108010050904 Interferons Proteins 0.000 description 5
- 102000014150 Interferons Human genes 0.000 description 5
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 238000007429 general method Methods 0.000 description 5
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 5
- 229940079322 interferon Drugs 0.000 description 5
- 150000002513 isocyanates Chemical class 0.000 description 5
- 238000011894 semi-preparative HPLC Methods 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- 235000017550 sodium carbonate Nutrition 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 239000006188 syrup Substances 0.000 description 5
- 235000020357 syrup Nutrition 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- JEFFGDGZXNZKEB-UHFFFAOYSA-N 1-[2-(2-aminoethoxy)ethyl]-2-(2-methoxyethyl)imidazo[4,5-c]quinolin-4-amine Chemical compound C1=CC=CC2=C(N(C(CCOC)=N3)CCOCCN)C3=C(N)N=C21 JEFFGDGZXNZKEB-UHFFFAOYSA-N 0.000 description 4
- RACDQIJYHQMBMG-UHFFFAOYSA-N 2-(2-methoxyethyl)-1-[2-[2-(methylamino)ethoxy]ethyl]imidazo[4,5-c]quinolin-4-amine Chemical compound C1=CC=CC2=C3N(CCOCCNC)C(CCOC)=NC3=C(N)N=C21 RACDQIJYHQMBMG-UHFFFAOYSA-N 0.000 description 4
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 4
- ZRFUZDDJSQVQBY-UHFFFAOYSA-N 4-chloro-3-nitroquinoline Chemical compound C1=CC=CC2=C(Cl)C([N+](=O)[O-])=CN=C21 ZRFUZDDJSQVQBY-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 229910019020 PtO2 Inorganic materials 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 150000004820 halides Chemical class 0.000 description 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- JAQSDPOQNDCKFI-UHFFFAOYSA-N tert-butyl n-[2-[2-[(3-aminoquinolin-4-yl)amino]ethoxy]ethyl]carbamate Chemical compound C1=CC=C2C(NCCOCCNC(=O)OC(C)(C)C)=C(N)C=NC2=C1 JAQSDPOQNDCKFI-UHFFFAOYSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 4
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 3
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 3
- 150000001204 N-oxides Chemical class 0.000 description 3
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000000908 ammonium hydroxide Substances 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 229910052681 coesite Inorganic materials 0.000 description 3
- 229910052906 cristobalite Inorganic materials 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 125000001188 haloalkyl group Chemical group 0.000 description 3
- 239000002955 immunomodulating agent Substances 0.000 description 3
- 229940121354 immunomodulator Drugs 0.000 description 3
- 239000012442 inert solvent Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
- 239000003607 modifier Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000012047 saturated solution Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 229910052682 stishovite Inorganic materials 0.000 description 3
- OIGBULWLGULHNH-UHFFFAOYSA-N tert-butyl n-[2-(2-azidoethoxy)ethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCOCCN=[N+]=[N-] OIGBULWLGULHNH-UHFFFAOYSA-N 0.000 description 3
- 229910052905 tridymite Inorganic materials 0.000 description 3
- DIKAUBKIDNXNNW-UHFFFAOYSA-N 1,1,1-triethoxypentane Chemical group CCCCC(OCC)(OCC)OCC DIKAUBKIDNXNNW-UHFFFAOYSA-N 0.000 description 2
- BHQIDZVUPSXYID-UHFFFAOYSA-N 1-[1-(2-piperidin-4-ylethoxy)butan-2-yl]imidazo[4,5-c]quinolin-4-amine Chemical compound C1=NC2=C(N)N=C3C=CC=CC3=C2N1C(CC)COCCC1CCNCC1 BHQIDZVUPSXYID-UHFFFAOYSA-N 0.000 description 2
- HAOBQBANULQALC-UHFFFAOYSA-N 1-[2-(2-aminoethoxy)ethyl]-2-(2-methoxyethyl)-6,7,8,9-tetrahydroimidazo[4,5-c]quinolin-4-amine Chemical compound C1CCCC2=C(N(C(CCOC)=N3)CCOCCN)C3=C(N)N=C21 HAOBQBANULQALC-UHFFFAOYSA-N 0.000 description 2
- QVDXKGWUSNDBKF-UHFFFAOYSA-N 1-[2-(2-aminoethoxy)ethyl]-2-butylimidazo[4,5-c]quinolin-4-amine Chemical compound C1=CC=CC2=C(N(C(CCCC)=N3)CCOCCN)C3=C(N)N=C21 QVDXKGWUSNDBKF-UHFFFAOYSA-N 0.000 description 2
- VCNWVTNERDDKEA-UHFFFAOYSA-N 1-imidazo[4,5-c]quinolin-1-yloxyimidazo[4,5-c]quinoline Chemical compound C1=NC2=CN=C3C=CC=CC3=C2N1ON1C2=C3C=CC=CC3=NC=C2N=C1 VCNWVTNERDDKEA-UHFFFAOYSA-N 0.000 description 2
- GCGNWZMOENODOJ-UHFFFAOYSA-N 2,3,3a,4-tetrahydro-1h-imidazo[4,5-h]quinoline Chemical class C1C=C2C=CC=NC2=C2C1NCN2 GCGNWZMOENODOJ-UHFFFAOYSA-N 0.000 description 2
- DEBJYYZYTFLAEB-UHFFFAOYSA-N 2-(2-methoxyethyl)-1-[2-[2-(methylamino)ethoxy]ethyl]-6,7,8,9-tetrahydroimidazo[4,5-c]quinolin-4-amine Chemical compound C1CCCC2=C3N(CCOCCNC)C(CCOC)=NC3=C(N)N=C21 DEBJYYZYTFLAEB-UHFFFAOYSA-N 0.000 description 2
- ZDLSZXWATPDDQS-UHFFFAOYSA-N 2-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethoxy]ethyl methanesulfonate Chemical compound CC(C)(C)OC(=O)NCCOCCOS(C)(=O)=O ZDLSZXWATPDDQS-UHFFFAOYSA-N 0.000 description 2
- JSMDUOFOPDSKIQ-UHFFFAOYSA-N 3-methoxypropanoyl chloride Chemical compound COCCC(Cl)=O JSMDUOFOPDSKIQ-UHFFFAOYSA-N 0.000 description 2
- SKPRPEJLFKCOAB-UHFFFAOYSA-N 3-nitroquinolin-4-amine Chemical compound C1=CC=C2C(N)=C([N+]([O-])=O)C=NC2=C1 SKPRPEJLFKCOAB-UHFFFAOYSA-N 0.000 description 2
- ZXVRNZRQQRBDLX-UHFFFAOYSA-N 3-nitroquinoline Chemical compound C1=CC=CC2=CC([N+](=O)[O-])=CN=C21 ZXVRNZRQQRBDLX-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- RRBRQNALHKQCAI-UHFFFAOYSA-N Acetildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1C(=O)CN1CCN(CC)CC1 RRBRQNALHKQCAI-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 150000004703 alkoxides Chemical class 0.000 description 2
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000001099 ammonium carbonate Substances 0.000 description 2
- 229940111121 antirheumatic drug quinolines Drugs 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 125000004692 haloalkylcarbonyl group Chemical group 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 125000005367 heteroarylalkylthio group Chemical group 0.000 description 2
- 238000009904 heterogeneous catalytic hydrogenation reaction Methods 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 150000002431 hydrogen Chemical group 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- XMWFMEYDRNJSOO-UHFFFAOYSA-N morpholine-4-carbonyl chloride Chemical compound ClC(=O)N1CCOCC1 XMWFMEYDRNJSOO-UHFFFAOYSA-N 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- UTOMICFLROGMAE-UHFFFAOYSA-N quinoline-3,4-diamine Chemical compound C1=CC=CC2=C(N)C(N)=CN=C21 UTOMICFLROGMAE-UHFFFAOYSA-N 0.000 description 2
- 150000003248 quinolines Chemical class 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 201000010153 skin papilloma Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- IONMNRHLZXJDJX-UHFFFAOYSA-N tert-butyl 4-(2-iodoethyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CCI)CC1 IONMNRHLZXJDJX-UHFFFAOYSA-N 0.000 description 2
- NAOJUCBTEYZBEI-UHFFFAOYSA-N tert-butyl n-[2-(2-aminoethoxy)ethyl]-n-methylcarbamate Chemical compound CC(C)(C)OC(=O)N(C)CCOCCN NAOJUCBTEYZBEI-UHFFFAOYSA-N 0.000 description 2
- VULKFBHOEKTQSF-UHFFFAOYSA-N tert-butyl n-[2-(2-aminoethoxy)ethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCOCCN VULKFBHOEKTQSF-UHFFFAOYSA-N 0.000 description 2
- ZHNOLNQLCBSIPZ-UHFFFAOYSA-N tert-butyl n-[2-(2-azidoethoxy)ethyl]-n-methylcarbamate Chemical compound CC(C)(C)OC(=O)N(C)CCOCCN=[N+]=[N-] ZHNOLNQLCBSIPZ-UHFFFAOYSA-N 0.000 description 2
- KSFVNEXYCULLEJ-UHFFFAOYSA-N tert-butyl n-[2-(2-hydroxyethoxy)ethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCOCCO KSFVNEXYCULLEJ-UHFFFAOYSA-N 0.000 description 2
- AHNGFJDMGMBKHS-UHFFFAOYSA-N tert-butyl n-[2-[2-(2-butyl-5-oxidoimidazo[4,5-c]quinolin-5-ium-1-yl)ethoxy]ethyl]carbamate Chemical compound C1=CC=CC2=C(N(C(CCCC)=N3)CCOCCNC(=O)OC(C)(C)C)C3=C[N+]([O-])=C21 AHNGFJDMGMBKHS-UHFFFAOYSA-N 0.000 description 2
- ZZRCLCGZNLGWRH-UHFFFAOYSA-N tert-butyl n-[2-[2-(2-butylimidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]carbamate Chemical compound C1=CC=CC2=C(N(C(CCCC)=N3)CCOCCNC(=O)OC(C)(C)C)C3=CN=C21 ZZRCLCGZNLGWRH-UHFFFAOYSA-N 0.000 description 2
- AWCIFUCKWHQQEY-UHFFFAOYSA-N tert-butyl n-[2-[2-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]carbamate Chemical compound C1=CC=CC2=C(N(C(CCCC)=N3)CCOCCNC(=O)OC(C)(C)C)C3=C(N)N=C21 AWCIFUCKWHQQEY-UHFFFAOYSA-N 0.000 description 2
- DCLPVQDYSMOEBS-UHFFFAOYSA-N tert-butyl n-[2-[2-(4-aminoimidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]carbamate Chemical compound C1=CC=CC2=C3N(CCOCCNC(=O)OC(C)(C)C)C=NC3=C(N)N=C21 DCLPVQDYSMOEBS-UHFFFAOYSA-N 0.000 description 2
- WEAYHTMSBKQEFF-UHFFFAOYSA-N tert-butyl n-[2-[2-(5-oxidoimidazo[4,5-c]quinolin-5-ium-1-yl)ethoxy]ethyl]carbamate Chemical compound C1=CC=CC2=C3N(CCOCCNC(=O)OC(C)(C)C)C=NC3=C[N+]([O-])=C21 WEAYHTMSBKQEFF-UHFFFAOYSA-N 0.000 description 2
- AYXPXAHRVRCZFV-UHFFFAOYSA-N tert-butyl n-[2-[2-[(3-nitroquinolin-4-yl)amino]ethoxy]ethyl]carbamate Chemical compound C1=CC=C2C(NCCOCCNC(=O)OC(C)(C)C)=C([N+]([O-])=O)C=NC2=C1 AYXPXAHRVRCZFV-UHFFFAOYSA-N 0.000 description 2
- SESRIODKVPJVFK-UHFFFAOYSA-N tert-butyl n-[2-[2-[2-(2-methoxyethyl)-5-oxidoimidazo[4,5-c]quinolin-5-ium-1-yl]ethoxy]ethyl]-n-methylcarbamate Chemical compound C1=CC=CC2=C(N(C(CCOC)=N3)CCOCCN(C)C(=O)OC(C)(C)C)C3=C[N+]([O-])=C21 SESRIODKVPJVFK-UHFFFAOYSA-N 0.000 description 2
- QJZOFJMBDNNMQK-UHFFFAOYSA-N tert-butyl n-[2-[2-[2-(2-methoxyethyl)imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]carbamate Chemical compound C1=CC=CC2=C(N(C(CCOC)=N3)CCOCCNC(=O)OC(C)(C)C)C3=CN=C21 QJZOFJMBDNNMQK-UHFFFAOYSA-N 0.000 description 2
- NMJVMWWEXUTEGC-UHFFFAOYSA-N tert-butyl n-[2-[2-[4-amino-2-(2-methoxyethyl)imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]-n-methylcarbamate Chemical compound C1=CC=CC2=C(N(C(CCOC)=N3)CCOCCN(C)C(=O)OC(C)(C)C)C3=C(N)N=C21 NMJVMWWEXUTEGC-UHFFFAOYSA-N 0.000 description 2
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 2
- YWWDBCBWQNCYNR-UHFFFAOYSA-N trimethylphosphine Chemical compound CP(C)C YWWDBCBWQNCYNR-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- YJKZDGOMTKOYQK-UHFFFAOYSA-N 1-(2-piperidin-4-ylethyl)imidazo[4,5-c]quinoline Chemical compound C1=NC2=CN=C3C=CC=CC3=C2N1CCC1CCNCC1 YJKZDGOMTKOYQK-UHFFFAOYSA-N 0.000 description 1
- HDDNSPWJCZZICL-UHFFFAOYSA-N 1-(6-methoxyquinolin-8-yl)-2-methylimidazo[4,5-c]quinoline Chemical compound N1=CC=CC2=CC(OC)=CC(N3C4=C5C=CC=CC5=NC=C4N=C3C)=C21 HDDNSPWJCZZICL-UHFFFAOYSA-N 0.000 description 1
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical group CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
- VEFOQIDEIFMNAX-UHFFFAOYSA-N 1-[2-(2-aminoethoxy)ethyl]imidazo[4,5-c]quinolin-4-amine Chemical compound C1=CC=CC2=C3N(CCOCCN)C=NC3=C(N)N=C21 VEFOQIDEIFMNAX-UHFFFAOYSA-N 0.000 description 1
- QUJSHZMLFMCARS-UHFFFAOYSA-N 1-hydroxyimidazo[4,5-c]quinoline Chemical compound C1=CC=CC2=C3N(O)C=NC3=CN=C21 QUJSHZMLFMCARS-UHFFFAOYSA-N 0.000 description 1
- UHUHBFMZVCOEOV-UHFFFAOYSA-N 1h-imidazo[4,5-c]pyridin-4-amine Chemical class NC1=NC=CC2=C1N=CN2 UHUHBFMZVCOEOV-UHFFFAOYSA-N 0.000 description 1
- HLFGXPKPTDQYBN-UHFFFAOYSA-N 2,3,3a,4-tetrahydro-1h-imidazo[4,5-c]quinolin-4-amine Chemical class NC1N=C2C=CC=CC2=C2C1NCN2 HLFGXPKPTDQYBN-UHFFFAOYSA-N 0.000 description 1
- SKOBGLOJJGVOSV-UHFFFAOYSA-N 2-imidazo[4,5-c]quinolin-1-ylbutan-1-ol Chemical compound C1=CC=CC2=C3N(C(CO)CC)C=NC3=CN=C21 SKOBGLOJJGVOSV-UHFFFAOYSA-N 0.000 description 1
- LDSQQXKSEFZAPE-UHFFFAOYSA-N 2-piperidin-4-ylethanol Chemical compound OCCC1CCNCC1 LDSQQXKSEFZAPE-UHFFFAOYSA-N 0.000 description 1
- SVNCRRZKBNSMIV-UHFFFAOYSA-N 3-Aminoquinoline Chemical compound C1=CC=CC2=CC(N)=CN=C21 SVNCRRZKBNSMIV-UHFFFAOYSA-N 0.000 description 1
- KGEGVJJFFQXJTG-UHFFFAOYSA-N 3h-imidazo[4,5-c][1,8]naphthyridin-4-amine Chemical class NC1=NC2=NC=CC=C2C2=C1N=CN2 KGEGVJJFFQXJTG-UHFFFAOYSA-N 0.000 description 1
- UQUPJGMZYBOGDJ-UHFFFAOYSA-N 3h-imidazo[4,5-c]quinoline-4-carboxamide Chemical class NC(=O)C1=NC2=CC=CC=C2C2=C1N=CN2 UQUPJGMZYBOGDJ-UHFFFAOYSA-N 0.000 description 1
- RHKWIGHJGOEUSM-UHFFFAOYSA-N 3h-imidazo[4,5-h]quinoline Chemical class C1=CN=C2C(N=CN3)=C3C=CC2=C1 RHKWIGHJGOEUSM-UHFFFAOYSA-N 0.000 description 1
- YHQPYMQQMBVULM-UHFFFAOYSA-N 6,7,8,9-tetrahydro-3h-imidazo[4,5-c]quinolin-4-amine Chemical compound C1CCCC2=C1N=C(N)C1=C2NC=N1 YHQPYMQQMBVULM-UHFFFAOYSA-N 0.000 description 1
- CZTQJCYFLGFVLG-UHFFFAOYSA-N 6,7,8,9-tetrahydro-3h-imidazo[4,5-c]quinoline Chemical compound C1CCCC2=C1N=CC1=C2NC=N1 CZTQJCYFLGFVLG-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- 206010059313 Anogenital warts Diseases 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000013165 Bowen disease Diseases 0.000 description 1
- 208000019337 Bowen disease of the skin Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010008263 Cervical dysplasia Diseases 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 208000000907 Condylomata Acuminata Diseases 0.000 description 1
- 208000006081 Cryptococcal meningitis Diseases 0.000 description 1
- 208000008953 Cryptosporidiosis Diseases 0.000 description 1
- 206010011502 Cryptosporidiosis infection Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241000250507 Gigaspora candida Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 201000002563 Histoplasmosis Diseases 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 206010027209 Meningitis cryptococcal Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000186367 Mycobacterium avium Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000233872 Pneumocystis carinii Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- QTENRWWVYAAPBI-YZTFXSNBSA-N Streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O QTENRWWVYAAPBI-YZTFXSNBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 208000005485 Thrombocytosis Diseases 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- CBIRSOMMPYLMJY-UHFFFAOYSA-N [N+]1(=CNC=2C=CC=3C=CC=NC=3C=21)[O-] Chemical class [N+]1(=CNC=2C=CC=3C=CC=NC=3C=21)[O-] CBIRSOMMPYLMJY-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000005236 alkanoylamino group Chemical group 0.000 description 1
- 125000005090 alkenylcarbonyl group Chemical group 0.000 description 1
- 125000005091 alkenylcarbonylamino group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000004949 alkyl amino carbonyl amino group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 description 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000004691 alkyl thio carbonyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 1
- 201000004201 anogenital venereal wart Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000005239 aroylamino group Chemical group 0.000 description 1
- 125000005333 aroyloxy group Chemical group 0.000 description 1
- 125000005126 aryl alkyl carbonyl amino group Chemical group 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000004659 aryl alkyl thio group Chemical group 0.000 description 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000004305 biphenyl Chemical group 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 206010006060 bowenoid papulosis Diseases 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 208000007951 cervical intraepithelial neoplasia Diseases 0.000 description 1
- WUUCVVFSWNXYRD-UHFFFAOYSA-N chembl19191 Chemical class C1=CC=C2C3=NC=NC3=C(N)NC2=C1 WUUCVVFSWNXYRD-UHFFFAOYSA-N 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- ZFTFAPZRGNKQPU-UHFFFAOYSA-N dicarbonic acid Chemical compound OC(=O)OC(O)=O ZFTFAPZRGNKQPU-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 125000004995 haloalkylthio group Chemical group 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 description 1
- 125000005224 heteroarylcarbonylamino group Chemical group 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- 125000005226 heteroaryloxycarbonyl group Chemical group 0.000 description 1
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 description 1
- 125000005419 heteroarylsulfonylamino group Chemical group 0.000 description 1
- 125000005368 heteroarylthio group Chemical group 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- NSHFLKZNBPJNPA-UHFFFAOYSA-N imidazo[4,5-c]quinolin-2-one Chemical class C1=CC=C2C3=NC(=O)N=C3C=NC2=C1 NSHFLKZNBPJNPA-UHFFFAOYSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 150000005232 imidazopyridines Chemical class 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 208000020082 intraepithelial neoplasia Diseases 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- NONOKGVFTBWRLD-UHFFFAOYSA-N isocyanatosulfanylimino(oxo)methane Chemical compound O=C=NSN=C=O NONOKGVFTBWRLD-UHFFFAOYSA-N 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 208000011379 keloid formation Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- ZKWFSTHEYLJLEL-UHFFFAOYSA-N morpholine-4-carboxamide Chemical compound NC(=O)N1CCOCC1 ZKWFSTHEYLJLEL-UHFFFAOYSA-N 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 150000002905 orthoesters Chemical class 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- YFZOUMNUDGGHIW-UHFFFAOYSA-M p-chloromercuribenzoic acid Chemical compound OC(=O)C1=CC=C([Hg]Cl)C=C1 YFZOUMNUDGGHIW-UHFFFAOYSA-M 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- BUXTXUBQAKIQKS-UHFFFAOYSA-N sulfuryl diisocyanate Chemical compound O=C=NS(=O)(=O)N=C=O BUXTXUBQAKIQKS-UHFFFAOYSA-N 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- YBNJZIDYXCGAPX-UHFFFAOYSA-N tert-butyl 4-(2-hydroxyethyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CCO)CC1 YBNJZIDYXCGAPX-UHFFFAOYSA-N 0.000 description 1
- SHESZTDTSWYYIG-UHFFFAOYSA-N tert-butyl 4-[2-[2-(4-aminoimidazo[4,5-c]quinolin-1-yl)butoxy]ethyl]piperidine-1-carboxylate Chemical compound C1=NC2=C(N)N=C3C=CC=CC3=C2N1C(CC)COCCC1CCN(C(=O)OC(C)(C)C)CC1 SHESZTDTSWYYIG-UHFFFAOYSA-N 0.000 description 1
- JNNUIPPNJWSORS-UHFFFAOYSA-N tert-butyl 4-[2-[2-(5-oxidoimidazo[4,5-c]quinolin-5-ium-1-yl)butoxy]ethyl]piperidine-1-carboxylate Chemical compound C1=NC2=C[N+]([O-])=C3C=CC=CC3=C2N1C(CC)COCCC1CCN(C(=O)OC(C)(C)C)CC1 JNNUIPPNJWSORS-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- ZYUZMGFEUHRWSZ-UHFFFAOYSA-N tert-butyl n-[2-(2-imidazo[4,5-c]quinolin-1-ylethoxy)ethyl]carbamate Chemical compound C1=CC=CC2=C3N(CCOCCNC(=O)OC(C)(C)C)C=NC3=CN=C21 ZYUZMGFEUHRWSZ-UHFFFAOYSA-N 0.000 description 1
- UPYNLGBEILFEFA-UHFFFAOYSA-N tert-butyl n-[2-[2-[4-amino-2-(2-methoxyethyl)imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]carbamate Chemical compound C1=CC=CC2=C(N(C(CCOC)=N3)CCOCCNC(=O)OC(C)(C)C)C3=C(N)N=C21 UPYNLGBEILFEFA-UHFFFAOYSA-N 0.000 description 1
- RNIZEKVSBRMXEU-UHFFFAOYSA-N tert-butyl n-methyl-n-[2-[2-[(3-nitroquinolin-4-yl)amino]ethoxy]ethyl]carbamate Chemical compound C1=CC=C2C(NCCOCCN(C)C(=O)OC(C)(C)C)=C([N+]([O-])=O)C=NC2=C1 RNIZEKVSBRMXEU-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000029069 type 2 immune response Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Description
Područje izuma
Ovaj izum se odnosi na imidazopiridinske spojeve koji imaju kao funkcionalne skupine eter i ureu u položaju 1 i na farmaceutske pripravke koji sadrže takve spojeve. Daljnji aspekt ovog izuma odnosi se na korištenje ovih spojeva kao imunomodulatora, za indukciju biosinteze citokina u životinjama, te za tretman bolesti uključujući virusne i neoplastične bolesti.
Dosadašnje spoznaje
U prvim pouzdanim rezultatima na 1H-imidazo[4,5-c]kinolinskom prstenu, Backman et al. J. Org. Chem. 15, 1278-1284 (1950) opisuju sintezu 1-(6-metoksi-8-kinolinil)-2-metil-1H-imidazo[4,5-c]kinolina za moguću uporabu kao antimalarijsko sredstvo. Iza toga je prikazana sinteza raznih supstituiranih 1H-imidazo[4,5-c]kinolina. Primjerice, Jain et al. J. Med. Chem. 11, str. 87-92 (1968), sintetizirali su 1-[2-(4-piperidil)etil]-1H-imidazo-[4,5-c]kinolin kao mogući antikonvuskulant i kardiovaskulant. Takoer su Baranov et al., J. Hetercyclic Chem. 18, 1537-1540 (1981) prikazali neke 2-okso-imidazo[4,5-c]kinoline.
Za neke 1H-imidazo[4,5-c]kinolin-4-amide i njihove 1- i 2- supstituirane derivate je kasnije nađeno da su korisni kao antivirusna sredstva, bronhodilatatori i imunomodulatori. Oni su, inter alia, opisani u U. S Patentima br. 4,689,338: 4,698,348; 4,929,624; 5,037,986; 5,268,376; 5,346,905, te 5,389,640, koji su ovdje ugrađeni citatom.
Time se nastavlja interes prema imazokinolinskom sustavu prstena.
Poznati su neki 1H-imidazo[4,5-c]naftiridin-4-amini, 1H-imidazo[4,5-c]piridin-4-amini, te 1H-imidazo[4,5-c]kinolin-4-amini koji imaju eterski supstituent na položaju 1. Oni su opisani u U.S. Patentima br. 5,268,376; 5,494,916; te WO 99/29693.
Usprkos pokušajima identifikacije spojeva koji su korisni kao modifikatori imunog odgovora, postoji stalna potreba za spojevima koji mogu modulirati imuni odgovor, a indukcijom biosinteze citokina ili drugim mehanizmima.
Sažetak izuma
Mi smo našli novu klasu spojeva koji su korisni u indukciji biosinteze citokina u životinjama. Prema tome, ovaj izum prikazuje imidazo[4,5-c]kinolin-4-amine i tetrahidroimidazo[4,5-c]kinolin-4-amine koji imaju eter i ureu kao supstituent na položaju 1. Spojevi su definirani Formulama (I) i (II) koje su definirane detaljnije infra. Spojevi dijele opću strukturnu formulu:
[image]
(I)
u kojoj X, R1, R2 i R jesu kao što je ovdje definirano za sve klase spojeva formule (I) i (II).
Spojevi Formula (I) i (II) su korisni kao modifikatori imunog odgovora, zahvaljujući sposobnosti da induciraju biosintezu citokina, te da na drugi način moduliraju imuni odgovor, a kada su dani životinjama. Ova sposobnost čini ove spojeve korisnim u tretmanu različitih stanja, primjerice virusnih bolesti i tumora, a na koje djeluju takve promjene imunološkog odgovora.
Izum nadalje prikazuje farmaceutske pripravke koji sadrže spojeve koji modificiraju imuni odgovor, te metode indukcije biosinteze citokina u životinjama, tretman virusnih infekcija u životinjama, i/ili tretman neoplastične bolesti u životinji, a davanjem životinjama spoja Formule (I) i (II).
Nadalje, prikazane su metode sinteze spojeva iz izuma i novih međuprodukata koji se koriste u tim sintezama.
Detaljni opis izuma
Kao što je prije spomenuto, mi smo našli da neki spojevi induciraju biosintezu citokina i modificiraju imuni odgovor u životinjama. Takvi spojevi su predstavljeni donjim Formulama (I) i (II).
Imidazokinolinski spojevi iz izuma koji imaju eter i ureu kao funkcionalne skupine u položaju 1 predstavljeni su formulom (I):
[image]
(I)
u kojoj
X jeste -CHR5, -CHR5-alkil ili -CHR5-alkenil,
R1 je odabran iz skupine koju čine:
-R4-NR8-CR3-NR5-Z-R6-alkil,
-R4-NR8-CR3-NR5-Z-R6-alkenil,
-R4-NR8-CR3-NR5-Z-R6-aril,
-R4-NR8-CR3-NR5-Z-R6-heteraril,
-R4-NR8-CR3-NR5-Z-R6-heterociklil,
-R4-NR8-CR3-NR5R7,
-R4-NR8-CR3-NR9-Z-R6-aril,
-R4-NR8-CR3-NR9-Z-R6-alkenil,
-R4-NR8-CR3-NR9-Z-R6-aril,
-R4-NR8-CR3-NR9-Z-R6-heteraril,
-R4-NR8-CR3-NR9-Z-R6-heterociklil,
R2 je odabran iz sljedeće skupine:
-vodik
-alkil,
-alkenil,
-aril,
-heteroaril,
-heterociklil,
-alkil-Y-alkil,
-alkil-Y-alkenil,
-alkil-Y-aril, te
-alkil ili alkenil supstituiran jednim ili s više supstituenata odabranih iz sljedeće skupine:
-OH,
-halogen
-N(R5)2,
-CO-N(R5)2,
-CO-C1-10alkil,
-CO-O-C1-10alkil,
-N3,
-aril,
-heteroaril,
-heterociklil,
-CO-aril, te
-CO-heteroaril;
svaki R3 jeste =O ili =S,
svaki R4je neovisno alkil ili alkenil koji može biti prekinut s jednom ili više -O- skupina,
svaki R5 jeste neovisno H ili C1-10alkil,
R6 jeste veza, alkil ili alkenil, koji mogu biti prekinuti s jednom ili više -O- skupina,,
R7 jeste H,C1-10alkil koji može biti prekinut heteroatomom ili R7 može biti spojen s R5 i tvoriti prsten,
R8jeste H,C1-10alkil ili arilalil, ili R4 i R8 mogu biti spojeni i tvoriti prsten,
svaki Y neovisno jeste -O- ili -S(O)0-2,
R9jeste C1-10alkil koji može biti spojen s R8 i tvoriti prsten,
Z jeste veza, -CO- ili -SO2-,
n jeste 0 do 4; te
svaki R je neovisno odabran iz sljedeće skupine: C1-10 alkil, C1-10alkoksi, hidroksi, halogen i trifluormetil,
ili odgovarajuća farmaceutski prihvatljiva sol.
Izum također uključuje tetrahidroimidazokinolinske spojeve koji imaju eter i ureu kao supstituent u položaju 1. Takvi tetrahidroimidazokinolinski spojevi predstavljeni su Formulom (II):
[image]
(II)
X jeste -CHR5, -CHR5-alkil ili -CHR5-alkenil,
R1 je odabran iz skupine koju čine:
-R4-NR8-CR3-NR5-Z-R6-alkil,
-R4-NR8-CR3-NR5-Z-R6-alkenil,
-R4-NR8-CR3-NR5-Z-R6-aril,
-R4-NR8-CR3-NR5-Z-R6-heteraril,
-R4-NR8-CR3-NR5-Z-R6-heterociklil,
-R4-NR8-CR3-NR5R7,
-R4-NR8-CR3-NR9-Z-R6-aril,
-R4-NR8-CR3-NR9-Z-R6-alkenil,
-R4-NR8-CR3-NR9-Z-R6-aril,
-R4-NR8-CR3-NR9-Z-R6-heteraril,
-R4-NR8-CR3-NR9-Z-R6-heterociklil,
R2 je odabran iz sljedeće skupine:
-vodik
-alkil,
-alkenil,
-aril,
-heteroaril,
-heterociklil,
-alkil-Y-alkil,
-alkil-Y-alkenil,
-alkil-Y-aril, te
-alkil ili alkenil supstituiran jednim ili s više supstituenata odabranih iz sljedeće skupine:
-OH,
-halogen
-N(R5)2,
-CO-N(R5)2,
-CO-C1-10alkil,
-CO-O-C1-10alkil,
-N3,
-aril,
-heteroaril,
-heterociklil,
-CO-aril, te
-CO-heteroaril;
svaki R3 jeste =O ili =S,
svaki R4je neovisno alkil ili alkenil koji može biti prekinut s jednom ili više -O- skupina,
svaki R5 jeste neovisno H ili C1-10alkil,
R6 jeste veza, alkil ili alkenil, koji mogu biti prekinuti s jednom ili više -O- skupina,,
R7 jeste H,C1-10alkil koji može biti prekinut heteroatomom ili R7 može biti spojen s R5 i tvoriti prsten,
R8jeste H,C1-10alkil ili arilalil, ili R4 i R8 mogu biti spojeni i tvoriti prsten,
svaki Y neovisno jeste -O- ili -S(O)0-2,
R9jeste C1-10alkil koji može biti spojen s R8 i tvoriti prsten,
Z jeste veza, -CO- ili -SO2-,
n jeste 0 do 4; te
svaki R je neovisno odabran iz sljedeće skupine: C1-10 alkil, C1-10alkoksi, hidroksi, halogen i trifluormetil,
ili odgovarajuća farmaceutski prihvatljiva sol.
Priprava spojeva
Spojevi iz izuma se mogu pripraviti prema Reakcijskoj shemi I u kojoj R, R1, R2, R3, R5, R8, X i n jesu kao što su gore definirani, BOC je tert-butoksikarbonil i R11 jeste -Z-R6-alkil, -Z-R6-alkenil, -Z-R6-heteroaril, -Z-R6-heterociklil ili R11 jeste R7 pri čemu R6 i R7 i Z jesu kao što je gore definirano.
U koraku (1) Reakcijske sheme I je amino-skupina aminoalkohola Formule X zaštićena s tert-butoksikarbonilnom skupinom. Otopini aminoalkohola je u tetrahidrofuranu dodan tert-butoksikarbonilna skupina. Otopini aminoalkohola u tetrahifdrofuranu je dodan di-tert-butil-dikarboat u prisutnosti baze kao što je natrijev hidroksid. Mnogi aminoalkoholi Formule X su komercijalno pristupačni, ostali se mogu pripraviti poznatim sintetskim metodama.
U koraku (2) Reakcijske sheme I je zaštićeni aminoalkihol Formule XI preveden u jodid Formule XII. Jodid je dodan u otopinu trimetilfosfina i imidazola u diklormetanu, te je dodana otopina zaštićenog aminoalkohola Formule XI u diklormetanu. Reakcija se izvodi u pri sobnoj temperaturi.
U koraku (3) Reakcijske sheme I je 1H-imidazo[4,5-c]kinolin-1-il-alkohol Formule XIII je alkiliran s jodidom Formule XII i dobiven je 1H-imidazo[4,5-c]kinolin-1-il-eter Formule XIV. Alkohol Formule XIII je reagirao s natrijevim hidridom u pogodnom otapalu kao što je N,N-dimeilformamid i nastao je alkoksid. A otopinu alkoksida je dodan jodid pri sobnoj temperaturi. Nakon što je dodavanje završeno reakcija je miješana pri povišenoj temeraturi (~100°C). Mnogi spojevi Formule XIII su poznati, vidi primjerice Gerster, U. S. Patent br. 4,689,338, a ostali se mogu lako pripraviti poznatim sintetskim putevima, vidi primjerice Gerster et al. U. S,. Patent 5,605,899 i Gerstener, U. S. Patent br. 5,175 ,296.
U koraku (4) Reakcijske sheme I je 1H-imidazo[4,5-c]kinolin-1-il-eter Formule XIV oksidiran i dobiven je 1H-imidazo[4,5-c]kinolin-5N-oksid Formule XV, a upotrebom uobičajenog sredstva za oksidaciju koji može tvoriti N-okside. Preferirano se otopina spoja Formule XIV u kloroformu oksidira upotrebom 3-klorperbenzojeve kiseline pri sobnoj temperaturi.
U koraku (5) Reakcije sheme I, 1H-imidazo[4,5-c]kinolin-5N-oksid Formule XV je aminiran pri čemu nastaje 1H-imidazo[4,5-c]kinolin-4-amin Formule XVI. Korak (5) obuhvaća (i) reakciju spoja Formule XV sa sredstvom za aciliranje, a zatim (ii) reakciju tog produkta sa sredstvom za aminiranje. Dio (i) koraka (5) obuhvaća reakciju N-oksida Formule XV sa sredstvom za aciliranje. Pogodna sredstva za aciliranje su alkil ili arilsulfonil-kloridi (npr. benzensulfonil-klorid, metansulfonil-klorid, p-toluen-sulfonil-klorid). Preferirani su arilsulfonil-kloridi. p-Toluensulfonil-klorid je najpreferiraniji. Dio (ii) koraka (6) obuhvaća reakciju produkta iz dijela (i) sa suviškom sredstva za aminiranje. Pogodna sredstva za aminiranje uključuju amonijak (npr. u obliku amonijevog hidroksida) i amonijeve soli (npr. amonijev karbonat, amonijev bikarbonat, amonijev fosfat). Preferiran je amonijev hidroksid. Reakcija se preferirano izvodi otapanjem N-oksida Formule XV u inertnom otapalu kao što je 1,2-dikloretan uz zagrijavanje ako je potrebno, dodavanjem sredstva za aminiranje u otopinu, a zatim polaganim dodavanjem sredstva za aciliranje. Reakcija se može izvesti u zataljenoj posudi koja podnosi povišeni tlak i pri povišenoj temperaturi (85-100°C).
U koraku (6) Reakcijske sheme I je zaštitna skupina uklonjena hidrolizom pod kiselim uvjetima i dobiven 1H-imidazo[4,5-c]kinolin-4-amin Formule XVII. Preferirano se u otopinu spoja XVI pri sobnoj temperaturi ili pri blagom zagrijavanju dodaje klorovodična kiselina u etanolu.
U koraku (7) Reakcijske sheme I je 1H-imidazo[4,5-c]kinolin-4-amin Formule XVII preveden u ureu ili tioureu Formule XVIII korištenjem uobičajenih sintetskih metoda. Primjerice, spoj Formule XVII može reagirati s izocijanatom formule R12-N=C=O gdje R12 jeste R6-alkil, R6-alkenil, R6-aril, R6-heteroaril ili R6-heterociklil. Reakcija se može izvesti dodavanjem otopine izocijanata u pogodnom otapalu, kao što je diklormetan ili 1-metil-2-pirolidinon, otopini spoja Formule XVII pri sobnoj temeraturi. Alternativno spoj Formule XVII može reagirati s tioizocijanatom formule R12-N=C=O i acil-izocijanatom formule R12-C(O)-N=C=O, sulfonil izocijanatom formule R12-S(O)2-N=C=O ili karbonil-kloridom formule R13-N-C(O)Cl gdje R13 jeste R12 ili R7. Produkt ili odgovarajuća farmaceutski prihvatljiva sol je izoliran upotrebom konvencionalnih metoda.
Reakcijska shema 1
[image]
Spojevi iz izuma se mogu pripraviti prema Reakcijskoj shemi I u kojoj R, R1, R2, R3, R5, R8, X i n jesu kao što su gore definirani, BOC je tert-butoksikarbonil
U koraku (1) Reakcijske sheme II je amino-skupina aminoalkohola Formule XIX zaštićena s tert-butoksikarbonilnom skupinom. Otopini aminoalkohola je u tetrahidrofuranu dodan di-tert-butil-dikarbonat u prisutnosti baze kao što je natrijev hidroksid. Mnogi aminoalkoholi Formule XIX su komercijalno pristupačni, ostali se mogu pripraviti poznatim sintetskim metodama.
U koraku (2) Reakcijske sheme II je aminoalkohol Formule XX preveden u metansulfonat Formule XXI. Otopini spoja Formule XX je u pogodnom otapalu kao što je diklormetan dodan metansulfonil-klorid u prisutnosti baze kao što je trietilamin. Reakcija se može izvesti pri sniženoj temperaturi (0°C).
U koraku (3a) Reakcijske sheme II je metansulfonat Formule XXI preveden u azid formule XXII. Natrijev azid je dodan u otopinu spoja Formule XXI u pogodnom otapalu kao što je N,N-dimetilformamid. Reakcija se može izvesti pri povišenoj temperaturi (80-100°C).
U koraku (3b) Reakcijske sheme II je spoj Formule XXII alkiliran halogenidom formule Hal-R8 i dobiven je spoj Formule XXIII. U spojevima u kojime R8 jeste vodik taj je korak preskočen. Spoj Formule XXII reagira s natrijevim hidridom u pogodnom otapalu kao što je N,N-dimetilformamid ili tetrahidrofuran i nastaje anion koje zatim reagira s halogenidom. Reakcija se može izvesti pri sobnoj temperaturi.
U koraku (4) Reakcijske sheme II je spoj Formule XXII ili XXIII reduciran i dobiven je spoj Formule XXIV. Preferirano se redukcija izvodi upotrebom uobičajenih heterogenih katalizatora za hidriranje, kao što je paladij na ugljenu. Reakcija se obično izvodi u Parrovoj aparaturi u pogodnom otapalu kao što je metanol ili izopropanol.
U koraku (5) Reakcijske sheme II je 4-klor-3-nitrokinolin Formule XXV reagirao s aminom Formule XXIV i dobiven je 3-nitrokinolin Formule XXVI. Reakcija se može izvesti dodavanjem amina Formule XXIV u otopinu spoja Formule XXV u pogodnom otapalu kao što je diklormetan u prisutnosti baze kao što je trietilamin. Mnogi kinolini Formule XXV su poznati spojevi ili se mogu pripraviti poznatim sintetskim metodama, vidi primjerice Gerstner, U. S. Patent 4,689,338, i tamo navedene reference.
U koraku (6) Reakcijske sheme II je 3-nitrokinolin Formule XXVI reduciran i dobiven je 3-aminokinolin Formule XXVII. Preferirano se redukcija izvodi upotrebom konvencionalnih heterogenih katalizatora za hidriranje, kao što je paladij na ugljenu. Reakcija se obično izvodi u Parrovoj aparaturi u pogodnom otapalu kao što je toluen.
U koraku (7) Reakcijske sheme II spoj Formule XXVII reagira s karboksilnom kiselinom ili njenim ekvivalentom tvoreći 1H-imidazo[4,5-c]kinolin Formule XIV. Pogodni ekvivalenti karboksilne kiseline uključuju ortoestere i 1,1-dialkoksialkil-alkanoate. Karboksilna kiselina ili ekvivalent su odabrani tako da se uvede željeni R2 supstituent u spoj Formule XXXVII. Primjerice, trietil-ortoformijat će dati spoj u kojem R2 jeste vodik, a trietil-ortovalerat će dati spoj u kojem R2 jeste butil. Reakcija se može izvesti u odsutnosti otapala ili u inertnom otapalu kao što je toluen. Reakcija se izvodi uz dovoljno zagrijavanje da se uklanjaju alkohol i voda nastali kao nusprodukti reakcije. Može se koristiti katalizator kao što je piridinijev hidroklorid.
Alternativno se korak (7) može izvesti (i) reakcijom spoja Formule XXVII s kiselinskim halogenidom formule R2C(O)Cl a zatim (ii) ciklizacijom. U dijelu (i) kiselinski halogenid je dodan u otopinu spoja Formule XXVII u inertnom otapalu kao što je acetonitril ili diklormetan. Reakcija se može izvesti pri sobnoj temperaturi. U dijelu (ii) produkt iz (i) je zagrijavan u alkoholnom otapalu u prisutnosti baze. Preferirano je produkt dijela (i) refluksiran u etanolu u prisutnosti suviška trietilamina ili je zagrijavan s metanolnim amonijakom.
Koraci (8), (9), (10) i (11) se izvode na isti način kao koraci (4), (5), (6) i (7) Reakcijske sheme I.
Reakcijska shema II
[image]
Spojevi iz izuma se mogu pripraviti prema Reakcijskoj shemi III u kojoj R, R2, R3, R5, R8, R11, X i n jesu kao što su gore definirani.
U koraku (1) Reakcijske sheme III je 1H-imidazo[4,5-c]kinolin-4-amin Formule XVII reduciran i dobiven 6,7,8,9-tetrahidro-1H-imidazo[4,5-c]kinolin-4-amin Formule XVIII. Preferirano se redukcija izvodi suspendiranjem ili otapanjem spoja Formule XVII u trifluoroctenoj kiselini, dodavanjem katalitičke količine platina(IV)-oksida, a zatim hidriranjem. Reakciju je pogodno izvesti u Parrovoj aparaturi.
Korak (2) se izvodi na isti način kao korak (7) Reakcijske sheme I i dobiva se 6,7,8,9-tetrahidro-1H-imidazo[4,5-c]kinolin-4-amin Formule XXIX. Produkt ili odgovarajuća farmaceutski prihvatljiva sol se može izolirati upotrebom konvencionalnih metoda.
Reakcijska shema III
[image]
Spojevi iz izuma se također mogu pripraviti prema Reakcijskoj shemi IV u kojoj R, R1, R2, X i n jesu kao što su gore definirani.
U koraku (1) Reakcijske sheme IV 4-klor-3-nitrokinolin Formule XXV reagira s aminom formule R1-O-X-NH2 i nastaje 3-nitrokinolin-4-amin Formule XXX. Reakcija se može izvesti dodavanjem amina u otopinu spoja Formule XXV u pogodnom otapalu kao što je kloroform ili diklormetan, a može i uz zagrijavanje. Mnogi kinolini Formule XXV su poznati spojevi, vidi primjerice Gerster, U. S. Patent 4,689,338 i tamo navedene reference.
U koraku (2) Reakcijske sheme IV je 3-nitrokinolin-4-amin Formule XXX je reduciran korištenjem metode iz koraka (6) Reakcijske sheme II i dobiven je kinolin-3,4-diamin Formule XXXI.
U koraku (3) Reakcijske sheme IV je kinolin-3,4-diamin Formule XXXI cikliziran korištenjem metode iz koraka (7) Reakcijske sheme II i dobiven je 1H-imidazo[4,5-c]kinolin Formule XXXII.
U koraku (4) Reakcijske sheme IV je 1H-imidazo[4,5-c]kinolin Formule XXXII oksidiran korištenjem metode iz koraka (4) Reakcijske sheme I i dobiven je 1H-imidazo[4,5-c]kinolin-5N-oksid Formule XXXIII
U koraku (5) Reakcijske sheme IV je 1H-imidazo[4,5-c]kinolin-5N-oksid Formule XXXIII aminiran korištenjem metode iz koraka (5) Reakcijske sheme I i dobiven je 1H-imidazo[4,5-c]kinolin-4-amin Formule I. Produkt ili odgovarajuća farmaceutski prihvatljiva sol se može izolirati upotrebom konvencionalnih metoda.
Reakcijska shema 4
[image]
Spojevi iz izuma se također mogu pripraviti prema Reakcijskoj shemi V u kojoj R, R2, R3, R5, R8, R11, X i n jesu kao što su gore definirani.
U koraku (1) Reakcijske sheme V je BOC skupina uklonjena iz spoja Formule XIV upotrebom metode iz koraka (6) Reakcijske sheme I i dobiven je 1H-imidazo[4,5-c]kinolin Formule XXXIV.
U koraku (2) Reakcijske sheme V je 1H-imidazo[4,5-c]kinolin Formule XXXIV preveden u ureu ili tioureu Formule XXXV korištenjem metode iz koraka (7) Reakcijske sheme I.
U koraku (3) Reakcijske sheme V je 1H-imidazo[4,5-c]kinolin Formule XXXV oksidiran korištenjem metode iz koraka (4) Reakcijske sheme I i dobiven je 1H-imidazo[4,5-c]kinolin-5N-oksid Formule XXXVI.
U koraku (4) Reakcijske sheme V je 1H-imidazo[4,5-c]kinolin-5N-oksid Formule XXXVI aminiran korištenjem metode iz koraka (5) Reakcijske sheme I i dobiven je 1H-imidazo[4,5-c]kinolin-4-amin Formule XVIII. Produkt ili odgovarajuća farmaceutski prihvatljiva sol se može izolirati upotrebom konvencionalnih metoda.
Reakcijska shema V
[image]
Izum također prikazuje nove spojeve koji su korisni kao međuprodukti u sintezi spojeva Formula (I) i (II). Ti međuprodukti koji imaju strukturne Formule (III) i (IV) su dolje opisani detaljnije.
[image]
(III)
X jeste -CHR5, -CHR5-alkil ili -CHR5-alkenil,
R1 je odabran iz skupine koju čine:
-R4-NR8-CR3-NR5-Z-R6-alkil,
-R4-NR8-CR3-NR5-Z-R6-alkenil,
-R4-NR8-CR3-NR5-Z-R6-aril,
-R4-NR8-CR3-NR5-Z-R6-heteraril,
-R4-NR8-CR3-NR5-Z-R6-heterociklil,
-R4-NR8-CR3-NR5R7,
-R4-NR8-CR3-NR9-Z-R6-aril,
-R4-NR8-CR3-NR9-Z-R6-alkenil,
-R4-NR8-CR3-NR9-Z-R6-aril,
-R4-NR8-CR3-NR9-Z-R6-heteraril,
-R4-NR8-CR3-NR9-Z-R6-heterociklil,
R2 je odabran iz sljedeće skupine:
-vodik
-alkil,
-alkenil,
-aril,
-heteroaril,
-heterociklil,
-alkil-Y-alkil,
-alkil-Y-alkenil,
-alkil-Y-aril, te
-alkil ili alkenil supstituiran jednim ili s više supstituenata odabranih iz sljedeće skupine:
-OH,
-halogen
-N(R5)2,
-CO-N(R5)2,
-CO-C1-10alkil,
-CO-O-C1-10alkil,
-N3,
-aril,
-heteroaril,
-heterociklil,
-CO-aril, te
-CO-heteroaril;
svaki R3 jeste =O ili =S,
svaki R4je neovisno alkil ili alkenil koji može biti prekinut s jednom ili više -O- skupina,
svaki R5 jeste neovisno H ili C1-10alkil,
R6 jeste veza, alkil ili alkenil, koji mogu biti prekinuti s jednom ili više -O- skupina,,
R7 jeste H,C1-10alkil koji može biti prekinut heteroatomom ili R7 može biti spojen s R5 i tvoriti prsten,
R8jeste H,C1-10alkil ili arilalil, ili R4 i R8 mogu biti spojeni i tvoriti prsten,
R9jeste C1-10alkil koji može biti spojen s R8 i tvoriti prsten,
svaki Y neovisno jeste -O- ili -S(O)0-2,
Z jeste veza, -CO- ili -SO2-,
n jeste 0 do 4; te
svaki R je neovisno odabran iz sljedeće skupine: C1-10 alkil, C1-10alkoksi, hidroksi, halogen i trifluormetil,
ili odgovarajuća farmaceutski prihvatljiva sol.
Sljedeća klasa međuprodukata su imidazokinolin-N-oksidi Formule (IV)
[image]
(IV)
X jeste -CHR5, -CHR5-alkil ili -CHR5-alkenil,
R1 je odabran iz skupine koju čine:
-R4-NR8-CR3-NR5-Z-R6-alkil,
-R4-NR8-CR3-NR5-Z-R6-alkenil,
-R4-NR8-CR3-NR5-Z-R6-aril,
-R4-NR8-CR3-NR5-Z-R6-heteraril,
-R4-NR8-CR3-NR5-Z-R6-heterociklil,
-R4-NR8-CR3-NR5R7,
-R4-NR8-CR3-NR9-Z-R6-aril,
-R4-NR8-CR3-NR9-Z-R6-alkenil,
-R4-NR8-CR3-NR9-Z-R6-aril,
-R4-NR8-CR3-NR9-Z-R6-heteraril,
-R4-NR8-CR3-NR9-Z-R6-heterociklil,
svaki Y neovisno jeste -O- ili -S(O)0-2,
Z jeste veza, -CO- ili -SO2-,
svaki R4je neovisno jeste alkil ili alkenil koji mogu biti prekinuti s jednom ili više -O- skupina,
svaki R5 jeste neovisno H ili C1-10alkil,
R6 jeste veza, alkil ili alkenil, koji mogu biti prekinuti s jednom ili više -O- skupina,,
R7 jeste H,C1-10alkil koji može biti prekinut heteroatomom ili R7 može biti spojen s R5 i tvoriti prsten,
R8jeste H,C1-10alkil ili arilalil, ili R4 i R8 mogu biti spojeni i tvoriti prsten,
R9jeste C1-10alkil koji može biti spojen s R8 i tvoriti prsten,
n jeste 0 do 4; te
svaki R je neovisno odabran iz sljedeće skupine: C1-10 alkil, C1-10alkoksi, hidroksi, halogen i trifluormetil,
ili odgovarajuća farmaceutski prihvatljiva sol.
Ovdje korišten termini “alkil”, “alkenil”, te prefiks “alk” uključuju ravne ili razgranate lančane grupe i cikličke skupine, tj. cikloalkilne i cikloalkenilne. Ako nije drugačije naznačeno, te skupine sadrže od 1 do 20 atoma ugljika, s alkenilnim i alkinilnim skupinama od 2 do 20 atoma ugljika. Preferirano skupine imaju ukupno do 10 atoma ugljika. Cikličke skupine mogu biti monocikličke ili policikličke, te preferirano imaju od 3 do 10 atoma u prstenu. Primjeri cikličkih skupina uključuju ciklopropil, ciklopentil, cikloheksil i adamantil.
Uz ovo, alkilni i alkenilni dijelovi -X- skupina mogu biti nesupstituirani ili supstituirani s jednim ili više supstituenata, a koji su odabrani iz skupine koju čine: alkil, alkenil, aril, heteroaril, heterociklil, arilalkil, heteroarilalkil i heterociklilalkil.
Termin "haloalkil" uključuje skupine koje su supstituirane s jednim ili više atoma halogena, perfluorinirane skupine. To se takoer odnosi na skupine koje uključuju prefiks "halo-". Primjeri pogodnih haloalkilnih skupina uključuju klormetil, trifluormetil i slično.
Termin “aril” koji se ovdje koristi uključuje karboksilne aromatske prstenove ili sustave prestenova. Primjeri arilnih grupa uključuju fenil, naftil, bifenil, fluorenil i indelil. Termin “heteroaril” uključuje aromatske prstenove ili sustave prstenova koji sadrže najmanje jedan prsten s heteroatomom (npr. O, S, N). Pogodne heteroarilne grupa uključuju furil, tienil, piridil, kinolinil, izokinolil, indolil, izoindolil, triazolil, pirolil, tetrazolil, imidazolil, pirazolil, oksazolil, tiazolil, benzofuranil, benzotiofenil, kabrazolil, benzoksazolil, pirimidinil, kinoksalinil, benzimidazolil, benzotiazolil, nafthidrinil, izoksazolil, izotiazolil, purinil, kinazolinil itd.
“Heterociklil” uključuje nearomatične prstenove ili sustav prstenova koji sadrže najmanje jedan prsten s heteroatomom (npr. O, S, N). Pimjeri heteroarilnih skupina jesu potpuno zasićeni i djelomično nezasićeni derivati gore spomenutih heteroarilnih skupina. Primjeri heterocikličkih skupina uključuju pirolidinil, tetrahidrofuranil, morfolinil, tiomorfolinil, piperidinil, piperazinil, tiazolidinil, imidazolidinil, izotiazolidinil i slično.
Aril, heteroaril i heterociklilne skupine mogu biti nesupstituirane ili supstituirane s jednim ili više supstituenata koji su neovisno odabrani iz sljedeće skupine: alkil, alkoksi, alkiltio, halogen, haloalkil, haloalkoksi, haloalkilntio, halogen, nitro, hidroksi, merkapto, cijano, karboksi, formil, aril, ariloksi, ariltio, arilalkoksi, arilalkiltio, heteroaril, heteroariloksi, heteroariltio, heteroarilalkoksi, heteroarilalkiltio, amino, alkilamino, dialkilamino, heterociklil, heterocikloalkil, alkilkarbonil, alkenil-karbonil, alkoksikarbilnil, haloalkilkarbonil, haloalkoksi-karbonil, alkiltiokarbonil, arilkarbonil, heteroarilkarbonil, ariloksikarbonil, heteroariloksi-karbonil, ariltiokarbonil, heteroariltiokarbonil, alkanoiloksi, alkanoiltio, alkanoilamino, aroiloksi, aroiltio, aroilamino, alkilaminosulfonil, alkilsulfonil, arilsulfonil, heteroarilsulfonil, arildiazinil, alkilsulfonilamino, arilsulfonilamino, arilalkilsulfonilamino, alkilkarbonilamino, alke-nilkarbonilamino, arilkarbonilamino, arilalkilkarbonilamino, heteroarilkarbonilamino, heteroarilalkilkarbonilamino, alkilsulfonilamino, alkenilsulfonilamino, arilsulfonil-amino, arilalkilsulfonilmino, heteroarilsulfonilamino, heteroarilalkilsulfonilamino, alkilaminokarbonil-amino, alkenilaminokarbonilamino, arilaminokarbonilamino, aril-alkilaminokarbonilamino, heteroarilaminokarbonilamino, heteroarilalkilamino-karbonilamino i u slučaju heterociklila, oksi. Ako je bilo koja skupina ovdje navedena kao "supstituirana" ili "može biti supstituirana", te skupine također mogu biti supstituirane s jednim ili više gore navedenih supstituenata.
Neki supstituenti su općenito preferirani. Primjerice, preferirane R1 skupine uključuju -R4-NR8-CR3-NR5-Z-R6-alkil i -R4-NR8-CR3-NR5-Z-R6-aril, pri čemu alkilna ili arilna skupina može biti nesupstituirana ili supstituirana, R5 je preferirano etilen ili n-butilen ili R4 i R8 spojeni tvore prsten. Preferirano nije prisutan R supstituent (tj. n jeste 0). Preferirane R2 skupine uključuju halogen, alkilne skupine koje imaju od 1 do 4 atoma ugljika (tj. metil, etil, propil, izopropil, n-butil, sec-butil, izobutil i ciklopeopilmetil), metoksietil i etoksimetil. Za supstituirane skupine kao što su supstituirane alkilne ili supstituirane arilne skupine, preferirani supstituenti uključuju halogen nitril, metoksi, metiltio, trifluormetil i triflormetoksi. Ako su jedan ili više od preferiranih supstituenata prisutni, mogu u spojevima biti u bilo kojoj kombinaciji.
Izum uključuje ovdje opisane spojeve u bilo kojem farmaceutski prihvatljivom obliku, uključujući izomere (npr. diastereomeri i enantiomeri), soli, solvate, polimorfe i slično. Ako je spoj optički aktivan, izum također uključuje svaki enantiomer spoja kao i racemične smjese enantiomera.
Farmaceutski pripravci i biološka aktivnost
Farmaceutski pripravci iz izuma sadrže terapijski učinkovite količine spoja iz izuma kao što je gore opisano i farmaceutski prihvatljiv nosač.
Termin “terapijski učinkovita količina” označuje količinu spoja dovoljnu da inducira terapijski učinak, kao što je indukcija citokina, antitumorna aktivnost i/ili antivirusna aktivnost. Mada će točne količine aktivnog spoja korištene u farmaceutskim pripravcima izuma varirati ovisno o faktorima koji su poznati stručnjacima, kao što su fizikalna i kemijska svojstva spoja kao i priroda nosača i određeni režim doziranja, očekuje se da će pripravak iz izuma sadržavati dovoljno aktivnog sastojka da doza bude od oko 100 ng/kg do oko 50 mg/kg, preferirano od oko 10 μg/kg do oko 5 mg/kg spoja. Može se koristiti bilo koji uobičajeniji oblik doze, kao što su tablete, pastile, parenteralne formulacije, sirupi, kreme, masti, aerosolne formulacije, transdermalni melem, transmukozni melem, itd.
Spojevi iz izuma se mogu dati kao jedno terapijsko sredstvo u režimu tretmana, ili se spojevi iz izuma mogu davati u kombinaciji s drugim ili drugima aktivnim sredstvima, uključujući druga sredstva za modifikaciju imunog odgovora, antivirusna sredstva, antibiotike itd.
Spojevi iz izuma su pokazali da induciraju proizvodnju nekih citokina u eksperimentima izvedenim prema testovima prikazanim niže. Ti rezultati pokazuju da su spojevi korisni kao modifikatori imunog odgovora, koji se može modulirati na brojne načine, čineći spojeve korisnim u tretmanu raznih poremećaja.
Citokini koji su inducirani davanjem spojeva prema ovom izumu općenito uključuju interferon-α (IFN)-α i faktor-α tumorne nekroze (TNF-α), kao i neke interleukine (IL). Citokini čija se biosinteza može inducirati spojevima iz izuma uključuju IFN-α, TNF-α, IL-1, 6, 10 i 12, te razne druge citokine. Među ostalim učincima, citokini inhibiraju nastajanje virusa i rast tumornih stanica čineći spojeve korisnim za tretman virusnih oboljenja i tumora. Prema tome, izum prikazuje metodu indukcije biosinteze citokina kod životinja, a koja se sastoji od davanja životinji učinkovite količine spoj ili pripravka iz izuma.
Nađeno je da neki spojevi iz izuma uglavnom induciraju ekspresiju IFN-α u populaciji hematopoietičnih stanica kao što su PBMC (mononukleoarne stanice periferne krvi) koje sadrže pDC2 stanice (prekursor dendrične stanice tipa 2) bez istovremene produkcije znatne razine upalnih citokina.
Uz mogućnost induciranja produkcije citokina, spojevi iz izuma djeluju na druge aspekte imunog odgovora. Primjerice, aktivnost prirodnih stanica ubojica se može stimulirati, a efekt potječe od indukcije citokina. Spojevi također aktiviraju makrofage, koji zbog toga stimuliraju izlučivanje dušikovog oksida i produkciju drugih citokina. Nadalje, spojevi mogu uzrokovati proliferaciju i diferencijaciju B-limfociata.
Spojevi iz izuma također imaju učinak na stečene imune odgovore. Primjerice, mada se ne vjeruje da mogu imati bilo koji izravni efekt na T stanice ili na izravnu indukciju citokina T stanica, produkcija IFN-γ citokina T pomoćnih stanica tipa 1 (Th1) je inducirana indirektno, a produkcija citokina IL-4, IL-5 i IL13 T pomoćnih stanica tipa 2 (Th2) je inhibirana je nakon davanja spojeva. Ova aktivnost pokazuje da su spojevi korisni u tretmanu bolesti u kojima je poželjno povećanje Th1 odgovora ili/ili smanjenje Th2 odgovora. S aspekta mogućnosti spojeva Formule I da inhibiraju Th2 imuni odgovor, očekuje se da su spojevi korisni u tretmanu atopičnih bolesti, npr. atopičnog drermatitisa, astme, alergije, alergijskog rinitisa, za sistemski lupus erithematozu, te za dodatak vakcini za održavanje imuniteta stanica, i moguće za tretman ponovljenih gljivičnih bolesti i klamidija.
Efekt modificiranja imunih odgovora čini spojeve korisnim u tretmanu velikog broja stanja. Zbog njihove mogućnosti da induciraju produkciju citokina kao što je IFN-α i/ili TNF-α, spojevi su posebno korisni u tretmanu virusnih bolesti i tumora. Ta imunomodulirajuća aktivnost ukazuje da su spojevi iz izuma korisni za tretman bolesti kao što su, ali bez ograničenje, virusne bolesti uključujući, genitalnu veruku, običnu veruku, biljnu veruku, hepatitis B, hepatitis C, virus herpes simpleks tipa I i tipa II, muscum contagiosm, vlike boginje, HIV, CMV, VZV, rinovirus, adenovirus, influencam te para-influenca, intraepitelne neoplazije kao što je intraepitalna neoplazija grlića maternice, humani papilomavirus (HPV) i s tim povezane neoplazije, gljivične bolesti npr. kandida, aspergilus, kriptokokalni menengitis, neoplazije npr. karcinom bazalnih stanica, karcinom vlaknastih stanica, Kaposhi sarkoma, karcinom bubrećnih stanica, karcinom supžvastih stanica, mijelogena leukemija, multipli mijelom, melanom, non-Hodgkin limfom, limfom kožnih T stanica, te ostali tumori, bolesti od parazita, npr. pneumocystis carinii, kriptosporidioza, histoplazmoza, toksiplazmoza, infekcija s tripanosomom, leishmaniaza, bakterijske infekcije npr. tuberkuloza, micobacterium avium. Daljnje bolesti ili stanja koja se mogu tretirati korištenjem spojeva iz izuma uključuju ekcem, eozinofiliju, trombocitemiju, lepru, multiple sklerozu, Ommenov sindrom, diskoidni lupus, Bowenovu bolest, Bowenoidnu papulozu, alopeciju areara, inhibiciju tvorbe Keloida nakon operacije i drugih postoperativnih ožiljaka. Uz ovo, spojevi mogu ubrzati ili stimulirati zacjeljenje rana, ukjučujući kronične rane. Spojevi mogu biti korisni za tretman oportunističkih infekcija i tumora koji se pojavljuju nakon supresije stanicama posredovani imunitet u, primjerice, pacijentima nakon transplantacije, pacijentima s karcinomom i pacijentima s HIV.
Količina učinkovita da inducira biosintezu citokina je količina dovoljna da uzrokuje da jedan ili više tipova stanica, kao što su monociti, makrofagi, dendritične stanice i B-stanice, produciraju količinu jednog ili više citokina kao što su primjerice IFN-α, TNF-α, IL-1, 6, 10 i 12 koji su se time povećali preko bazalne razine tih citokina. Točne količine će se mijenjati prema faktorima poznatim u struci, ali se očekuje da doza bude od oko 100 ng/kg do oko 50 mg/kg, preferirano od oko 10 μg/kg do oko 5 mg/kg. Izum nadalje prikazuje metodu tretmana virusnih infekcija u životinjama koja sadrži davanje životinjama učinkovite količine spoja Formule I. Količina učinkovita u tretmanu ili inhibiciji virusnih infekcija u životinji, te metodu tretmana neoplastične bolesti u životinjama koja sadrži davanje životinji učinkovite količine spoja ili pripravka iz izuma. Količina koja je učinkovita za tretman ili inhibiciju virusne infekcije uzrokuje smanjivanje jedne ili više manifestacija virusnih infekcija, kao što je virusna lezija, količina unosa virusa, brzina produkcije virusa i smrtnost, a u usporedbi s kontrolnim životinjama. Točna količina će se mijenjati prema faktorima poznatim u struci, ali se očekuje da doza bude od oko 100 ng/kg do oko 50 mg/kg, preferirano od oko 10 μg/kg do oko 5 mg/kg. Količina spoja učinkovita u tretmanu neoplastičnih stanja je količina koja uzrokuje smanjivanje veličine tumora ili broja tumornih središta. Ponovo, točna količina će se mijenjati prema faktorima poznatim u struci, ali se očekuje da doza bude od oko 100 ng/kg do oko 50 mg/kg, preferirano od oko 10 μg/kg do oko 5 mg/kg.
Izum nadalje opisuje sljedeće primjere, koji su prikazani da za ilustraciju a nije bila namjera da ograniče izum na bilo koji način.
U donjim primjerima neki spojevi su čišćeni upotrebom semipreparativne HPLC. Korišten je automatizirani sustav za pročišćavanje Waters Fraction Lync. Semipreparativne HPLC frakcije su analizirane pomoću Micromass LC-TOFMS i odgovarajuće frakcije su spojene uparene centrifugiranjem i dobiven je trifluoracetat željenog spoja. Strukture su potvrđene 1H NMR..
Kolona: kolona Phenomenex Luna C18(2), 10 x 50 mm, veličina čestica od 5mikrona, pore 100 Å, brzina protoka 25 mL/min, gradijent eluiranja od 5-65% B kroz 4 minuta, zatim 65 do 95% B u 0.1 min, a zatim je zadržano 95% B kroz 0.4 minuta, pri čemu A=0.05% trifluoroctena kiselina/voda i B=0.05% trifluoroctena kiselina/acetonitril, detekcija signala pri 254 nm čime započinje sakupljanje frakcija
Primjer 1
N-(2-{2-[4-amino-2-(2-metoksietil)- 1H-imidazo[4,5-c]kinolin-1-il]etoksi} etil)-N'-fenilurea
[image]
Dio A
Otopina 2-(2-aminometoksi)etanola (29.0 g, 0.276 mol) u 180 mL tetrahidrofurana (THF) je ohlađena i u atmosferi dušika je dodano 140 mL 2M otopine NaOH. Zatim je dokapana otopina di-tert-dutil-dikarbonata (60.2 g, 0.276 mol) u 180 mL THF u periodu od 1 h uz intezivno miješanje. Reakcijska smjesa je ostavljena da se ugrije do sobne temerature i miješana je još 18 sati. THF je uklonjen pod sniženim tlakom, a zaostala vodena smjesa je dovedena do pH 3 dodatkom 150 mL 1M otopine H2SO4. To je ekstrahirano etil-acetatom (300 mL, 100 mL) i spojeni organski slojevi su prani vodom (2x) i otopinom soli. Organski dio je sušen iznad Na2SO4 i uparen pri čemu je dobiven tert-butil-2-(2-hidroksietoksi)-etilkarbamat kao bezbojno ulje (47.1 g).
Dio B
Otopinu tert-butil-2-(2-hidroksietoksi)etilkarbamata (4.71 g, 0.230 mol) u 1 L bezvodnog CH2Cl2 je ohlaena na 0°C, te je uz intenzivno miješanje dodan trietliamin (48.0 mL, 0.345 mol). Dokapan je metansulfonil-klorid (19.6 mL, 0.253 mol) kroz 30 minuta. Reakcijska smjesa je ostavljena da se ugrije do sobne temperature i miješana je još 22 sata. Reakcija je prekinuta dodatkom zasićene otopine NaHCO3 i organski sloj je odijeljen. Organska faza je zatim prana vodom (3x500 mL). Organski dio je sušen iznad Na2SO4 i uparen, pri čemu je dobiven 2-{2-[(tert-butoksikarbonil)amino]etoksi}etil-metansulfonat kao smeđe ulje (63.5 g).
Dio C
Otopini 2-{2-[(tert-butoksikarbonil)amino]etoksi} etil-metansulfonata (63.5 g, 0.224 mol) u 400 mL N,N-dimetilformamida (DMF) je dodan NaN3 (16.1 g, 0.224 mol) i reakcijska smjesa je zagrijavana pri 90°C u atmosferu dušika. Nakon 5 h je otopina ohlađena na sobnu temperaturu i dodano je 500 mL hladne vode. Reakcijska smjesa je ekstrahirana eterom (3x300 mL). Spojeni organski ekstrakti su prani vodom (4x100 mL) i otopinom soli (2x100 mL). Organski dio je sušen iznad MgSO4 i uparen, pri čemu je dobiveno 52.0 g tert-butil-2-(2-azidoetoksi)etilkarbamata u obliku svjetlosmeđeg ulja.
Dio D
Otopini tert-butil-2-(2-azidoetoksi)etilkarbamata (47.0 g, 0.204 mol) u metanolu je dodano 4 g 10% Pd na ugljenu i potresano je u atmosferi vodika (3 kg/cm2) kroz 24 h. Otopina je filtrirana preko umetka Celita i uparena pri čemu je dobiveno 35.3 g sirovog tert-butil-2-(2-aminoetoksi)etilkarbamata u obliku bezbojne tekućine koja je korištena bez daljnjeg čišćenja.
Dio E
U otopinu 4-klor-3-nitrokinolina (31.4 g, 0.151 mol) u 500 mL bezvodnog CH2Cl2 je u atmosferi dušika dodan tretilamin (43 mL, 0.308 mol) i tert-butil-2-(2-aminoetoksi)etilkarbamat (0.151 mol). Nakon miješanja preko noći, reakcijska smjesa je prana vodom (2x300 mL) i otopinom soli (300 mL). Organski dio je sušen iznad Na2SO4 i uparen te je dobivena sjajna žuta krutina. Prekristalizacijom iz etil-acetat/heksana dobiveno je 43.6 g tert-butil-2-{2-[(3-nitrokinolin-4-il)amino]etoksi}-etilkarbamata u obliku sjajnih žutih kristala.
Dio F
Otopini tert-butil-2-{2-[(3-nitrokinolin-4-il)amino]etoksi}etilkarbamata (7.52 g, 20.0 mmol) u toluenu je dodano 1.5 g 5% Pt na ugljenu i potresano je u atmosferi vodika (3 kg/cm2) kroz 24 h. Otopina je filtriana preko umetka Celita i uparena pri čemu je dobiveno 6.92 g sirovog tert-butil-2-{2-[(3-aminokinolin-4-il)amino]etoksi}etilkarbamata u obliku žutog sirupa.
Dio G
Otopina tert-butil-2-{2-[(3-aminokinolin-4-il)amino]etoksi} etilkarbamata (10.2 g, 29.5 mmol) u 250 mL bezvodnog CH2Cl2 je hlađena na 0°C i dodan je trietilamin (4.18 mL, 30.0 mmol). Zatim je kroz 5 minuta dokapan metoksipropionil-klorid (3.30 mL, 30.3 mmol). Reakcija je zatim ugrijana do sobne temperature i miješanje je nastavljeno 1 h. Reakcijska smjesa je zatim uparena pod sniženim tlakom i dobivena je narančasta krutina. Ona je otopljena u 250 mL etanola i dodano je 12.5 mL trietliamina. Smjesa je zagrijavana uz refluksiranje u atmosferi dušika preko noći. Reakcija je zatim uparena do suha pod sniženim tlakom i dodano je 300 mL etera. Smjesa je zatim filtrirana i filtrat je uparen pod sniženim tlakom pri čemu nastaje smeđa krutina. Krutina je otopljena u 200 mL vrućeg metanola i dodan je aktivni ugljen. Vruća otopina je filtirana i uparena, pri čemu je dobiveno 11.1 g tert-butil-2-{2-[(2-metoksietil)-1H-imidazo[4,5-c]kinolin-1-il]etoksi}etilkarbamata u obliku žutog sirupa.
Dio H
Otopini tert-butil-2-{2-[(2-metoksietil)-1H-imidazo[4,5-c]kinolin-1-il]etoksi}etil-karbamata (10.22 g, 24.7 mmol) u 250 mL kloroforma je dodana 3-klorper-benzojeva kiselina (MCPBA, 77%, 9.12 g, 40.8 mmol). Nakon miješanja 30 minuta je reakcijska smjesa prana 1% otopinom Na2CO3 i uparena i dobiveno je 10.6 g tert-butil-2-{2-[(2-metoksietil)-5-oksido-1H-imidazo[4,5-c]kinolin-1-il]etoksi}etilkarbamata kao narančasta pjena koja je korištena bez daljnjeg čišćenja.
Dio I
Otopini tert-butil-2-{2-[(2-metoksietil)-5-oskdo-1H-imidazo[4,5-c]kinolin-1-il]-etoksi} etilkarbamata (10.6 g, 24.6 mmol) u 100 mL 1,2-dikloretana koja je zagrijana na 60°C je dodano 10 mL koncentrirane otopine NH4OH. Uz brzo miješanje je u otopinu dodan čvrsti p-toluensulfonil-klorid (7.05 g, 37.0 mmol) u periodu od 10 minuta. Reakcijskoj smjesi je dodan još 1 mL koncentriane otopine NH4OH te je zataljena u posudi koja podnosi povišen tlak i zagrijavanje je nastavljeno 2 sata. Reakcijska smjesa je zatim ohlađena i dodano je 100 mL kloroforma. Reakcijska smjesa je prana vodom, 1% otopinom Na2CO3 (2x), te otopinom soli. Organski dio je sušen iznad Na2SO4 i uparen pri čemu je dobiveno 10.6 g tert-butil-2-{2-[4-amino-2-(2-metoksietil)-1H-imidazo[4,5-c]kinolin-1-il]etoksi} etilkarbamata u obliku smeđe pjene.
Dio J
tert-Butil-2-{2-[4-amino-2-(2-metoksietil)-1H-imidazo[4,5-c]kinolin-1-il]etoksi}-etilkarbamatu (10.6 g, 24.6 mmol) je dodano 75 mL 2M HCl u etanolu i smjesa je zagrijavana uz refluksiranje i miješanje. Nakon 1.5 h je reakcijska smjesa ohlaena i filtrirana, a dobivena je gumasta krutina. Krutina je prana etanolom i eterom i sušena u vakuumu, pri čemu je dobivena hidrokloridna sol kao svjetlosmeđa krutina. Slobodna baza je dobivena otapanjem hidroklorida u 50 mL vode i djelovanjem s 10% otopinom NaOH. Vodena suspenzija je zatim uparena do suha i ostatku je dodan kloroform. Nastale soli su uklonjene filtracijom i filtrat je uparen dajući 3.82 g 1-[2-(2-aminoetoksi)etil]-2-(2-metoksietil)-1H-imidazo[4,5-c]kinolin-4-amina u obliku tamnog praška.
MS 330 (M+H)+
1H NMR (300 MHz, DMSO-d6) δ 8.10 (d, J=8.1 Hz, 1H), 7.66 (s, J=8.2 Hz, 1H), 7.40 (m, 1H), 7.25 (m, 1H), 6.88 (_širok s, 2H), 4.78 (t, J=5.4 Hz, 2H), 3.89 (t, J=4.8 Hz, 2H), 3.84 (t, J=6.9 Hz, 2H), 3.54 (t, J=5.4 Hz, 2H), 3.31 (s, 3H), 3.23 (t, J=6.6 Hz, 2H), 2.88 (t, J=5.3 Hz, 2H).
Dio K
1-[2-(2-aminoetoksi)etil]-2-(2-metoksietil)-1H-imidazo[4,5-c]kinolin-4-amina (750 mg, 2.28 mmol) je u atmosferi dušika otopljen u 30 mL bezvodnog CH2Cl2 i ohlađenna 0°C. Reakcijskoj smjesi je zatim dodan fenil-izocijanat (247 μL, 2.28 mmol) i trietliamin (0.64 mL, 4.56 mmol) i ostavljeno je da se polako ugrije do sobne temperature. Nakon miješanja 2 sata, reakcijska smjesa je uparena pod sniženi tlakom i dobivena je žuta krutina. Žuta krutina je otopljena u minimalnoj količini CH2Cl2 i dodan je etil-acetat do pojave zamagljenja. Smjesa je smještena u zamrzivač preko noći i nastali su bijeli kristali. Kristali su izolirani filtracijom i sušeni su u vakuumu, pri čemu je dobiveno 126 mg N-(2-{2-[4-amino-2-(2-metoksietil)-1H-imidazo[4,5-c]kinolin-1-il]etoksi} etil)-N'-feniluree, talište 171.0-174.0°C,
MS 449 (M+H)+;
1H NMR (300 MHz, DMSO-d6) δ 8.50 (s, 1H), 8.05 (d, J=7.7 Hz, 1H), 7.62 (d, J=8.8 Hz, 1H), 7.44-7.18 (m, 3H), 7.27-7.18 (m, 3H), 6.88 (t, J=7.3 Hz, 1H), 6.54 (s, 2H), 6.12 (t, J=5.5 Hz, 2H), 4.76 (t, J=4.8 Hz, 2H), 3.88 (t, J=5.3 Hz, 2H), 3.81 (t, J=6.7 Hz, 2H), 3.40 (t, J=6.0 Hz, 2H), 3.28 (s, 3H), 3.25-3.14 (m, 4H);
13C NMR (75 MHz, DMSO-d6) δ 155.5, 152.0, 144.9, 140.8, 132.7, 129.0, 126.8, 126.5, 121.5, 121.4, 120.5, 117.9, 115.1, 70.5, 69.4, 58.4, 45.5, 27.6;
Analiza, izračunato za C24H28N6O3•0.21 H2O: %C 63.73, %H 6.33, %N 18.58, nađeno %C 63.33, %H 6.28, %N 18.67.
Primjer 2
N-(2-{2-[4-amino-2-(2-metoksietil)-6,7,8,9-1H-imidazo[4,5-c]kinolin-1-il]etoksi} etil)-N'-fenilurea
[image]
Dio A
1-[2-(2-Aminoetoksi)etil]-2-(2-metoksietil)-1H-imidazo[4,5-c]kinolin-4-amin (10.0 g, 27.3 mmol) je otopljen u 50 mL trifluoroctene kiseline i dodan je PtO2 (1.0 g). Reakcijska smjesa je potresana u atmosferi vodika (3 kg/cn2). Nakon 4 sata je dodano još 0.5 g PtO2 i hidriranje je nastavljeno još 3 dana. Reakcija je filtriana preko Celita i uparena pod sniženim tlakom i dobiveno je smeđe ulje. Ulje je otopljeno u 200 mL vode te je zaluženo (pH~11) dodatkom 10% otopine NaOH. To je ekstrahirano kloroformom (5x75 mL) i spojeni organski slojevi su sušeni iznad Na2SO4 i upareni, te je dobiveno 5.17 g 1-[2-(2-aminoetoksi)etil]-2-(2-metoksietil)-6,7,8,9-tetrahidro-1H-imidazo[4,5-c]kinolin-4-amina u obliku tamne krutine.
MS 449 (M+H)+;
1H NMR (300 MHz, CDCl3) δ 5.19 (s, 1H), 4.49 (d, J=5.4 Hz, 2H), 3.84 (t, J=6.6 Hz, 2H), 3.71 (t, J=5.4 Hz, 2H), 3.36 (t, J=5.2 Hz, 2H), 3.51 (s, 3H), 3.15 (t, J=6.6 Hz, 2H), 2.95 (m, 2H), 2.82 (m, 2H), 2.76 (t, J=5.1 Hz, 2H), 1.84 (m, 4H), 1.47 (_širok s, 2H).
Dio B
1-[2-(2-Aminoetoksi)etil]-2-(2-metoksietil)-6,7,8,9-tetrahidro-1H-imidazo[4,5-c]kinolin-4-amin (919 mg, 2.76 mmol) je u atmosferi dušika otopljen u 30 mL bezvodnog CH2Cl2 i ohlađenna 0°C. Reakcijskoj smjesi je zatim dodan fenil-izocijanat (300 μL, 2.76 mmol) i trietliamin (0.77 mL, 5.51 mmol) i ostavljeno je da se polako ugrije do sobne temperature. Nakon miješanja preko noći, reakcijska smjesa je ugašena dodatkom zasićene otopine NaHCO3 (30 mL). Organski sloj je odijeljen i pran vodom i otopinom soli, sušen iznad Na2SO4 i uparen pod sniženim tlakom, te je dobivena žuta krutina. Krutina je razmuljena u eteru (30 mL) i nekoliko kapi metanola. Krutina je izolirana filtracijom i sušena u vakuumu, pri čemu je dobiveno 460 mg N-(2-{2-[4-amino-2-(2-metoksietil)-6,7,8,9-tetrahidro-6,7,8,9-tetrahidro-1H-imidazo[4,5-c]kinolin-1-il]etoksi} etil)-N'-feniluree u obliku bijelog praška, talište 180-182 °C,
MS 453 (M+H)+;
1H NMR (300 MHz, DMSO-d6) δ 8.51 (s, 1H), 7.37 (d, J=7.7 Hz, 2H), 7.19 (d, J=8.2 Hz, 2H), 6.86 (t, J=7.7 Hz, 1H), 6.11 (t, J=5.5 Hz, 2H), 5.70 (s, 2H), 3.32 (t, J=5.1 Hz, 2H), 3.78-3.69 (m, 4H), 3.39 (t, J=5.6 Hz, 2H), 3.25 (s, 3H), 3.19 (m, 2H), 3.10 (t, J=6.8 Hz, 2H), 2.91 (m, 2H), 2.64 (m, 2H), 1.72 (m, 4H);
13C NMR (75 MHz, DMSO-d6) δ 155.5, 151.3, 149.3, 146.3, 140.8, 138.5, 129.0, 125.0, 121.4, 118.0, 105.6, 70.6, 70.5, 70.4, 58.4, 44.6, 39.2, 32.7, 27.6, 23.8, 23.1, 23.0;
Analiza, izračunato za C24H32N6O3•0.21 H2): %C 63.70, %H 7.13, %N 18.578, nađeno %C 63.33, %H 7.16, %N 18.66.
Primjer 3
N-(2-{2-[4-amino-2-(2-metoksietil)- 1H-imidazo[4,5-c]kinolin-1-il]etoksi} etil)-N'-fenilurea
[image]
Dio A
Natrijev hidrid (60% disperzija u ulju, 9.1 g, 228 mmol) je smješten u okruglu tikvicu i pran je heksanom (3x) u atmosferi dušika. Osušenom natrijevom hidridu je dodano 800 mL bezvodnog THF. Zatim je u otopinu natrijevog hidrida uz miješanje dodana otopina tert-butil-2-(2-azidoetoksi)etilkarbamata (41.9 g, 182 mmol) u 200 mL THF kroz 40 minuta. Nakon što je dodavanje završeno reakcija je miješanja još 20 minuta, te je dodan metil-jodid (13.6 mL, 218 mmol). Nakon miješanja preko noći, reakcija je ugašena dodatkom 300 mL zasićene otopine NaHCO3. Reakcijskoj smjesi je zatim dodano 200 mL vode i 1 L etera. Organska faza je odijeljena i prana vodom i otopinom soli. Organski dio je zatim sušen iznad MgSO4 i uparen pod sniženim tlakom, pri čemu je dobiveno 41.9 g tert-butil-2-(2-azidoetoksi)-etil(metil)karbamata u obliku žute tekućine.
Dio B
Otopini tert-butil-2-(2-azidoetoksi)etil(metil)karbamata (41.9 g, 170 mmol) u 600 mL metanola je dodano 2.5 g 10% Pd na ugljenu i potresano je u atmosferi dušika (3 kg/cm2) kroz 24 h. Otopina je filtrirana preko umetka od Celita i uparena, pri čemu je dobiveno 37.2 g tert-butil-2-(2-aminoetoksi)etil(metil)karbamata u obliku svjetložute tekućine.
Dio C
U otopinu 4-klor-3-nitrokinolina (32.3 g, 155 mmol) u 400 mL bezvodnog CH2Cl2 su u atmosferi dušika dodani tretilamin (43.1 mL, 310 mmol) i tert-butil-2-(2-aminoetoksi)etil(metil)karbamat (37.2 g 171 mmol). Nakon miješanja preko noći, reakcijska smjesa je prana vodom (2x300 mL) i otopinom soli (300 mL). Organski dio je sušen iznad Na2SO4 i uparen, te je dobiveno smeđe ulje. Kolonskom kromatografijom (SiO2, 33% etil-acetat/heksan-67% etil-acetat/heksan) je dobiveno 46.7 g tert-butil-metil-(2-{2-[(3-nitrokinolin-4-il)amino]etoksi} etil)karbamata u obliku krutine.
Dio D
Otopini butil-metil-(2-{2-[(3-nitrokinolin-4-il)amino]etoksi} etil)karbamata (6.56 g, 16.8 mmol) u 75 mL toluena je dodano 0.5 g 5% Pt na ugljenu i potresana je u atmosferi vodika (3 kg/cm2) kroz 24 sata. Otopina je zatim filtrirana preko umetka celita i uparena, te je dobiveno 6.8 g sirovog tert-butil-metil-(2-{2-[(3-aminokinolin-4-il)amino]etoksi} etil(metil)karbamata u obliku narančastog sirupa koji je korišten bez daljnjeg čišćenja.
Dio E
Otopina tert-butil-metil-(2-{2-[(3-aminokinolin-4-il)amino]etoksi} etil(metil)karbamata (6.05 g, 16.8 mmol) u 200 mL bezvodnog CH2Cl2 je ohlađena na 0°C i dodan je trietilamin (2.40 mL, 17.2 mmol). Zatim je kroz 5 minuta dokapan metoksipropionil-klorid (1.72 mL, 17.2 mmol). Reakcija je zatim ugrijana do sobne temperature i miješanje je nastavljeno 1 h. Reakcijska smjesa je zatim ugrijana do sobne temperature i miješanje je nastavljeno 3 sata. Reakcijska smjesa je zatim uparena pod sniženim tlakom i dobivena je narančasta krutina. Ona je otopljena u 200 mL etanola i dodano je 7.2 mL trietliamina. Smjesa je zagrijavana uz refluksiranje u atmosferi dušika preko noći. Reakcija je zatim uparena do suha pod sniženim tlakom i dodano je 300 mL etera. Smjesa je zatim filtrirana i filtrat je uparen pod sniženim tlakom pri čemu nastaje smeđa krutina. Krutina je otopljena u 300 mL CH2Cl2 te je prana vodom i otopinom soli. Organski dio je sušen iznad Na2SO4 i uparen pod sniženim tlakom pri čemu je dobiveno smeđe ulje. Ulje je otopljeno u 100 mL vrućeg metanola i dodan uje aktivni ugljen. Vruća otopina je filtrirana i uparena, pri čemu je dobiveno 7.20 g tert-butil-2-{2-[(metoksietil)-1H-imidazo[4,5-c]kinolin-1-il]etoksi} etil(metil)karbamata u obliku žutog sirupa.
Dio F
Otopini tert-butil-2-{2-[(metoksietil)-1H-imidazo[4,5-c]kinolin-1-il]etoksi} etil-(metil)karbamata (7.05 g, 15.9 mmol) u 200 mL CH2Cl2 dodana MCPBA (77%, 4.32 g, 19.3 mmol). Nakon miješanja 6 h, reakcijskoj smjesi je dodana zasićena otopina NaHCO3 i slojevi su odijeljeni. Organski dio je pran vodom i otopinom soli, te je sušen iznad Na2SO4 i uparen, pri čemu je dobiveno 7.05 g tert-butil-2-{2-[2-(2-metoksietil)-5-oksido-1H-imidazo[4,5-c]kinolin-1-il]etoksi} etil(metil)karbamata u obliku svjetle smeđe ulje.
Dio G
Otopina tert-butil-2-{2-[2-(2-metoksietil)-5-oksido-1H-imidazo[4,5-c]kinolin-1-il]etoksi} etil(metil)karbamata (7.05 g, 15.9 mmol) u 100 mL 1,2-dikloretana je zagrijana na 80°C i dodano je 5 mL koncentrirane otopine NH4OH. Uz brzo miješanje je u otopinu dodan čvrsti p-toluensulfonil-klorid (3.3 g, 17.5 mmol) u periodu od 10 minuta. Reakcijskoj smjesi je dodano još 5 mL koncentrirane otopine NH4OH te je zataljena u posudi koja podnosi povišen tlak i zagrijavanje je nastavljeno 4 sata. Reakcijska smjesa je zatim ohlađena i dodano je 100 mL CH2Cl2. Reakcijska smjesa je prana vodom, 1% otopinom Na2CO3 (3x), te otopinom soli. Organski dio je sušen iznad Na2SO4 i uparen, pri čemu je dobiveno 6.50 g tert-butil-2-{2-[4-amino-2-(2-metoksietil)-1H-imidazo[4,5-c]kinolin-1-il]etoksi} -etil(metil)karbamata u obliku smeđe pjene.
Dio H
tert-Butil-2-{2-[4-amino-2-(2-metoksietil)-1H-imidazo[4,5-c]kinolin-1-il]etoksi}-etil(metil)karbamatu (6.50 g, 14.7 mmol) koji je otopljen u 100 mL etanola je dodano 20 mL 2M HCl u etanolu i smjesa je zagrijavana uz refluksiranje i miješanje. Nakon 6 h je reakcijska smjesa ohlađena i filtrirana, te je dobivena gumasta krutina. Krutina je prana etanolom i eterom i sušena u vakuumu, pri čemu je dobivena hidrokloridna sol kao svjetlosmeđi prašak. Slobodna baza je dobivena otapanjem hidroklorida u 50 mL vode i djelovanjem s 5 mL koncentrirane otopine NH4OH. Vodena suspenzija je zatim ekstrahirana diklormetanom (5x50 mL). Spojeni organski slojevi su sušeni iznad Na2SO4 i upareni, pri čmu je dobiveno 3.93 g 2-(2-metoksietil)-1-{2-[2-(metilamino)etoksi]etil}-1H-imidazo[4,5-c]kinolin-4-amina u obliku tamnog praška
MS 344 (M+H)+
1H NMR (300 MHz, DMSO-d6) δ 8.07 (d, J=7.7 Hz, 1H), 7.62 (dd, J=8.2 Hz, 1H), 7.42 (ddd, J=1.0, 7.1, 8.2 Hz, 1H), 7.22 ddd, J=1.1, 7.1, 8.2 Hz, 1H), 6.498 (s, 2H), 4.75 (t, J=5.1 Hz, 2H), 3.83 (t, J=6.8 Hz, 4H), 3.35 (t, J=5.6 Hz, 2H), 3.30 (s, 3H), 3.21 (t, J=6.9 Hz, 2H), 2.45 (t, J=5.6 Hz, 2H), 2.12 (s, 3H).
Dio I
2-(2-Metoksietil)-1-{2-[2-(metilamino)etoksi]etil}-1H-imidazo[4,5-c]kinolin-4-amin (929 mg, 2.71 mmol) je u atmosferi dušika otopljen u 30 mL bezvodnog CH2Cl2 i ohlaenna 0°C, te je dodan fenil-izocijanat (300 μL, 2.76 mmol). Nakon miješanja preko noći, reakcijska smjesa je uparena pod sniženim tlakom. Čišćenjem kolonskom kromatografijom (SiO2, 3% metanol/kloroform zasićen vodenom otopinom NH4OH) dobiveno je 610 mg N-(2-{2-[4-amino-2-(metoksietil)-1H-imidazo[4,5-c]kinolin-1-il]etoksi} etil)-N'-feniluree, talište 184.8-185.8°C,
MS 463 (M+H)+;
1H NMR (300 MHz, DMSO-d6) δ 8.16 (s, 1H), 8.06 (d, J=7.7 Hz, 1H), 7.61 (dd, J=1.0, 8.3 Hz, 1H), 7.43-7.38 (m, 3H), 7.25-7.17 (m, 3H), 6.91 (t, J=7.3 Hz, 1H), 6.47 (s, 2H), 4.76 (t, J=5.0 Hz, 2H), 3.88 (t, J=5.1 Hz, 2H), 3.78 (t, J=6.8 Hz, 2H), 3.48 (t, J=5.2 Hz, 2H), 3.39 (t, J=5.4 Hz, 2H), 3.27 (s, 3H), 3.20 (t, J=6.8 Hz, 2H), 2.82 (s, 3H);
13C NMR (75 MHz, DMSO-d6) δ 155.6, 152.0, 151.9, 145.1, 140.9, 132.7, 128.5, 126.7, 126.6, 122.0, 121.4, 120.5, 120.5, 115.1, 70.5, 69.6, 69.4, 58.4, 47.7, 45.5, 35.4, 27.6;
Analiza, izračunato za C25H30N6O3•0.121 H2O: %C 64.62, %H 6.56, %N 18.08, nađeno %C 64.69, %H 6.65, %N 18.09.
Primjer 4
N-(2-{2-[4-amino-2-(2-metoksietil)- 6,7,8,9-tetrahidro-1H-imidazo[4,5-c]kinolin-1-il]etoksi} etil)-N'-fenilurea
[image]
Dio A
2-(2-Metoksietil)-1-{2-[2-(metilamino)etoksi]etil}-1H-imidazo[4,5-c]kinolin-4-amin (4.22 g, 12.3 mmol) je otopljen u 25 mL trifluoroctene kiseline i dodan je PtO2 (0.5 g). Reakcijska smjesa je potresana u atmosferi vodika (3 kg/cn2). Nakon 4 dana je dodano još 0.5 g PtO2 i hidriranje je nastavljeno još 3 dana. Reakcija je filtriana preko Celita i uparena pod sniženim tlakom te je dobiveno žuto ulje. Ulje je otopljeno u 50 mL vode te je ekstrahirano s 50 mL kloroforma. Organski dio je uklonjen i odbačen. Vodeni dio je zatim zalužen (pH~12) dodatkom 10% otopine NaOH. To je ekstrahirano kloroformom (6x50 mL) te su spojeni organski slojevi su_eni iznad Na2SO4 i upareni, a dobiveno je smee ulje. Smeđe ulje je otopljeno u 100 mL vrućeg metanola i dodan je 1 g aktivnog ugljena. Vruća otopina je filtrirana preko Celita i uparena do suha. Nastala gumasta krutina je uparena nekoliko puta iz etera i dobiveno je 3.19 g 2-(2-metoksietil)-1-{2-[2-(metilamino)etoksi]etil}-6,7,8,9-tetrahidro-1H-imidazo[4,5-c]kinolin-4-amina u obliku bjelkastog praška.
MS 348 (M+H)+;
1H NMR (300 MHz, CDCl3) δ 4.84 (s, 2H), 4.48 (t, J=5.7 Hz, 2H), 3.84 (t, J=6.7 Hz, 2H), 3.70 (t, J=5.7 Hz, 2H), 3.46 (t, J=5.1 Hz, 2H), 3.36 (s, 3H), 3.14 (t, J=6.7 Hz, 2H), 2.96 (m, 2H), 2.83 (m, 2H), 2.65 (t, J=5.1 Hz, 2H), 2.36 (s, 3H), 1.85 (m, 4H).
Dio B
2-(2-metoksietil)-1-{2-[2-(metilamino)etoksi]etil} -6,7,8,9-tetrahidro-1H-imidazo[4,5-c]kinolin-4-amin (750 mg, 2.16 mmol) je u atmosferi dušika otopljen u 30 mL bezvodnog CH2Cl2 i ohlađenna 0°C te je dodan fenil-izocijanat (239 μL, 2.20 mmol). Nakon miješanja preko noći, reakcijska smjesa je uparena pod sniženim tlakom. Kristalizacijom iz etil-acetata i diklormetana je dobiveno 170 mg N-(2-{2-[4-amino-2-(2-metoksietil)-6,7,8,9-tetrahidro-1H-imidazo[4,5-c]kinolin-1-il]etoksi} etil)-N'-feniluree, talište 167.7-170.0°C.
MS 467 (M+H)+;
1H NMR (300 MHz, DMSO-d6) δ 8.17 (s, 1H), 7.43 (d, J=7.6 Hz, 2H), 7.21 (t, J=7.9 Hz, 2H), 6.91 (t, J=7.3 Hz, 1H), 5.65 (s, 2H), 4.43 (t, J=5.0 Hz, 2H), 3.72 (t, .J=7.0 Hz, 2H), 3.70 (t. J=5.2 Hz, 2H), 3.46-3.41 (m, 4H), 3.24 (s, 3H), 3.07 (t, J=6.9 Hz, 2H), 2.92 (m, 2H), 2.85 (s, 3H), 2.64 (m, 2H), 1.72 (m, 4H);
13C NMR (75 MHz, DMSO-d6) δ 155.6, 152.0, 151.2, 149.3, 146.3, 140.9, 138.4, 128.5, 124.9, 122.0, 120.1, 105.5, 70.7, 70.5, 69.5, 58.4, 48.0, 44.6, 35.5, 32.8, 27.6, 23.8, 23.1, 23.0;
Analiza, izračunato za C25H34N6O3•0.121 H2O: %C 64.36, %H 7.35, %N 18.01, nađeno %C 64.04, %H 7.38, %N 18.02.
Primjer 5
N-(2-{2-[4-amino-2-(2-metoksietil)- 1H-imidazo[4,5-c]kinolin-1-il]etoksi} etil)morfolin-4-karboksamid
[image]
U atmosferi dušika je 1-[2-(2-aminoetoksi)etil]-2-(2-metoksietil)- 1H-imidazo[4,5-c]kinolin-4-amin (0.75 g, 2.3 mmol) otopljen u diklormetanu (30 mL) i dodan je trietilamin (0.64 mL, 4.6 mmol) uz blago zagrijavanje i intenzivno miješanje. Otopina je ohlađena u ledenoj kupelji i dokapan je 4-morfolinkarbonil-klorid (0.27 mL, 2.3 mmol). Ledena kupelj je uklonjena i reakcija je miješana još 4 sata. Reakcija je ugašena dodatkom zasićene otopine natrijevog bikarbonata (25 mL). Faze su odijeljene i organska faza je prana vodom (3x25 mL), otopinom soli (25 mL), sušena (Na2SO4), filtrirana i uparena, pri čemu je dobivena žuta pjena. Produkt je prekristaliziran iz diklormetana i etil-acetata. Kristali su razmuljeni s eterom (2x5 mL) da se ukloni zaostalo otapalo. Konačan produkt je sušen u vakkum-sušioniku i dobiveno je 200 mg N-(2-{2-[4-amino-2-(2-metoksietil)-1H-imidazo[4,5-c]kinolin-1-il]etoksi}etil)morfolin-4-karboksamida u obliku tamne kristalinične krutine, talište 164-166°C.
1H NMR (300 MHz, DMSO-d6) δ 8.06 (d, J=7.6 Hz, 2H), 7.61 (d, J=7.3 Hz, 2H), 7.42 (t, J=7.2 Hz, 1H), 7.23 (t, J=7.8 Hz, 1H), 6.51 (s, 2H), 6.33 (t, J=5.0 Hz, 1H), 4.74 (t, J=4.3 Hz, 2H), 3.83-3.81 (m, 4H), 3.49 (t, J=4.3 Hz, 4H), 3.33 (t, J=5.9 Hz, 2H), 3.30 (s, 3H), 3.21 (t, J=6.8 Hz, 2H), 3.14 (t, J=4.5 Hz, 4H), 3.08 (t, J=6.0 Hz, 2H);
13C NMR (75 MHz, DMSO-d6) δ 157.8, 151.9, 145.0, 132.7, 126.7, 126.6, 121.4, 120.5, 115.1, 70.4, 70.2, 69.2, 58.4, 45.5, 44.0, 27.6;
Analiza, izračunato za C25H34N6O3•0.121 H2O: %C 59.71, %H 6.83, %N 18.99, nađeno %C 59.71, %H 6.80, %N 18.78;
MS 443 (M+H)+.
Primjer 6
N-(2-{2-[4-amino-2-(2-metoksietil)- 1H-imidazo[4,5-c]kinolin-1-il]etoksi} etil)-N-metilmorfolin-4-karboksamid
[image]
U atmosferi dušika je 2-(2-metoksietil)-1-{2-[2-(metilamino)etoksi]etil}-1H-imidazo[4,5-c]kinolin-4-amin (802 mg, 2.34 mmol) otopljen u 30 mL diklormetana i ohlađen je na 0°C. Uz miješanje je dodan trietilamin (0.65 mL, 4.68 mmol) i morfolinkarbonil-klorid (273 μL, 2.34 mmol) te je reakcija ostavljena preko noći da se ugrije na sobnu temperaturu. Reakcija je ugašena dodatkom zasićene otopine NaHCO3 (30 mL) i diklormetana (30 mL). Organski sloj je odijeljen i pran vodom, otopinom soli, sušen iznad Na2SO4, i uparen pod sniženim tlakom. Čišćenjem kolonskom kromatografijom (SiO2, 2-5% metanol/diklormetan zasićen vodenom otopinom NH4OH) je dobiven produkt u obliku bezbojne pjene. Kristalizacijom iz etil-acetata je dobiveno 640 mg N-(2-{2-[4-amino-2-(2-metoksietil)-1H-imidazo[4,5-c]kinolin-1-il]etoksi} etil)N-metilmorfolin-4-karboksamida u obliku bijelih kristala, talište 121.8-122.3°C.
MS 457 (M+H)+.
1H NMR (300 MHz, DMSO-d6) δ 8.06 (dd, J=0.9, 8.3 Hz, 1H), 7.61 (dd, J=1.1, 8.3 Hz, 1H), 7.41 (ddd, J=1.3, 7.0, 8.1 Hz, 1H), 6.44 (s, 2H), 4.74 (t, J=5.2 Hz, 2H), 3.84 (t, J=5.2 Hz, 2H), 3.82 (t, J=6.9 Hz, 2H), 3.50-3.43 (m, 6H), 3.30 (s, 3H), 3.20 (t, J=6.9 Hz, 2H), 3.16 (t, J=5.5 Hz, 2H), 2.88 (t, J=4.7 Hz, 4H), 2.59 (s, 3H);
13C NMR (75 MHz, DMSO-d6) δ 163.8, 152.0, 151.8, 145.2, 132.7, 126.7, 121.3, 120.6, 115.1, 70.4, 69.4, 68.9, 66.1, 58.5, 49.1, 47.3, 45.5, 36.9, 27.7;
Analiza, izračunato za C23H32N6O4: %C 60.51, %H 7.07, %N 18.41, nađeno %C 60.56, %H 6.85, %N 18.19;
Primjeri 7-21
Dio A
Otopini tert-butil-2-{2-[(3-aminokinolin-4-il)amino]etoksi} etilkarbamata (3.46 g, 10.0 mmol) u 50 mL toluena je dodan trietil-ortovalerat (2.5 mL, 14.5 mmol) i reakcijska smjesa je zagrijavana uz refluksiranje. Zatim je dodan obrok od 25 mg piridinijevog hidroklroida i refluksiranje je nastavljeno 4 h. Reakcija je zatim uparena do suha pod sniženim tlakom. Ostatak je otopljen u 50 mL diklormetana i pran zasićenom otopinom NaHCO3, vodom i otopinom soli. Organski dio je sušen iznad Na2SO4 i uparen dajući zeleno ulje. Zeleno ulje je otopljeno u 50 mL vrućeg metanola i dodan je aktivni ugljen. Vruća otopina je filtrirana i uparena, pri čemu je dobiveno 4.12 g tert-butil-2-[2-(2-butil-1H-imidazo[4,5-c]kinolin-1-il)etoksi]etilkarbamata u obliku žutog ulja.
Dio B
Otopini tert-butil-2-[2-(2-butil-1H-imidazo[4,5-c]kinolin-1-il)etoksi]etilkarbamata (4.12 g, 10.0 mmol) u 50 mL diklormetana je dodana 3-klorperbenzojeva kiselina (MCPBA, 77%, 2.5 g, 11.2 mmol). Nakon miješanja 5 h, reakcijskoj smjesi je dodana zasićena otopina NaHCO3 i slojevi su odijeljeni. Organski dio je pran vodom i sušen je iznad Na2SO4 te je uparen dajući 3.68 g tert-butil-2-[2-(2-butil-5-oksido-1H-imidazo[4,5-c]kinolin-1-il)etoksi]etilkarbamat u obliku svjetlosmeđe pjene.
Dio C
Otopina tert-butil-2-[2-(2-butil-5-oksido-1H-imidazo[4,5-c]kinolin-1-il)etoksi]-etilkarbamata (3.68 g, 8.60 mmol) u 100 mL 1,2-dikloretana je zagrijana na 80°C i dodano je 10 mL koncentrirane otopine NH4OH. U otopinu je uz brzo miješanje dodan je p-toluensulfonil-klorid (1.87 g, 9.81 mmol) u periodu od 10 minuta. Reakcijska smjesa je zatim zataljena u posudi koja podnosi povišeni tlak i zagrijavana 2 h. Reakcijska smjesa je zatim ohlađena i dodano je 100 mL diklormetana. Reakcijska smjesa je zatim prana vodom, 1% otopinom Na2CO3 (3x) i otopinom soli. Organski dio je sušen iznad Na2SO4 i uparen pri čemu je dobiveno 3.68 g tert-butil-2-[2-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)etoksi]etilkarbamata u obliku svjetlosmeđe pjene.
Dio D
tert-Butil-2-[2-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)etoksi]etilkarbamat (3.68 g, 8.60 mmol) je suspendiran u 20 mL 2M HCl u etanolu i smjesa je zagrijavana uzrefluksiranje i miješanje. Nakon 3 h je reakcijska smjesa uparena i dobivena je krutina. Krutina je razmuljena u vrućem etanolu (50 mL) i filtrirana, te je dobiveno 2.90 g produkta koji je hidrokloridna sol. Slobodna baza je dobivena otapanjem hidroklorida u 50 mL vode i djelovanjem s koncentriranim NH4OH. Vodena suspenzija je ekstrahirana diklormetanom (3x50 mL). Spojeni organski slojevi su sušeni iznad Na2SO4 i upareni, te je dobiven 1-[2-(2-aminoetoksi)etil]-2-butil-1H-imidazo[4,5-c]kinolin-4-amina u obliku tamnog praška.
MS 328 (M+H)+.
1H NMR (300 MHz, CDCl3) δ d 7.95 (d, J=8.3 Hz, 1H), 7.83 (d, J=8.4 Hz, 1H), 7.50 (m, 1H), 7.30 (m, 1H), 5.41 (s, 2H), 4.69 (t, J=5.6 Hz, 2H), 3.93 (t, J=5.6 Hz, 2H), 3.39 (t, J-5.1 Hz, 2H), 2.97 (t, J=7.9 Hz, 2H), 2.76 (t, J=5.1 Hz, 2H), 1.89 (m, 2H), 1.52 (m, 2H), 1.26 (_širok s, 2H), 1.01 (t, J=7.3 Hz, 3H).
Dio E
Spojevi iz donje tablice su pripravljeni prema sintetskoj metodi iz koraka (7) Reakcijska sheme I koristeći sljedeću opću metodu.
Izocijanat (84 μmol) je dodan u epruvetu koja sadrži otopinu 1-[2-(2-aminoetoksi)etil]-2-butil-1H-imidazo[4,5-c]kinolin-4-amina (25 mg, 76 μmol) u diklormetanu (5 mL). Epruveta je začepljena i smještena u protresivač pri sobnoj temperaturi kroz 20 h. Otapalo je uklonjeno vakuum centrifugiranjem. Ostatak je čišćen semipreparativnom HPLC koristeći gore opisanu metodu. Donja tablica pokazuje strukture slobodne baze i opaženu točnu masu (M+H).
[image] [image] [image] [image] [image]
Primjeri 22-36
Dio A
Koristeći opću metodu iz Dijela A Primjera 7-21, 4-piperidin-etanol (10 g, 77.4 mmol) je reagirao s di-tert-butil-dikarbonatom (17.7 g, 81.3 mmol) i dobiveno je 13.1 g tert-butil-4-(2-hidroksietil)piperidin-1-karboksilata u obliku bistrog ulja.
Dio B
Jod (7.97 g) je u tri obroka dodan u otopinu imidazola (3.89 g, 57.1 mmol) i trifenilfosfina (14.98 g, 57.1 mmol) i diklormetana (350 mL). Nakon 5 minuta je dodana otopina materijala iz Dijela A u diklormetanu (70 mL). Reakcijska smjesa je miješana pri sobnoj temperaturi preko noći. Dodano je još jodida i reakcija je miješana pri sobnoj temperaturi 1 h. Reakcijska smjesa je prana zasićenom otopinom natrijevog tiosulfata (2x) i otopinom soli, sušena iznad natrijevog sulfata, filtrirana te je uparena pod sniženim tlakom pri čemu zasotaje ulje. Ostatak je čišćen kolonskom kromatograifjom (silikagel, euliranje s 20% etil-acetatom u heksanu) i dobiveno je 15.52 g tert-butil-4-(2-jodetil)piperidin-1-karboksilata u obliku blijedožutog ulja.
Dio C
U atmosferu dušika je 2-(1H-imidazo[4,5-c]kinolin-1-il)butan-1-ol (6.5 g, 26.9 mmol) dodan u tri obroka u suspenziju natrijevog hidrida (1.4 g, 60%, 35.0 mmol) u bezvodnom N,N-dimetilformamidu. Reakcijska smjesa je ostavljena uz miješanje 45 minuta u koje vrijeme je prestalo oslobađanje plina. Dokapan je tert-butil-4-(2-jodetil)piperidin-1-karboksilat (10.05 g, 29.6 mmol) u periodu od 15 minuta. Reakcijska smjesa je ostavljena uz miješanje pri sobnoj temperaturi 2.5 h, te je zagrijavana pri 100°C preko noći. HPLC analiza je pokazala da je reakcija završena oko 35%. Dodana je zasićena otopina amonijevog klorida i nastala smjesa je ostavljena uz miješanje 20 minuta, te je ekstrahirana etil-acetatom (2x). Ekstrakti etil-acetat su prani vodom (2x) zatim otopinom soli, spojeni, sušen iznad natrijevog sulfata, filtrirani i upareni pod sniženim tlakom u dobiveno je smeđe ulje. Ulje je čišćeno kolonskom kromatografijom (silikagel, eluirano s 30% etil-acetatom u heksanu, zatim s 50% etil-acetatom u heksanu, te s etil-acetatom) i dobiveno je 2.2 g tert-butil-4-{2-[2-(2-(1H-imidazo[4,5-c]kinolin-1-il)butoksi]etil} piperidin-1-karboksilata u obliku ulja.
Dio D
Koristeći opću metodu iz Dijela H Primjera 7-21, materijal iz Dijela C je oksidiran i dobiven je tert-butil-4-{2-[2-(5-oksido-1H-imidazo[4,5-c]kinolin-1-il)but-oksi]etil} piperidin-1-karboksilat u obliku ulja.
Dio E
Otopina amonijevog hidroskida (20 mL) je dodana u otopinu materijala iz Dijela D u diklormetanu (10 mL). Dodana je otopina tosil-klorida (0.99 g, 5.2 mmol) u diklormetanu (10 mL) u periodu od 5 minuta. Nastala dvofazna reakcijska smjesa je ostavljena da se miješa preko noći. Reakcijska smjesa je razrijeđena kloroformom i zasićenom otopinom natrijevog bikarbonata. Slojevi su odijeljeni. Organski sloj je sušen iznad natrijevog sulfata, filtriran i uparen pod sniženim tlakom i dobiveno je smeđe staklo. Taj materijal je čišćen kolonskom kromatografijom (silikagel, eluirano prvo s 50% etil-acetatom u heksanu, a zatim s etil-acetatom) i dobiveno je 1.0 g tert-butil-4-{2-[2-(4-amino-1-H-imidazo[4,5-c]-kinolin-1-il)butoksi]etil} piperidin-1-karboksilata u obliku žute staklaste pjene.
Dio F
U atmosferi dušika su pomiješani tert-butil-4-{2-[2-(4-amino1H-imidazo[4,5-c]kinolin-1-il)butoksi]etil} piperidin-1-karboksilat (1.00 g, 2.1 mmol) i 2M etanolna otopina klorovodične kiseline (10 mL, 20 mmol) i otopina je miješana pri sobnoj temperaturi 14 sati. Otapalo je uklonjeno u vakuumu i nastala krutina je otopljena u vodi. Dodana je zasićena otopina natrijevog karbonata do dostizanja pH 10. Nakon ekstrakcije diklormetanom (3x), organske frakcije su spojene, prane otopinom soli, sušene (Na2SO4), filtrirane i glavnina otapala je uklonjena u vakuumu. Dodan je heksan i nastaje talog. Vakuum filtracijom je dobiveno 0.5 g 1-{1-[(2-piperidin-4-iletoksii)metil]propil}-1-H-imidazo[4,5-c]kinolin-4-amina u obliku obojenog praška.
1H NMR (300 MHz, DMSO-d6) δ 8.34 (širok s, 1H), 8.19 (d, J=8.49 Hz, 1H), 7.61 (dd, J=8.31, 1.13 Hz, 1H), 7.45-7.39 (m, 1H), 7.25-7.19 (m, 1H), 6.55 (s, 2H), 5.25-5.15 (m, 1H), 4.00-3.80 (m, 2H), 3.5-3.3 (m, 2H), 2.8-2.64 (m, 2H), 2.22-2.11 (m, 2H), 2.09-1.99 (m, 2H), 1.8-1.63 (širok s, 1H), 1.37-1.0 (m, 5H), 0.95-0.7 (m, 5H);
13C NMR (75 MHz, DMSO-d6) δ 152.8, 145.8, 140.6, 133.0, 127.8, 127.0, 126.9, 121.3, 121.0, 115.5, 71.8, 68.1, 58.4, 46.1, 36.3, 33.1, 32.7, 24.5, 9.9;
MS (CI) m/e 368.2459 (368.2450 izračunato za C21H30N5O.
Dio G
Spojevi iz donje tablice su pripravljeni prema sintetskoj metodi iz koraka (7) Reakcijska sheme I koristeći sljedeću opću metodu.
Izocijanat (75 μmol) je dodan u epruvetu koja sadrži otopinu 1-{1-[(2-piperidin-4-iletoksii)metil]propil}-1-H-imidazo[4,5-c]kinolin-4-amina (25 mg, 68 μmol) u diklormetanu (5 mL). Epruveta je začepljena i smještena u potresivač pri sobnoj temperaturi kroz 20 h. Otapalo je uklonjeno vakuum centrifugiranjem. Ostatak je čišćen semipreparativnom HPLC koristeći gore opisanu metodu. Donja tablica pokazuje strukture slobodne baze i opaženu točnu masu (M+H).
[image] [image] [image]
Primjeri 37-44
Dio A
Otopini tert-butil-2-{2-[(3-aminokinolin-4-il)amino]etoksi} etilkarbamata (6.92 g, 20.0 mmol) u 100 mL toluena je dodan trietil-ortoformijat (4.65 mL, 28.0 mmol) i reakcijska smjesa je zagrijavana uz refluksiranje. Zatim je dodano 100 mg piridinijevog hidroklorida i refluksiranje je nastavljeno 2 h. Reakcija je uparena do suha pod sniženim tlakom. Ostatak je otopljen u 200 mL diklormetana i pran zasićenom otopinom NaHCO3, vodom i otopinom soli. Organski dio je sušen iznad Na2SO4 i uparen, te je dobiveno zeleno ulje. Zeleno ulje je otopljeno u 200 mL vrućeg metanola i dodan je aktivni ugljen. Vruća otopina je filtrirana i uparena, pri čemu je dobiveno 5.25 g tert-butil-2-[2-(1H-imidazo[4,5-c]kinolin-1-il)etoksi]etilkarbamata u obliku svjetložutog ulja.
Dio B
Otopini tert-butil-2-[2-(1H-imidazo[4,5-c]kinolin-1-il)etoksi]etilkarbamata (5.25 g, 14.7 mmol) u 150 diklormetana je dodana MCPBA (77%, 3.63 g, 16.3 mmol). Nakon miješanja preko noći, reakcijskoj smjesi je dodana zasićena otopina NaHCO3 i slojevi su odijeljeni. Organski dio je pran vodom i sušen je iznad Na2SO4 i uparen dajući 4.60 g tert-butil-2-[2-(5-oksido-1H-imidazo[4,5-c]kinolin-1-il)etoksi]-etilkarbamata u obliku svjetlosmeđe pjene.
Dio C
Otopina tert-butil-2-[2-(5-oksido-1H-imidazo[4,5-c]kinolin-1-il)etoksi]etilkarbamata (4.6 g, 12.4 mmol) u 150 mL 1,2-dikloretana je zagrijana na 80°C i dodano je 10 mL koncentrirane otopine NH4OH. U otopinu je uz brzo miješanje dodan je p-toluensulfonil-klorid (2.71 g, 14.2 mmol) u periodu od 10 minuta. Reakcijskoj smjesi je dodano još 2 mL koncentrirane otopine NH4OH te je zatim zataljena u posudi koja podnosi povišeni tlak i zagrijavana je 3 h. Reakcijska smjesa je ohlađena i dodano je 100 mL diklormetana. Reakcijska smjesa je zatim prana vodom, 1% otopinom Na2CO3 (3x) i otopinom soli. Organski dio je sušen iznad Na2SO4 i uparen, pri čemu je dobiveno 4.56 g tert-butil-2-[2-(4-amino-1H-imidazo[4,5-c]kinolin-1-il)etoksi]etilkarbamata u obliku svjetlosmeđe pjene.
Dio D
tert-Butil-2-[2-(4-amino-1H-imidazo[4,5-c]kinolin-1-il)etoksi]etilkarbamat (4.56 g, 12.3 mmol) je otopljen u 100 mL etanola i dodano je 30 mL 2M HCl u etanolu i smjesa je zagrijavana uz refluksiranje i miješanje. Nakon 3 h je reakcijska smjesa uparena i dobivena je krutina. Krutina je razmuljena u etanolu (100 mL) i filtrirana čime je dobivena hidrokloridna sol. Slobodna baza je dobivena otapanjem hidroklorida u 50 mL vode i 5 mL koncentriranog NH4OH. Vodena suspenzija je ekstrahirana diklormetanom (3x50 mL). Spojeni organski slojevi su sušeni iznad Na2SO4 i upareni, te je dobiveno 1.35 1-[2-(2-aminoetoksi)etil]- 1H-imidazo[4,5-c]kinolin-4-amina u obliku tamnog praška.
MS 272 (M+H)+.
1H NMR (300 MHz, CDCl3) δ d 7.98 (d, J=8.2 Hz, 1H), 7.88 (s, 1H), 7.84 (d, J=8.4 Hz, 1H), 7.54 (m, 1H), 7.32 (m, 1H), 5.43 (s, 2H), 4.74 (t, J=5.2 Hz, 2H), 3.97 (t, J=5.2 Hz, 2H), 3.42 (t, J=5.1 Hz, 2H), 2.78 (t, J=5.1 Hz, 2H), 1.10 (širok s, 2H).
Dio E
Spojevi iz donje tablice su pripravljeni prema sintetskoj metodi iz koraka (7) Reakcijska sheme I koristeći sljedeću opću metodu.
Izocijana1-[2-(2-Aminoetoksi)etil]-1H-imidazo[4,5-c]kinolin-4-amin (20 mg, 74 μmol) je pomiješan u epruveti s 1-metil-2-pirolidinom (5 mL) te je sonificiran uz zagrijavanje da bi nastala otopina. Dodan je izocijanat (81 μmol) i epruveta je začepljena i smještena u potresivač pri sobnoj temperaturi kroz 20 h. Otapalo je uklonjeno vakuum centrifugiranjem. Ostatak je čišćen semipreparativnom HPLC koristeći gore opisanu metodu. Donja tablica pokazuje strukture slobodne baze i opaženu točnu masu (M+H).
[image] [image]
INDUKCIJA CITOKINA U HUMANIM STANICAMA
Humane krvne stanice su korištene in vitro da se procjeni indukcija citokina spojevima iz izuma. Aktivnost je zasnovana na mjerenju interferona i faktora (α) tumorne nekroze (IFN odnosno TFN) izlučenih u medij, kao što je opisano od Testerman et al., u "Cytokine Induction by the Imunomodulators Imiquimod and S-27609", Journal of Leukocyte Biology, 58, 365-372 (rujan, 1995).
Priprava krvnih stanica za kulturu
Krv izvađena iz vene zdravih ljudi je smještena u “EDTA epruvete”. Mononuklearne stanice periferne krvi (PBM, engl. peripheral blood mononuclear cells) su izdvojene centrifugiranjem gradijenta gustoće korištenjem Histopaque®-1077 (Sigma chemicals, St. Louis, MO). PMBC su suspendirane pri 3-4 x 106 stanica/mL u RPMI 1640 mediju koji sadrži 10% fetalni goveđi serum, 2 mM L-glutamin i 1% otopina penicilin/streptomycina (RPMI komplet). Suspenzija PCMB je dodana na sterilnu ploču za kulturu s 48 jažica ravnog dna (Costar, Cambridge, MA ili Becton Dickinson Labware, Lincoln Park, NJ) koji sadrži jednaki volumen RPMI kompletnog medija koji sadrži testirani spoj.
Priprava spojeva
Spojevi su otopljeni u dimetlsulfoksidu (DMSO). Koncentracija u DMSO ne treba prelaziti konačnu koncentraciju od 1% za dodatak u jažice za kulturu
Inkubacija
Otopina testiranog spoja je dodana u prvu jažicu koja sadrži RPMI, te su izvedena potpuna ili djelomična razrjeđenja u jažicama, Zatim je dodana suspenzija PBMC u jažice u jednakom volumenu, čime se dobivaju koncentracije testiranog spoja u željenom rasponu. Konačna koncentracija PBMC suspenzije je 1.5-2 x 106 stanica/mL. Ploče su prekrivene plastičnim poklopcem, blago su pomiješane i inkubirane su 18 do 24 sata pri 37°C i atmosferi 5% ugljičnog dioksida.
Odvajanje
Nakon inkubacije, ploče su centrifugirane su 5-10 minuta pri 1000 rpm (~200xg) pri 4°C. Supernatant kulture je uklonjen sterilnom polipropilenskom pipetom i prenešen je u sterilne polipropilenske epruvetice. Uzorci su održavani pri -30 do -70°C do analize. Uzorci su analizirani na interferon (α) i na faktor tumorske nekroze (α) pomoću ELISA.
Analiza pomoću ELISA testa interferona (α) i faktora tumorske nekroze (α)
Koncentracija interferon (α) je određena s ELISA korištenjem "Human Muti-Species" kita od PBL Biomedical Laboratories, New Brunswick, NJ. Rezultati su izrađeni u pg/mL.
Koncentracija faktora tumorske nekroze (α) (TFN) je određena s ELISA korištenjem kitova koji se mogu pribaviti od Genzyme, Cambridge, MA; R&D Systems, Minneapolis, MN; ili Pharmingen, San Diego, CA. Rezultati su izrađeni u pg/mL.
Donja tablica prikazuje najnižu koncentraciju za koju je nađeno da inducira interferon i najnižu koncentraciju za koju je nađeno da inducira faktor tumorne nekroze za svaki spoj. "*” pokazuje da nije zamjećena indukcija pri bilo kojoj testiranoj koncentraciji, općenito je najviša testirana koncentracija iznosila 10 ili 30μM.
[image] [image]
Claims (23)
1. Spoj formule (I)
[image]
(I)
naznačeno time da
X jeste -CHR5, -CHR5-alkil ili -CHR5-alkenil,
R1 je odabran iz skupine koju čine:
-R4-NR8-CR3-NR5-Z-R6-alkil,
-R4-NR8-CR3-NR5-Z-R6-alkenil,
-R4-NR8-CR3-NR5-Z-R6-aril,
-R4-NR8-CR3-NR5-Z-R6-heteraril,
-R4-NR8-CR3-NR5-Z-R6-heterociklil,
-R4-NR8-CR3-NR5R7,
-R4-NR8-CR3-NR9-Z-R6-aril,
-R4-NR8-CR3-NR9-Z-R6-alkenil,
-R4-NR8-CR3-NR9-Z-R6-aril,
-R4-NR8-CR3-NR9-Z-R6-heteraril,
-R4-NR8-CR3-NR9-Z-R6-heterociklil,
R2 je odabran iz sljedeće skupine:
-vodik
-alkil,
-alkenil,
-aril,
-heteroaril,
-heterociklil,
-alkil-Y-alkil,
-alkil-Y-alkenil,
-alkil-Y-aril, te
-alkil ili alkenil supstituiran jednim ili s više supstituenata odabranih iz sljedeće skupine:
-OH,
-halogen
-N(R5)2,
-CO-N(R5)2,
-CO-C1-10alkil,
-CO-O-C1-10alkil,
-N3,
-aril,
-heteroaril,
-heterociklil,
-CO-aril, te
-CO-heteroaril;
svaki R3 jeste =O ili =S,
svaki R4je neovisno alkil ili alkenil koji mogu biti prekinuti s jednom ili više -O- skupina,
svaki R5 jeste neovisno H ili C1-10alkil,
R6 jeste veza, alkil ili alkenil, koji mogu biti prekinuti s jednom ili više -O- skupina,,
R7 jeste H,C1-10alkil koji može biti prekinut heteroatomom ili R7 može biti spojen s R5 i tvoriti prsten,
R8jeste H,C1-10alkil ili arilalil, ili R4 i R8 mogu biti spojeni i tvoriti prsten,
svaki Y neovisno jeste -O- ili -S(O)0-2,
R9jeste C1-10alkil koji može biti spojen s R8 i tvoriti prsten,
Z jeste veza, -CO- ili -SO2-,
n jeste 0 do 4; te
svaki R je neovisno odabran iz sljedeće skupine: C1-10 alkil, C1-10alkoksi, hidroksi, halogen i trifluormetil,
ili odgovarajuća farmaceutski prihvatljiva sol.
2. Spoj ili sol iz patentnog zahtjeva 1, naznačeno time da X jeste -CH(alkil)(alkil)-, gdje alkilne skupine mogu biti iste ili različite.
3. Spoj ili sol iz patentnog zahtjeva 1, naznačeno time da X jeste -CH2-CH2-.
4. Spoj ili sol iz patentnog zahtjeva 1, naznačeno time da X jeste -CH(C2H5(CH2)-.
5. Spoj ili sol iz patentnog zahtjeva 1, naznačeno time da R2 jeste H.
6. Spoj ili sol iz patentnog zahtjeva 1, naznačeno time da R2 jeste alkil.
7. Spoj ili sol iz patentnog zahtjeva 1, naznačeno time da R2 jeste alkil-O-alkil.
8. Spoj, naznačeno time da je odabran iz skupine koju čine:
N-(2-{2-[4-amino-2-(2-metoksietil)- 1H-imidazo[4,5-c]kinolin-1-il]etoksi} etil)-N'-fenilurea,
N-(2-{2-[4-amino-2-(2-metoksietil)-6,7,8,9-1H-imidazo[4,5-c]kinolin-1-il]etoksi} etil)-N'-fenilurea,
N-(2-{2-[4-amino-2-(2-metoksietil)- 1H-imidazo[4,5-c]kinolin-1-il]etoksi} etil)morfolin-4-karboksamid
N-(2-{2-[4-amino-2-(2-metoksietil)- 1H-imidazo[4,5-c]kinolin-1-il]etoksi} etil)-N-metilmorfolin-4-karboksamid, te
N-(2-{2-[4-amino-2-(2-metoksietil)- 6,7,8,9-tetrahidro-1H-imidazo[4,5-c]kinolin-1-il]etoksi} etil)-N'-fenilurea,
ili odgovarajuća farmaceutski prihvatljiva sol.
9. Spoj formule (I)
[image]
(II)
naznačeno time da
X jeste -CHR5, -CHR5-alkil ili -CHR5-alkenil,
R1 je odabran iz skupine koju čine:
-R4-NR8-CR3-NR5-Z-R6-alkil,
-R4-NR8-CR3-NR5-Z-R6-alkenil,
-R4-NR8-CR3-NR5-Z-R6-aril,
-R4-NR8-CR3-NR5-Z-R6-heteraril,
-R4-NR8-CR3-NR5-Z-R6-heterociklil,
-R4-NR8-CR3-NR5R7,
-R4-NR8-CR3-NR9-Z-R6-aril,
-R4-NR8-CR3-NR9-Z-R6-alkenil,
-R4-NR8-CR3-NR9-Z-R6-aril,
-R4-NR8-CR3-NR9-Z-R6-heteraril,
-R4-NR8-CR3-NR9-Z-R6-heterociklil,
R2 je odabran iz sljedeće skupine:
-vodik
-alkil,
-alkenil,
-aril,
-heteroaril,
-heterociklil,
-alkil-Y-alkil,
-alkil-Y-alkenil,
-alkil-Y-aril, te
-alkil ili alkenil supstituiran jednim ili s više supstituenata odabranih iz sljedeće skupine:
-OH,
-halogen
-N(R5)2,
-CO-N(R5)2,
-CO-C1-10alkil,
-CO-O-C1-10alkil,
-N3,
-aril,
-heteroaril,
-heterociklil,
-CO-aril, te
-CO-heteroaril;
svaki R3 jeste =O ili =S,
svaki R4je neovisno alkil ili alkenil koji može biti prekinut s jednom ili više -O- skupina,
svaki R5 jeste neovisno H ili C1-10alkil,
R6 jeste veza, alkil ili alkenil, koji mogu biti prekinuti s jednom ili više -O- skupina,,
R7 jeste H,C1-10alkil koji može biti prekinut heteroatomom ili R7 može biti spojen s R5 i tvoriti prsten,
R8jeste H,C1-10alkil ili arilalil, ili R4 i R8 mogu biti spojeni i tvoriti prsten,
svaki Y neovisno jeste -O- ili -S(O)0-2,
R9jeste C1-10alkil koji može biti spojen s R8 i tvoriti prsten,
Z jeste veza, -CO- ili -SO2-,
n jeste 0 do 4; te
svaki R je neovisno odabran iz sljedeće skupine: C1-10 alkil, C1-10alkoksi, hidroksi, halogen i trifluormetil,
ili odgovarajuća farmaceutski prihvatljiva sol.
10. Spoj ili sol iz patentnog zahtjeva 9, naznačeno time da R2 jeste H ili alkil.
11. Spoj ili sol iz patentnog zahtjeva 9, naznačeno time da R2 jeste alkil-O-alkil.
12. Farmaceutski pripravak, naznačeno time da sadrži farmaceutski učinkovitu količinu spoja iz patentnog zahtjeva 1 i farmaceutski prihvatljiv nosač.
13. Metoda indukcije biosinteze citokina u životinji, naznačeno time da sadrti davanje životinjama učinkovite količine spoja iz patentnog zahtjeva 1.
14. Metoda iz patentnog zahtjeva 13, naznačeno time da citokin jeste IFN-α
15. Metoda tretmana virusne infekcije u životinji, naznačeno time da sadrži davanje životinjama učinkovite količine spoja iz patentnog zahtjeva 1.
16. Metoda tretmana neoplastične bolesti u životinji, naznačeno time da sadrži davanje životinjama učinkovite količine spoja iz patentnog zahtjeva 1.
17. Spoj formule (III)
[image]
(III)
naznačeno time da
X jeste -CHR5, -CHR5-alkil ili -CHR5-alkenil,
R1 je odabran iz skupine koju čine:
-R4-NR8-CR3-NR5-Z-R6-alkil,
-R4-NR8-CR3-NR5-Z-R6-alkenil,
-R4-NR8-CR3-NR5-Z-R6-aril,
-R4-NR8-CR3-NR5-Z-R6-heteraril,
-R4-NR8-CR3-NR5-Z-R6-heterociklil,
-R4-NR8-CR3-NR5R7,
-R4-NR8-CR3-NR9-Z-R6-aril,
-R4-NR8-CR3-NR9-Z-R6-alkenil,
-R4-NR8-CR3-NR9-Z-R6-aril,
-R4-NR8-CR3-NR9-Z-R6-heteraril,
-R4-NR8-CR3-NR9-Z-R6-heterociklil,
R2 je odabran iz sljedeće skupine:
-vodik
-alkil,
-alkenil,
-aril,
-heteroaril,
-heterociklil,
-alkil-Y-alkil,
-alkil-Y-alkenil,
-alkil-Y-aril, te
-alkil ili alkenil supstituiran jednim ili s više supstituenata odabranih iz sljedeće skupine:
-OH,
-halogen
-N(R5)2,
-CO-N(R5)2,
-CO-C1-10alkil,
-CO-O-C1-10alkil,
-N3,
-aril,
-heteroaril,
-heterociklil,
-CO-aril, te
-CO-heteroaril;
svaki R3 jeste =O ili =S,
svaki R4je neovisno alkil ili alkenil koji može biti prekinut s jednom ili više -O- skupina,
svaki R5 jeste neovisno H ili C1-10alkil,
R6 jeste veza, alkil ili alkenil, koji mogu biti prekinuti s jednom ili više -O- skupina,,
R7 jeste H,C1-10alkil koji može biti prekinut heteroatomom ili R7 može biti spojen s R5 i tvoriti prsten,
R8jeste H,C1-10alkil ili arilalil, ili R4 i R8 mogu biti spojeni i tvoriti prsten,
R9jeste C1-10alkil koji može biti spojen s R8 i tvoriti prsten,
svaki Y neovisno jeste -O- ili -S(O)0-2,
Z jeste veza, -CO- ili -SO2-,
n jeste 0 do 4; te
svaki R je neovisno odabran iz sljedeće skupine: C1-10 alkil, C1-10alkoksi, hidroksi, halogen i trifluormetil,
ili odgovarajuća farmaceutski prihvatljiva sol.
18. Spoj formule (IV)
[image]
(IV)
nanačeno time da
X jeste -CHR5, -CHR5-alkil ili -CHR5-alkenil,
R1 je odabran iz skupine koju čine:
-R4-NR8-CR3-NR5-Z-R6-alkil,
-R4-NR8-CR3-NR5-Z-R6-alkenil,
-R4-NR8-CR3-NR5-Z-R6-aril,
-R4-NR8-CR3-NR5-Z-R6-heteraril,
-R4-NR8-CR3-NR5-Z-R6-heterociklil,
-R4-NR8-CR3-NR5R7,
-R4-NR8-CR3-NR9-Z-R6-aril,
-R4-NR8-CR3-NR9-Z-R6-alkenil,
-R4-NR8-CR3-NR9-Z-R6-aril,
-R4-NR8-CR3-NR9-Z-R6-heteraril,
-R4-NR8-CR3-NR9-Z-R6-heterociklil,
svaki Y neovisno jeste -O- ili -S(O)0-2,
Z jeste veza, -CO- ili -SO2-,
svaki R4je neovisno jeste alkil ili alkenil koji mogu biti prekinuti s jednom ili više -O- skupina,
svaki R5 jeste neovisno H ili C1-10alkil,
R6 jeste veza, alkil ili alkenil, koji mogu biti prekinuti s jednom ili više -O- skupina,,
R7 jeste H,C1-10alkil koji može biti prekinut heteroatomom ili R7 može biti spojen s R5 i tvoriti prsten,
R8jeste H,C1-10alkil ili arilalil, ili R4 i R8 mogu biti spojeni i tvoriti prsten,
R9jeste C1-10alkil koji može biti spojen s R8 i tvoriti prsten,
n jeste 0 do 4; te
svaki R je neovisno odabran iz sljedeće skupine: C1-10 alkil, C1-10alkoksi, hidroksi, halogen i trifluormetil,
ili odgovarajuća farmaceutski prihvatljiva sol.
19. Farmaceutski pripravak, naznačeno time da sadrži farmaceutski učinkovitu količinu spoja iz patentnog zahtjeva 9 i farmaceutski prihvatljiv nosač.
20. Metoda indukcije biosinteze citokina u životinji, naznačeno time da sadrži davanje životinjama učinkovite količine spoja iz patentnog zahtjeva 9.
21. Metoda iz patentnog zahtjeva 20, naznačeno time da citokin jeste IFN-α
22. Metoda tretmana virusne infekcije u životinji, naznačeno time da sadrži davanje životinjama učinkovite količine spoja iz patentnog zahtjeva 9.
23. Metoda tretmana neoplastične bolesti u životinji, naznačeno time da sadrži davanje životinjama učinkovite količine spoja iz patentnog zahtjeva 9.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25421800P | 2000-12-08 | 2000-12-08 | |
PCT/US2001/046696 WO2002046191A2 (en) | 2000-12-08 | 2001-12-06 | Urea substituted imidazoquinoline ethers |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20030466A2 true HRP20030466A2 (en) | 2004-06-30 |
Family
ID=22963391
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20030463A HRP20030463A2 (en) | 2000-12-08 | 2003-06-06 | Heterocyclic ether substited imidazoquinolines |
HR20030462A HRP20030462A2 (en) | 2000-12-08 | 2003-06-06 | Aryl ether substituted imidazoquinolines |
HR20030461A HRP20030461A2 (en) | 2000-12-08 | 2003-06-06 | Amido ether substituted imidazoquinolines |
HR20030467A HRP20030467B1 (hr) | 2000-12-08 | 2003-06-06 | Tioeterom supstituirani imidazokinolini |
HR20030466A HRP20030466A2 (en) | 2000-12-08 | 2003-06-06 | Urea substituted imidazoquinoline ethers |
HR20030464A HRP20030464A2 (en) | 2000-12-08 | 2003-06-06 | Sulfonamido ether substituted imidazoquinolines |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20030463A HRP20030463A2 (en) | 2000-12-08 | 2003-06-06 | Heterocyclic ether substited imidazoquinolines |
HR20030462A HRP20030462A2 (en) | 2000-12-08 | 2003-06-06 | Aryl ether substituted imidazoquinolines |
HR20030461A HRP20030461A2 (en) | 2000-12-08 | 2003-06-06 | Amido ether substituted imidazoquinolines |
HR20030467A HRP20030467B1 (hr) | 2000-12-08 | 2003-06-06 | Tioeterom supstituirani imidazokinolini |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20030464A HRP20030464A2 (en) | 2000-12-08 | 2003-06-06 | Sulfonamido ether substituted imidazoquinolines |
Country Status (32)
Country | Link |
---|---|
US (8) | US6670372B2 (hr) |
EP (6) | EP1341789A2 (hr) |
JP (7) | JP2004523498A (hr) |
KR (6) | KR20040047733A (hr) |
CN (6) | CN1252070C (hr) |
AR (6) | AR035665A1 (hr) |
AT (3) | ATE353895T1 (hr) |
AU (12) | AU3249702A (hr) |
BR (6) | BR0116052A (hr) |
CA (6) | CA2436980C (hr) |
CY (2) | CY1105586T1 (hr) |
CZ (6) | CZ295848B6 (hr) |
DE (3) | DE60117859T2 (hr) |
DK (3) | DK1343784T3 (hr) |
EE (6) | EE200300272A (hr) |
ES (3) | ES2260323T3 (hr) |
HK (3) | HK1064383A1 (hr) |
HR (6) | HRP20030463A2 (hr) |
HU (6) | HUP0400710A2 (hr) |
IL (6) | IL156043A0 (hr) |
MX (6) | MXPA03004972A (hr) |
NO (6) | NO20032449D0 (hr) |
NZ (6) | NZ526105A (hr) |
PL (7) | PL361948A1 (hr) |
PT (2) | PT1341790E (hr) |
RU (6) | RU2003116063A (hr) |
SI (1) | SI1341790T1 (hr) |
SK (6) | SK6842003A3 (hr) |
TW (3) | TWI222972B (hr) |
UA (2) | UA74852C2 (hr) |
WO (6) | WO2002046192A2 (hr) |
ZA (6) | ZA200305275B (hr) |
Families Citing this family (206)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5741908A (en) | 1996-06-21 | 1998-04-21 | Minnesota Mining And Manufacturing Company | Process for reparing imidazoquinolinamines |
UA67760C2 (uk) * | 1997-12-11 | 2004-07-15 | Міннесота Майнінг Енд Мануфакчурінг Компані | Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки |
US6756382B2 (en) | 1999-06-10 | 2004-06-29 | 3M Innovative Properties Company | Amide substituted imidazoquinolines |
US6331539B1 (en) * | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
US6573273B1 (en) | 1999-06-10 | 2003-06-03 | 3M Innovative Properties Company | Urea substituted imidazoquinolines |
US6541485B1 (en) | 1999-06-10 | 2003-04-01 | 3M Innovative Properties Company | Urea substituted imidazoquinolines |
US6916925B1 (en) | 1999-11-05 | 2005-07-12 | 3M Innovative Properties Co. | Dye labeled imidazoquinoline compounds |
JP3436512B2 (ja) * | 1999-12-28 | 2003-08-11 | 株式会社デンソー | アクセル装置 |
US6677348B2 (en) | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Aryl ether substituted imidazoquinolines |
US6677347B2 (en) | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamido ether substituted imidazoquinolines |
US6664264B2 (en) * | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
US6525064B1 (en) | 2000-12-08 | 2003-02-25 | 3M Innovative Properties Company | Sulfonamido substituted imidazopyridines |
US6667312B2 (en) | 2000-12-08 | 2003-12-23 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
US6545016B1 (en) | 2000-12-08 | 2003-04-08 | 3M Innovative Properties Company | Amide substituted imidazopyridines |
UA74852C2 (en) | 2000-12-08 | 2006-02-15 | 3M Innovative Properties Co | Urea-substituted imidazoquinoline ethers |
US6545017B1 (en) | 2000-12-08 | 2003-04-08 | 3M Innovative Properties Company | Urea substituted imidazopyridines |
US6664265B2 (en) * | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
US6660747B2 (en) * | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
US6660735B2 (en) | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Urea substituted imidazoquinoline ethers |
US7226928B2 (en) * | 2001-06-15 | 2007-06-05 | 3M Innovative Properties Company | Methods for the treatment of periodontal disease |
NZ532769A (en) * | 2001-11-29 | 2005-12-23 | 3M Innovative Properties Co | Pharmaceutical formulations comprising an immune response modifier |
CA2365732A1 (en) | 2001-12-20 | 2003-06-20 | Ibm Canada Limited-Ibm Canada Limitee | Testing measurements |
US6677349B1 (en) | 2001-12-21 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
IL147953A (en) | 2002-02-01 | 2008-04-13 | Meir Bialer | Derivatives and pharmaceutical compositions of n-hydroxymethyl tetramethylcyclopropyl- |
US7030129B2 (en) * | 2002-02-22 | 2006-04-18 | 3M Innovative Properties Company | Method of reducing and treating UVB-induced immunosuppression |
GB0211649D0 (en) * | 2002-05-21 | 2002-07-03 | Novartis Ag | Organic compounds |
AU2003237386A1 (en) | 2002-06-07 | 2003-12-22 | 3M Innovative Properties Company | Ether substituted imidazopyridines |
US7718651B2 (en) | 2002-07-02 | 2010-05-18 | Southern Research Institute | Inhibitors of FtsZ and uses thereof |
CA2495570C (en) | 2002-08-15 | 2012-12-04 | 3M Innovative Properties Company | Immunostimulatory compositions and methods of stimulating an immune response |
AU2003299082A1 (en) | 2002-09-26 | 2004-04-19 | 3M Innovative Properties Company | 1h-imidazo dimers |
JP2006513212A (ja) | 2002-12-20 | 2006-04-20 | スリーエム イノベイティブ プロパティズ カンパニー | アリール/ヘタリール置換されたイミダゾキノリン |
EP2572715A1 (en) | 2002-12-30 | 2013-03-27 | 3M Innovative Properties Company | Immunostimulatory Combinations |
US7375180B2 (en) * | 2003-02-13 | 2008-05-20 | 3M Innovative Properties Company | Methods and compositions related to IRM compounds and Toll-like receptor 8 |
EP1599726A4 (en) | 2003-02-27 | 2009-07-22 | 3M Innovative Properties Co | SELECTIVE MODULATION OF TLR-MEDIATED BIOLOGICAL ACTIVITY |
EP1601365A4 (en) | 2003-03-04 | 2009-11-11 | 3M Innovative Properties Co | PROPHYLACTIC TREATMENT OF UV-INDUCED EPIDERMAL NEOPLASIA |
BRPI0408125A (pt) * | 2003-03-07 | 2006-03-01 | 3M Innovative Properties Co | 1-amino 1h-imidazoquinolinas |
US7163947B2 (en) * | 2003-03-07 | 2007-01-16 | 3M Innovative Properties Company | 1-Amino 1H-imidazoquinolines |
CA2518282C (en) * | 2003-03-13 | 2012-11-06 | 3M Innovative Properties Company | Methods of improving skin quality |
US7179253B2 (en) | 2003-03-13 | 2007-02-20 | 3M Innovative Properties Company | Method of tattoo removal |
AU2004220466A1 (en) * | 2003-03-13 | 2004-09-23 | 3M Innovative Properties Company | Methods for diagnosing skin lesions |
US20040192585A1 (en) | 2003-03-25 | 2004-09-30 | 3M Innovative Properties Company | Treatment for basal cell carcinoma |
US20040265351A1 (en) | 2003-04-10 | 2004-12-30 | Miller Richard L. | Methods and compositions for enhancing immune response |
WO2004091500A2 (en) * | 2003-04-10 | 2004-10-28 | 3M Innovative Properties Company | Delivery of immune response modifier compounds |
WO2004096144A2 (en) * | 2003-04-28 | 2004-11-11 | 3M Innovative Properties Company | Compositions and methods for induction of opioid receptors |
US20050032829A1 (en) * | 2003-06-06 | 2005-02-10 | 3M Innovative Properties Company | Process for imidazo[4,5-c]pyridin-4-amines |
WO2004110991A2 (en) * | 2003-06-06 | 2004-12-23 | 3M Innovative Properties Company | PROCESS FOR IMIDAZO[4,5-c]PYRIDIN-4-AMINES |
JP2007501252A (ja) * | 2003-08-05 | 2007-01-25 | スリーエム イノベイティブ プロパティズ カンパニー | 免疫応答調整剤を含有する製剤 |
CA2535117A1 (en) * | 2003-08-12 | 2005-03-03 | 3M Innovative Properties Company | Oxime substituted imidazo-containing compounds |
ES2545826T3 (es) * | 2003-08-14 | 2015-09-16 | 3M Innovative Properties Company | Modificadores de la respuesta inmune modificados con lípidos |
CA2535338C (en) * | 2003-08-14 | 2013-05-28 | 3M Innovative Properties Company | Substituted 1h-imidazo[4,5-c]pyridin-4-amines,1h-imidazo[4,5-c]quinolin -4-amines and 1h-imidazo[4,5-c]naphthyridin-4-amines as immune response modifiers |
WO2005018574A2 (en) * | 2003-08-25 | 2005-03-03 | 3M Innovative Properties Company | Immunostimulatory combinations and treatments |
AU2004268616B2 (en) * | 2003-08-25 | 2010-10-07 | 3M Innovative Properties Company | Delivery of immune response modifier compounds |
EP1658076B1 (en) * | 2003-08-27 | 2013-03-06 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted imidazoquinolines |
CA2536578A1 (en) * | 2003-09-02 | 2005-03-10 | 3M Innovative Properties Company | Methods related to the treatment of mucosal associated conditions |
CA2537763A1 (en) * | 2003-09-05 | 2005-03-17 | 3M Innovative Properties Company | Treatment for cd5+ b cell lymphoma |
US20050059072A1 (en) * | 2003-09-17 | 2005-03-17 | 3M Innovative Properties Company | Selective modulation of TLR gene expression |
US7544697B2 (en) | 2003-10-03 | 2009-06-09 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and analogs thereof |
SG149829A1 (en) | 2003-10-03 | 2009-02-27 | 3M Innovative Properties Co | Pyrazolopyridines and analogs thereof |
US20090075980A1 (en) * | 2003-10-03 | 2009-03-19 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and Analogs Thereof |
EP1673087B1 (en) | 2003-10-03 | 2015-05-13 | 3M Innovative Properties Company | Alkoxy substituted imidazoquinolines |
CA2543685A1 (en) * | 2003-10-31 | 2005-05-12 | 3M Innovative Properties Company | Neutrophil activation by immune response modifier compounds |
US8598192B2 (en) | 2003-11-14 | 2013-12-03 | 3M Innovative Properties Company | Hydroxylamine substituted imidazoquinolines |
US7897767B2 (en) * | 2003-11-14 | 2011-03-01 | 3M Innovative Properties Company | Oxime substituted imidazoquinolines |
WO2005054237A1 (en) * | 2003-11-21 | 2005-06-16 | Novartis Ag | 1h-imidazoquinoline derivatives as protein kinase inhibitors |
AR046845A1 (es) * | 2003-11-21 | 2005-12-28 | Novartis Ag | Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas |
EP1686992A4 (en) * | 2003-11-25 | 2009-11-04 | 3M Innovative Properties Co | HYDROXYLAMINE, AND IMIDAZOQUINOLEINS, AND IMIDAZOPYRIDINES AND IMIDAZONAPHTYRIDINE SUBSTITUTED WITH OXIME |
RU2409576C2 (ru) | 2003-11-25 | 2011-01-20 | 3М Инновейтив Пропертиз Компани | Системы, содержащие имидазольное кольцо с заместителями, и способы их получения |
WO2005055932A2 (en) | 2003-12-02 | 2005-06-23 | 3M Innovative Properties Company | Therapeutic combinations and methods including irm compounds |
JP2007513170A (ja) * | 2003-12-04 | 2007-05-24 | スリーエム イノベイティブ プロパティズ カンパニー | スルホン置換イミダゾ環エーテル |
US7888349B2 (en) * | 2003-12-29 | 2011-02-15 | 3M Innovative Properties Company | Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds |
EP1701955A1 (en) * | 2003-12-29 | 2006-09-20 | 3M Innovative Properties Company | Arylalkenyl and arylalkynyl substituted imidazoquinolines |
WO2005065678A1 (en) * | 2003-12-30 | 2005-07-21 | 3M Innovative Properties Company | Immunomodulatory combinations |
US8735421B2 (en) | 2003-12-30 | 2014-05-27 | 3M Innovative Properties Company | Imidazoquinolinyl sulfonamides |
WO2005067500A2 (en) * | 2003-12-30 | 2005-07-28 | 3M Innovative Properties Company | Enhancement of immune responses |
AU2005222995B2 (en) | 2004-03-15 | 2010-08-26 | 3M Innovative Properties Company | Immune response modifier formulations and methods |
CA2559863A1 (en) | 2004-03-24 | 2005-10-13 | 3M Innovative Properties Company | Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
US20070166384A1 (en) * | 2004-04-09 | 2007-07-19 | Zarraga Isidro Angelo E | Methods , composition and preparations for delivery of immune response modifiers |
US20050267145A1 (en) * | 2004-05-28 | 2005-12-01 | Merrill Bryon A | Treatment for lung cancer |
US20080015184A1 (en) * | 2004-06-14 | 2008-01-17 | 3M Innovative Properties Company | Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines |
US8017779B2 (en) * | 2004-06-15 | 2011-09-13 | 3M Innovative Properties Company | Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines |
US8541438B2 (en) | 2004-06-18 | 2013-09-24 | 3M Innovative Properties Company | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
WO2006065280A2 (en) | 2004-06-18 | 2006-06-22 | 3M Innovative Properties Company | Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods |
US7897609B2 (en) | 2004-06-18 | 2011-03-01 | 3M Innovative Properties Company | Aryl substituted imidazonaphthyridines |
WO2006028545A2 (en) * | 2004-06-18 | 2006-03-16 | 3M Innovative Properties Company | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
WO2006009832A1 (en) * | 2004-06-18 | 2006-01-26 | 3M Innovative Properties Company | Substituted imidazo ring systems and methods |
US8026366B2 (en) * | 2004-06-18 | 2011-09-27 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines |
WO2006026760A2 (en) * | 2004-09-02 | 2006-03-09 | 3M Innovative Properties Company | 1-amino imidazo-containing compounds and methods |
CA2578975A1 (en) | 2004-09-02 | 2006-03-16 | 3M Innovative Properties Company | 2-amino 1h imidazo ring systems and methods |
PL1789042T3 (pl) * | 2004-09-02 | 2012-09-28 | 3M Innovative Properties Co | Układy pierścieni 1-alkoksy 1H-imidazo i sposoby |
WO2006029223A2 (en) * | 2004-09-08 | 2006-03-16 | Children's Medical Center Corporation | Method for stimulating the immune response of newborns |
JP4769810B2 (ja) * | 2004-09-14 | 2011-09-07 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド | イミダゾキノリン化合物 |
WO2006042254A2 (en) * | 2004-10-08 | 2006-04-20 | 3M Innovative Properties Company | Adjuvant for dna vaccines |
US20110070575A1 (en) * | 2004-12-08 | 2011-03-24 | Coley Pharmaceutical Group, Inc. | Immunomodulatory Compositions, Combinations and Methods |
US8080560B2 (en) | 2004-12-17 | 2011-12-20 | 3M Innovative Properties Company | Immune response modifier formulations containing oleic acid and methods |
US8461174B2 (en) * | 2004-12-30 | 2013-06-11 | 3M Innovative Properties Company | Treatment for cutaneous metastases |
JP5313502B2 (ja) | 2004-12-30 | 2013-10-09 | スリーエム イノベイティブ プロパティズ カンパニー | 置換キラル縮合[1,2]イミダゾ[4,5−c]環状化合物 |
AU2005322898B2 (en) | 2004-12-30 | 2011-11-24 | 3M Innovative Properties Company | Chiral fused (1,2)imidazo(4,5-c) ring compounds |
US8436176B2 (en) * | 2004-12-30 | 2013-05-07 | Medicis Pharmaceutical Corporation | Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine |
US20080188513A1 (en) * | 2004-12-30 | 2008-08-07 | Taked Pharmaceutical Company Limited | 1-(2-Methylpropyl)-1H-Imidazo[4,5-C](1,5]Naphthyridin-4-Amine Ethanesulfonate and 1-(2-Methylpropyl)-1H-Imidazo[4,5-C](1,5]Naphthyridin-4-Amine Methanesulfonate |
US9248127B2 (en) | 2005-02-04 | 2016-02-02 | 3M Innovative Properties Company | Aqueous gel formulations containing immune response modifiers |
AU2006212765B2 (en) * | 2005-02-09 | 2012-02-02 | 3M Innovative Properties Company | Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines |
WO2007120121A2 (en) | 2005-02-09 | 2007-10-25 | Coley Pharmaceutical Group, Inc. | Oxime and hydroxylamine substituted thiazolo[4,5-c] ring compounds and methods |
JP2008532933A (ja) * | 2005-02-11 | 2008-08-21 | コーリー ファーマシューティカル グループ,インコーポレイテッド | 置換イミダゾキノリン類および置換イミダゾナフチリジン類 |
US7968563B2 (en) | 2005-02-11 | 2011-06-28 | 3M Innovative Properties Company | Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods |
WO2006091517A2 (en) | 2005-02-18 | 2006-08-31 | Novartis Vaccines And Diagnostics Inc. | Immunogens from uropathogenic escherichia coli |
PL2351772T3 (pl) | 2005-02-18 | 2017-01-31 | Glaxosmithkline Biologicals Sa | Białka i kwasy nukleinowe z bakterii Escherichia coli związanej z zapaleniem opon mózgowo-rdzeniowych/posocznicą |
JP2008543725A (ja) | 2005-02-23 | 2008-12-04 | コーリー ファーマシューティカル グループ,インコーポレイテッド | ヒドロキシアルキル置換イミダゾキノリン |
WO2006091567A2 (en) | 2005-02-23 | 2006-08-31 | Coley Pharmaceutical Group, Inc. | Hydroxyalkyl substituted imidazoquinoline compounds and methods |
CA2598639A1 (en) | 2005-02-23 | 2006-08-31 | Coley Pharmaceutical Group, Inc. | Hydroxyalkyl substituted imidazonaphthyridines |
AU2006216686A1 (en) | 2005-02-23 | 2006-08-31 | Coley Pharmaceutical Group, Inc. | Method of preferentially inducing the biosynthesis of interferon |
AU2006223148A1 (en) | 2005-03-14 | 2006-09-21 | 3M Innovative Properties Company | Method of treating actinic keratosis |
US7943636B2 (en) | 2005-04-01 | 2011-05-17 | 3M Innovative Properties Company | 1-substituted pyrazolo (3,4-C) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases |
AU2006232377A1 (en) | 2005-04-01 | 2006-10-12 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridine-1,4-diamines and analogs thereof |
CA2605808A1 (en) * | 2005-04-25 | 2006-11-02 | 3M Innovative Properties Company | Immunostimulatory compositions |
EP2614709A1 (en) | 2005-07-18 | 2013-07-17 | Novartis AG | Small animal model for HCV replication |
US8476292B2 (en) | 2005-09-09 | 2013-07-02 | 3M Innovative Properties Company | Amide and carbamate derivatives of N-{2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c] quinolin-1-Yl]-1,1-dimethylethyl}methanesulfonamide and methods |
ZA200803029B (en) | 2005-09-09 | 2009-02-25 | Coley Pharm Group Inc | Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods |
US8889154B2 (en) | 2005-09-15 | 2014-11-18 | Medicis Pharmaceutical Corporation | Packaging for 1-(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-4-amine-containing formulation |
DK1951299T3 (da) | 2005-11-04 | 2012-04-02 | Novartis Vaccines & Diagnostic | Influenzavacciner indeholdende kombinationer af partikelformige adjuvanser og immunforstærkere |
EP1948173B1 (en) * | 2005-11-04 | 2013-07-17 | 3M Innovative Properties Company | Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods |
EP2377552A3 (en) | 2005-11-04 | 2013-05-15 | Novartis Vaccines and Diagnostics S.r.l. | Influenza vaccines with reduced amount of emulsion adjuvant |
ES2420829T3 (es) | 2005-11-04 | 2013-08-27 | Novartis Vaccines And Diagnostics S.R.L. | Vacunas adyuvantadas con antígeno de no virión preparadas a partir de virus de la gripe cultivados en cultivo celular |
US20110180430A1 (en) | 2005-11-04 | 2011-07-28 | Novartis Vaccines And Diagnostics Srl | Adjuvanted influenza vaccines including cytokine-inducing agents |
NZ570106A (en) | 2006-01-27 | 2012-04-27 | Novartis Vaccines & Diagnostic | Influenza vaccines containing hemagglutinin and matrix proteins |
EP1988896A4 (en) | 2006-02-22 | 2011-07-27 | 3M Innovative Properties Co | CONJUGATES TO MODIFY IMMUNE REACTIONS |
WO2007106854A2 (en) * | 2006-03-15 | 2007-09-20 | Coley Pharmaceutical Group, Inc. | Hydroxy and alkoxy substituted 1h-imidazonaphthyridines and methods |
ATE539079T1 (de) * | 2006-03-23 | 2012-01-15 | Novartis Ag | Imidazochinoxalinverbindungen als immunmodulatoren |
CA2647100A1 (en) * | 2006-03-23 | 2007-09-27 | Novartis Ag | Methods for the preparation of imidazole-containing compounds |
US8063063B2 (en) * | 2006-03-23 | 2011-11-22 | Novartis Ag | Immunopotentiating compounds |
EP2382987A1 (en) | 2006-03-24 | 2011-11-02 | Novartis Vaccines and Diagnostics GmbH | Storage of influenza vaccines without refrigeration |
US20100285062A1 (en) | 2006-03-31 | 2010-11-11 | Novartis Ag | Combined mucosal and parenteral immunization against hiv |
EP2054431B1 (en) | 2006-06-09 | 2011-08-31 | Novartis AG | Conformers of bacterial adhesins |
US7906506B2 (en) | 2006-07-12 | 2011-03-15 | 3M Innovative Properties Company | Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods |
GB0614460D0 (en) | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
AU2007285484B2 (en) | 2006-08-16 | 2013-05-02 | Novartis Ag | Immunogens from uropathogenic Escherichia coli |
US8178539B2 (en) | 2006-09-06 | 2012-05-15 | 3M Innovative Properties Company | Substituted 3,4,6,7-tetrahydro-5H-1,2a,4a,8-tetraazacyclopenta[cd]phenalenes and methods |
JP5954921B2 (ja) | 2006-09-11 | 2016-07-20 | ノバルティス アーゲー | 卵を使用しないインフルエンザウイルスワクチンの作製 |
US20110045022A1 (en) | 2006-12-06 | 2011-02-24 | Theodore Tsai | Vaccines including antigen from four strains of influenza virus |
US20080149123A1 (en) | 2006-12-22 | 2008-06-26 | Mckay William D | Particulate material dispensing hairbrush with combination bristles |
GB0700562D0 (en) | 2007-01-11 | 2007-02-21 | Novartis Vaccines & Diagnostic | Modified Saccharides |
EP2185191B1 (en) | 2007-06-27 | 2012-09-12 | Novartis AG | Low-additive influenza vaccines |
GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
JP2011509956A (ja) * | 2008-01-15 | 2011-03-31 | メダ アクチエボラーグ | イミダゾリキノリン誘導体を用いた大腸疾病の治療又は結腸直腸癌腫の予防 |
DK2268618T3 (en) * | 2008-03-03 | 2015-08-17 | Novartis Ag | Compounds and compositions as TLR aktivitetsmodulatorer |
EP2268309B1 (en) | 2008-03-18 | 2015-01-21 | Novartis AG | Improvements in preparation of influenza virus vaccine antigens |
CA2754618A1 (en) | 2009-03-06 | 2010-09-10 | Novartis Ag | Chlamydia antigens |
MX2011010050A (es) | 2009-03-25 | 2011-12-14 | Univ Texas | Composiciones para estimulación de resistencia inmune innata de mamiferos a patógenos. |
AU2010238255B2 (en) | 2009-04-14 | 2014-10-16 | Novartis Ag | Compositions for immunising against Staphylococcus aureus |
JP2012525370A (ja) | 2009-04-27 | 2012-10-22 | ノバルティス アーゲー | インフルエンザに対して防御するためのアジュバント添加ワクチン |
GB0907551D0 (en) * | 2009-05-01 | 2009-06-10 | Univ Dundee | Treatment or prophylaxis of proliferative conditions |
AU2013203591B2 (en) * | 2009-05-01 | 2017-01-19 | University Court Of The University Of Dundee | Treatment or prophylaxis of proliferative conditions |
EP3178490B1 (en) | 2009-07-15 | 2022-04-20 | GlaxoSmithKline Biologicals S.A. | Rsv f protein compositions and methods for making same |
CA2768343A1 (en) | 2009-07-16 | 2011-01-20 | Novartis Ag | Detoxified escherichia coli immunogens |
GB0918392D0 (en) | 2009-10-20 | 2009-12-02 | Novartis Ag | Diagnostic and therapeutic methods |
GB0919690D0 (en) | 2009-11-10 | 2009-12-23 | Guy S And St Thomas S Nhs Foun | compositions for immunising against staphylococcus aureus |
GB201009861D0 (en) | 2010-06-11 | 2010-07-21 | Novartis Ag | OMV vaccines |
DK2606047T3 (en) | 2010-08-17 | 2017-03-27 | 3M Innovative Properties Co | COMPOSITIONS AND FORMULATIONS WITH LIPIDIZED IMMUNE RESPONSE-MODIFIING COMPOUND AND PROCEDURES THEREOF |
JP5978225B2 (ja) | 2010-12-16 | 2016-08-24 | 大日本住友製薬株式会社 | 治療に有用なイミダゾ[4,5−c]キノリン−1−イル誘導体 |
WO2012103361A1 (en) | 2011-01-26 | 2012-08-02 | Novartis Ag | Rsv immunization regimen |
CN103842374A (zh) | 2011-05-13 | 2014-06-04 | 诺华股份有限公司 | 融合前的rsv f抗原 |
US8728486B2 (en) | 2011-05-18 | 2014-05-20 | University Of Kansas | Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds |
CN103582496B (zh) | 2011-06-03 | 2016-05-11 | 3M创新有限公司 | 具有聚乙二醇链段的异双官能连接基以及由其制成的免疫应答调节剂缀合物 |
EP2718292B1 (en) * | 2011-06-03 | 2018-03-14 | 3M Innovative Properties Company | Hydrazino 1h-imidazoquinolin-4-amines and conjugates made therefrom |
US20130023736A1 (en) | 2011-07-21 | 2013-01-24 | Stanley Dale Harpstead | Systems for drug delivery and monitoring |
EP2776069A1 (en) | 2011-11-07 | 2014-09-17 | Novartis AG | Carrier molecule comprising a spr0096 and a spr2021 antigen |
WO2013108272A2 (en) | 2012-01-20 | 2013-07-25 | International Centre For Genetic Engineering And Biotechnology | Blood stage malaria vaccine |
CN112587658A (zh) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
PT2941233T (pt) | 2013-01-07 | 2020-11-13 | Univ Pennsylvania | Composições e métodos para tratar linfoma cutâneo de células t |
EP3024476A1 (en) | 2013-07-26 | 2016-06-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of bacterial infections |
RU2687279C2 (ru) | 2013-11-05 | 2019-05-13 | 3М Инновейтив Пропертиз Компани | Инъекционные композиции на основе кунжутного масла |
EP2870974A1 (en) | 2013-11-08 | 2015-05-13 | Novartis AG | Salmonella conjugate vaccines |
CA2936377A1 (en) | 2014-01-10 | 2015-07-16 | Shanghai Birdie Biotech, Inc. | Compounds and compositions for treating egfr expressing tumors |
RS59971B1 (sr) | 2014-03-26 | 2020-03-31 | Glaxosmithkline Biologicals Sa | Mutantni stafilokokni antigeni |
CN105440135A (zh) | 2014-09-01 | 2016-03-30 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
TWI727427B (zh) | 2014-07-09 | 2021-05-11 | 英屬開曼群島商博笛生物科技有限公司 | 用於治療腫瘤的抗pd-1組合 |
CN105233291A (zh) * | 2014-07-09 | 2016-01-13 | 博笛生物科技有限公司 | 用于治疗癌症的联合治疗组合物和联合治疗方法 |
CN105461767B (zh) * | 2014-08-07 | 2019-03-12 | 富力 | 一种连翘苷的化学合成方法 |
WO2016044839A2 (en) | 2014-09-19 | 2016-03-24 | The Board Of Regents Of The University Of Texas System | Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds |
AU2016322813B2 (en) * | 2015-09-14 | 2021-04-01 | Pfizer Inc. | Novel imidazo (4,5-c) quinoline and imidazo (4,5-c)(1,5) naphthyridine derivatives as LRRK2 inhibitors |
WO2017058996A1 (en) * | 2015-09-29 | 2017-04-06 | The University Of Chicago | Polymer conjugate vaccines |
US10526309B2 (en) | 2015-10-02 | 2020-01-07 | The University Of North Carolina At Chapel Hill | Pan-TAM inhibitors and Mer/Axl dual inhibitors |
CN115252792A (zh) | 2016-01-07 | 2022-11-01 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-egfr组合 |
CN106943596A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | 用于治疗肿瘤的抗-cd20组合 |
CN106943598A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | 用于治疗肿瘤的抗-her2组合 |
US11826422B2 (en) | 2016-11-09 | 2023-11-28 | Board Of Regents, The University Of Texas System | Methods and compositions for adaptive immune modulation |
CN108794467A (zh) | 2017-04-27 | 2018-11-13 | 博笛生物科技有限公司 | 2-氨基-喹啉衍生物 |
AU2017419352A1 (en) | 2017-06-23 | 2019-12-12 | Birdie Biopharmaceuticals, Inc. | Pharmaceutical compositions |
CA3086439A1 (en) | 2017-12-20 | 2019-06-27 | 3M Innovative Properties Company | Amide substitued imidazo[4,5-c]quinoline compounds with a branched chain linking group for use as an immune response modifier |
PE20210367A1 (es) | 2018-02-02 | 2021-02-26 | Maverix Oncology Inc | Conjugados de farmacos de molecula pequena de monofosfato de gemcitabina |
BR112020016859A2 (pt) | 2018-02-28 | 2020-12-29 | Pfizer Inc. | Variantes de il-15 e usos da mesma |
CN111788202B (zh) * | 2018-02-28 | 2024-03-01 | 3M创新有限公司 | 具有N-1支链基团的经取代的咪唑并[4,5-c]喹啉化合物 |
KR20230146098A (ko) | 2018-05-23 | 2023-10-18 | 화이자 인코포레이티드 | GUCY2c에 특이적인 항체 및 이의 용도 |
WO2019224715A1 (en) | 2018-05-23 | 2019-11-28 | Pfizer Inc. | Antibodies specific for cd3 and uses thereof |
WO2019224765A1 (en) | 2018-05-24 | 2019-11-28 | 3M Innovative Properties Company | N-1 branched cycloalkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods |
US20210213010A1 (en) * | 2018-07-24 | 2021-07-15 | Torque Therapeutics, Inc. | Tlr7/8 agonists and liposome compositions |
CN113166143A (zh) * | 2018-11-26 | 2021-07-23 | 3M创新有限公司 | N-1支链烷基醚取代的咪唑并[4,5-c]喹啉化合物、组合物和方法 |
WO2020128893A1 (en) | 2018-12-21 | 2020-06-25 | Pfizer Inc. | Combination treatments of cancer comprising a tlr agonist |
US10906923B1 (en) * | 2019-02-07 | 2021-02-02 | Canwell Biotech Limited | Phosphorus imidazoquinoline amine derivatives, pharmaceutical compositions and therapeutic methods thereof |
JP2022520792A (ja) | 2019-02-12 | 2022-04-01 | アンブルックス,インコーポレイテッド | 抗体-tlrアゴニストコンジュゲートを含有する組成物、その方法、及び使用 |
BR112022008039A2 (pt) * | 2019-10-29 | 2022-07-12 | Prime Reach Trading Ltd | Compostos de 4-amino-imidazoquinolina e usos relacionados |
WO2021116420A1 (en) | 2019-12-13 | 2021-06-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of tlr7 and/or tlr8 agonists for the treatment of leptospirosis |
US11702474B2 (en) | 2019-12-17 | 2023-07-18 | Pfizer Inc. | Antibodies specific for CD47, PD-L1, and uses thereof |
EP4182346A1 (en) | 2020-07-17 | 2023-05-24 | Pfizer Inc. | Therapeutic antibodies and their uses |
JP2023538071A (ja) | 2020-08-20 | 2023-09-06 | アンブルックス,インコーポレイテッド | 抗体-tlrアゴニストコンジュゲート、その方法及び使用 |
Family Cites Families (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2135210A (en) * | 1937-03-13 | 1938-11-01 | John R Farrar | Golf ball |
US3314941A (en) | 1964-06-23 | 1967-04-18 | American Cyanamid Co | Novel substituted pyridodiazepins |
US3692907A (en) * | 1970-10-27 | 1972-09-19 | Richardson Merrell Inc | Treating viral infections with bis-basic ethers and thioethers of fluorenone and fluorene and pharmaceutical compositons of the same |
US3819190A (en) * | 1972-10-02 | 1974-06-25 | D Nepela | Golf ball |
US4284276A (en) * | 1980-02-13 | 1981-08-18 | Worst Joseph C | Grooved golf ball |
ZA848968B (en) | 1983-11-18 | 1986-06-25 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines |
IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
US4880779A (en) * | 1987-07-31 | 1989-11-14 | Research Corporation Technologies, Inc. | Method of prevention or treatment of AIDS by inhibition of human immunodeficiency virus |
US5238944A (en) | 1988-12-15 | 1993-08-24 | Riker Laboratories, Inc. | Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine |
US5756747A (en) | 1989-02-27 | 1998-05-26 | Riker Laboratories, Inc. | 1H-imidazo 4,5-c!quinolin-4-amines |
US5037986A (en) | 1989-03-23 | 1991-08-06 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo[4,5-c]quinolin-4-amines |
US4929624A (en) | 1989-03-23 | 1990-05-29 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo(4,5-c)quinolin-4-amines |
NZ232740A (en) | 1989-04-20 | 1992-06-25 | Riker Laboratories Inc | Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster |
US4988815A (en) * | 1989-10-26 | 1991-01-29 | Riker Laboratories, Inc. | 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines |
US5054153A (en) * | 1989-12-01 | 1991-10-08 | Silliman Paul D | Golf club cleaner |
WO1992006093A1 (en) * | 1990-10-05 | 1992-04-16 | Minnesota Mining And Manufacturing Company | Process for the preparation of imidazo[4,5-c]quinolin-4-amines |
HU222250B1 (hu) * | 1991-03-01 | 2003-05-28 | Minnesota Mining And Manufacturing Company | 1- és 2-helyzetben szubsztituált 1H-imidazo[4,5-c]kinolin-4-amin-származékok előállításában alkalmazható intermedierek |
US5389640A (en) * | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
US5175296A (en) * | 1991-03-01 | 1992-12-29 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-c]quinolin-4-amines and processes for their preparation |
US5268376A (en) | 1991-09-04 | 1993-12-07 | Minnesota Mining And Manufacturing Company | 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
US5266575A (en) | 1991-11-06 | 1993-11-30 | Minnesota Mining And Manufacturing Company | 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines |
IL105325A (en) | 1992-04-16 | 1996-11-14 | Minnesota Mining & Mfg | Immunogen/vaccine adjuvant composition |
FR2692159B1 (fr) * | 1992-06-10 | 1996-10-11 | Vartan Berberian | Boule pour jeux de boules et procedes d'obtention d'une telle boule. |
US5395937A (en) * | 1993-01-29 | 1995-03-07 | Minnesota Mining And Manufacturing Company | Process for preparing quinoline amines |
US5352784A (en) * | 1993-07-15 | 1994-10-04 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
ES2149276T3 (es) | 1993-07-15 | 2000-11-01 | Minnesota Mining & Mfg | Imidazo(4,5-c)piridin-4-aminas. |
US5648516A (en) | 1994-07-20 | 1997-07-15 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
US5644063A (en) | 1994-09-08 | 1997-07-01 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-c]pyridin-4-amine intermediates |
US5482936A (en) | 1995-01-12 | 1996-01-09 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-C]quinoline amines |
JPH09116911A (ja) * | 1995-10-20 | 1997-05-02 | Canon Inc | 撮像システム |
JPH09208584A (ja) | 1996-01-29 | 1997-08-12 | Terumo Corp | アミド誘導体、およびそれを含有する医薬製剤、および合成中間体 |
JPH09255926A (ja) | 1996-03-26 | 1997-09-30 | Diatex Co Ltd | 粘着テープ |
US5741908A (en) * | 1996-06-21 | 1998-04-21 | Minnesota Mining And Manufacturing Company | Process for reparing imidazoquinolinamines |
US5693811A (en) * | 1996-06-21 | 1997-12-02 | Minnesota Mining And Manufacturing Company | Process for preparing tetrahdroimidazoquinolinamines |
US5759109A (en) * | 1996-09-09 | 1998-06-02 | Martini; Byron Rocco | Simulated golf ball instructional device |
KR100518903B1 (ko) | 1996-10-25 | 2005-10-06 | 미네소타 마이닝 앤드 매뉴팩춰링 캄파니 | Th2 매개 질병 및 관련 질병의 치료용 면역 반응 조절 화합물 |
US5939090A (en) | 1996-12-03 | 1999-08-17 | 3M Innovative Properties Company | Gel formulations for topical drug delivery |
US6069149A (en) | 1997-01-09 | 2000-05-30 | Terumo Kabushiki Kaisha | Amide derivatives and intermediates for the synthesis thereof |
UA67760C2 (uk) * | 1997-12-11 | 2004-07-15 | Міннесота Майнінг Енд Мануфакчурінг Компані | Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки |
JPH11222432A (ja) | 1998-02-03 | 1999-08-17 | Terumo Corp | インターフェロンを誘起するアミド誘導体を含有する外用剤 |
JPH11255926A (ja) | 1998-03-13 | 1999-09-21 | Toray Ind Inc | シリコーン成型品およびその製造方法 |
CN1220997C (zh) * | 1998-05-22 | 2005-09-28 | 松下电器产业株式会社 | 电解电容器及其制造方法 |
US6110929A (en) | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
JP2000119271A (ja) | 1998-08-12 | 2000-04-25 | Hokuriku Seiyaku Co Ltd | 1h―イミダゾピリジン誘導体 |
US20020058674A1 (en) * | 1999-01-08 | 2002-05-16 | Hedenstrom John C. | Systems and methods for treating a mucosal surface |
AU776654B2 (en) * | 1999-01-08 | 2004-09-16 | 3M Innovative Properties Company | Formulations and methods for treatment of mucosal associated conditions with an immune response modifier |
US6558951B1 (en) * | 1999-02-11 | 2003-05-06 | 3M Innovative Properties Company | Maturation of dendritic cells with immune response modifying compounds |
JP2000247884A (ja) | 1999-03-01 | 2000-09-12 | Sumitomo Pharmaceut Co Ltd | アラキドン酸誘発皮膚疾患治療剤 |
US6451810B1 (en) * | 1999-06-10 | 2002-09-17 | 3M Innovative Properties Company | Amide substituted imidazoquinolines |
US6756382B2 (en) | 1999-06-10 | 2004-06-29 | 3M Innovative Properties Company | Amide substituted imidazoquinolines |
US6573273B1 (en) * | 1999-06-10 | 2003-06-03 | 3M Innovative Properties Company | Urea substituted imidazoquinolines |
US6331539B1 (en) | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
US6541485B1 (en) | 1999-06-10 | 2003-04-01 | 3M Innovative Properties Company | Urea substituted imidazoquinolines |
US6376669B1 (en) * | 1999-11-05 | 2002-04-23 | 3M Innovative Properties Company | Dye labeled imidazoquinoline compounds |
US6894060B2 (en) | 2000-03-30 | 2005-05-17 | 3M Innovative Properties Company | Method for the treatment of dermal lesions caused by envenomation |
US20020055517A1 (en) * | 2000-09-15 | 2002-05-09 | 3M Innovative Properties Company | Methods for delaying recurrence of herpes virus symptoms |
JP2002145777A (ja) | 2000-11-06 | 2002-05-22 | Sumitomo Pharmaceut Co Ltd | アラキドン酸誘発皮膚疾患治療剤 |
UA74852C2 (en) | 2000-12-08 | 2006-02-15 | 3M Innovative Properties Co | Urea-substituted imidazoquinoline ethers |
US6545016B1 (en) * | 2000-12-08 | 2003-04-08 | 3M Innovative Properties Company | Amide substituted imidazopyridines |
US6664260B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Heterocyclic ether substituted imidazoquinolines |
US6525064B1 (en) * | 2000-12-08 | 2003-02-25 | 3M Innovative Properties Company | Sulfonamido substituted imidazopyridines |
US6660747B2 (en) * | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
UA74593C2 (en) | 2000-12-08 | 2006-01-16 | 3M Innovative Properties Co | Substituted imidazopyridines |
US6664264B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
US6545017B1 (en) * | 2000-12-08 | 2003-04-08 | 3M Innovative Properties Company | Urea substituted imidazopyridines |
US6677348B2 (en) | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Aryl ether substituted imidazoquinolines |
US6660735B2 (en) * | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Urea substituted imidazoquinoline ethers |
US6667312B2 (en) | 2000-12-08 | 2003-12-23 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
WO2002046749A2 (en) | 2000-12-08 | 2002-06-13 | 3M Innovative Properties Company | Screening method for identifying compounds that selectively induce interferon alpha |
US6664265B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
US6677347B2 (en) * | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamido ether substituted imidazoquinolines |
WO2002102377A1 (en) | 2001-06-15 | 2002-12-27 | 3M Innovative Properties Company | Immune response modifiers for the treatment of periodontal disease |
EP1427445A4 (en) | 2001-08-30 | 2006-09-06 | 3M Innovative Properties Co | METHOD FOR MATURIZING PLASMACYTIDES DENDRITIC CELLS USING IMMUNE RESPONSE MODIFYING MOLECULES |
CA2462203A1 (en) | 2001-10-12 | 2003-11-20 | University Of Iowa Research Foundation | Methods and products for enhancing immune responses using imidazoquinoline compounds |
PT1719511E (pt) | 2001-11-16 | 2009-03-06 | Coley Pharm Group Inc | N-[4-(4-amino-2-etil-1h-imidazo[4,5-c]quinolina-1- -il)-butil]-metano-sulfonamida, uma composição farmacêutica que a contém e sua utilização |
NZ532769A (en) | 2001-11-29 | 2005-12-23 | 3M Innovative Properties Co | Pharmaceutical formulations comprising an immune response modifier |
US6677349B1 (en) | 2001-12-21 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
US7030129B2 (en) | 2002-02-22 | 2006-04-18 | 3M Innovative Properties Company | Method of reducing and treating UVB-induced immunosuppression |
GB0211649D0 (en) | 2002-05-21 | 2002-07-03 | Novartis Ag | Organic compounds |
US6743920B2 (en) | 2002-05-29 | 2004-06-01 | 3M Innovative Properties Company | Process for imidazo[4,5-c]pyridin-4-amines |
AU2003237386A1 (en) | 2002-06-07 | 2003-12-22 | 3M Innovative Properties Company | Ether substituted imidazopyridines |
CA2495570C (en) | 2002-08-15 | 2012-12-04 | 3M Innovative Properties Company | Immunostimulatory compositions and methods of stimulating an immune response |
AU2003299082A1 (en) | 2002-09-26 | 2004-04-19 | 3M Innovative Properties Company | 1h-imidazo dimers |
AU2003287316A1 (en) | 2002-12-11 | 2004-06-30 | 3M Innovative Properties Company | Assays relating to toll-like receptor activity |
AU2003287324A1 (en) | 2002-12-11 | 2004-06-30 | 3M Innovative Properties Company | Gene expression systems and recombinant cell lines |
JP2006513212A (ja) * | 2002-12-20 | 2006-04-20 | スリーエム イノベイティブ プロパティズ カンパニー | アリール/ヘタリール置換されたイミダゾキノリン |
EP2572715A1 (en) | 2002-12-30 | 2013-03-27 | 3M Innovative Properties Company | Immunostimulatory Combinations |
US7375180B2 (en) | 2003-02-13 | 2008-05-20 | 3M Innovative Properties Company | Methods and compositions related to IRM compounds and Toll-like receptor 8 |
EP1599726A4 (en) | 2003-02-27 | 2009-07-22 | 3M Innovative Properties Co | SELECTIVE MODULATION OF TLR-MEDIATED BIOLOGICAL ACTIVITY |
EP1601365A4 (en) | 2003-03-04 | 2009-11-11 | 3M Innovative Properties Co | PROPHYLACTIC TREATMENT OF UV-INDUCED EPIDERMAL NEOPLASIA |
BRPI0408125A (pt) | 2003-03-07 | 2006-03-01 | 3M Innovative Properties Co | 1-amino 1h-imidazoquinolinas |
US7179253B2 (en) | 2003-03-13 | 2007-02-20 | 3M Innovative Properties Company | Method of tattoo removal |
CA2518282C (en) | 2003-03-13 | 2012-11-06 | 3M Innovative Properties Company | Methods of improving skin quality |
AU2004220466A1 (en) | 2003-03-13 | 2004-09-23 | 3M Innovative Properties Company | Methods for diagnosing skin lesions |
WO2004087049A2 (en) | 2003-03-25 | 2004-10-14 | 3M Innovative Properties Company | Selective activation of cellular activities mediated through a common toll-like receptor |
US20040192585A1 (en) | 2003-03-25 | 2004-09-30 | 3M Innovative Properties Company | Treatment for basal cell carcinoma |
WO2004091500A2 (en) | 2003-04-10 | 2004-10-28 | 3M Innovative Properties Company | Delivery of immune response modifier compounds |
AP2006003542A0 (en) | 2003-09-05 | 2006-04-30 | Anadys Pharmaceuticals Inc | Administration of TLR7 ligands and prodrugs for treatment of infection by hepatitis C virus. |
-
2001
- 2001-06-12 UA UA2003065275A patent/UA74852C2/uk unknown
- 2001-06-12 UA UA2003065277A patent/UA75622C2/uk unknown
- 2001-12-06 CZ CZ20031560A patent/CZ295848B6/cs not_active IP Right Cessation
- 2001-12-06 PL PL01361948A patent/PL361948A1/xx not_active Application Discontinuation
- 2001-12-06 EE EEP200300272A patent/EE200300272A/xx unknown
- 2001-12-06 CN CNB018199070A patent/CN1252070C/zh not_active Expired - Fee Related
- 2001-12-06 CZ CZ20031592A patent/CZ303462B6/cs not_active IP Right Cessation
- 2001-12-06 CZ CZ20031561A patent/CZ20031561A3/cs unknown
- 2001-12-06 AU AU3249702A patent/AU3249702A/xx active Pending
- 2001-12-06 RU RU2003116063/04A patent/RU2003116063A/ru not_active Application Discontinuation
- 2001-12-06 PL PL01365883A patent/PL365883A1/xx not_active Application Discontinuation
- 2001-12-06 MX MXPA03004972A patent/MXPA03004972A/es active IP Right Grant
- 2001-12-06 SK SK684-2003A patent/SK6842003A3/sk not_active Application Discontinuation
- 2001-12-06 RU RU2003116060/04A patent/RU2302418C2/ru active
- 2001-12-06 HU HU0400710A patent/HUP0400710A2/hu unknown
- 2001-12-06 NZ NZ526105A patent/NZ526105A/en unknown
- 2001-12-06 AU AU2002239516A patent/AU2002239516B2/en not_active Ceased
- 2001-12-06 AU AU2002230618A patent/AU2002230618B2/en not_active Ceased
- 2001-12-06 EE EEP200300274A patent/EE200300274A/xx unknown
- 2001-12-06 SK SK712-2003A patent/SK7122003A3/sk unknown
- 2001-12-06 DK DK01992018T patent/DK1343784T3/da active
- 2001-12-06 KR KR10-2003-7007539A patent/KR20040047733A/ko not_active Application Discontinuation
- 2001-12-06 RU RU2003116123/04A patent/RU2003116123A/ru not_active Application Discontinuation
- 2001-12-06 EP EP01987282A patent/EP1341789A2/en not_active Ceased
- 2001-12-06 NZ NZ526086A patent/NZ526086A/en unknown
- 2001-12-06 EP EP01987297A patent/EP1341791B1/en not_active Expired - Lifetime
- 2001-12-06 WO PCT/US2001/046697 patent/WO2002046192A2/en active IP Right Grant
- 2001-12-06 EE EEP200300275A patent/EE200300275A/xx unknown
- 2001-12-06 BR BRPI0116052-4A patent/BR0116052A/pt not_active Application Discontinuation
- 2001-12-06 CA CA2436980A patent/CA2436980C/en not_active Expired - Fee Related
- 2001-12-06 WO PCT/US2001/046704 patent/WO2002046193A2/en active IP Right Grant
- 2001-12-06 AU AU3061802A patent/AU3061802A/xx active Pending
- 2001-12-06 JP JP2002547926A patent/JP2004523498A/ja active Pending
- 2001-12-06 ES ES01992018T patent/ES2260323T3/es not_active Expired - Lifetime
- 2001-12-06 MX MXPA03005011A patent/MXPA03005011A/es active IP Right Grant
- 2001-12-06 SK SK711-2003A patent/SK7112003A3/sk unknown
- 2001-12-06 AU AU2002239530A patent/AU2002239530B2/en not_active Ceased
- 2001-12-06 PL PL01365995A patent/PL365995A1/xx unknown
- 2001-12-06 ES ES01987283T patent/ES2281456T3/es not_active Expired - Lifetime
- 2001-12-06 AT AT01987283T patent/ATE353895T1/de not_active IP Right Cessation
- 2001-12-06 WO PCT/US2001/046582 patent/WO2002046190A2/en active IP Right Grant
- 2001-12-06 MX MXPA03004973A patent/MXPA03004973A/es not_active Application Discontinuation
- 2001-12-06 CN CNB018201598A patent/CN1247575C/zh not_active Expired - Fee Related
- 2001-12-06 IL IL15604301A patent/IL156043A0/xx unknown
- 2001-12-06 BR BR0116047-8A patent/BR0116047A/pt not_active IP Right Cessation
- 2001-12-06 AU AU3248202A patent/AU3248202A/xx active Pending
- 2001-12-06 CA CA002436984A patent/CA2436984A1/en not_active Abandoned
- 2001-12-06 KR KR10-2003-7007535A patent/KR20040028690A/ko not_active Application Discontinuation
- 2001-12-06 JP JP2002547928A patent/JP2004521092A/ja not_active Ceased
- 2001-12-06 PT PT01987283T patent/PT1341790E/pt unknown
- 2001-12-06 CN CNA018201725A patent/CN1894244A/zh active Pending
- 2001-12-06 CN CNB018201679A patent/CN1297554C/zh not_active Expired - Fee Related
- 2001-12-06 ES ES01987297T patent/ES2242782T3/es not_active Expired - Lifetime
- 2001-12-06 US US10/013,202 patent/US6670372B2/en not_active Expired - Fee Related
- 2001-12-06 RU RU2003116059/04A patent/RU2308456C2/ru not_active IP Right Cessation
- 2001-12-06 BR BR0116470-8A patent/BR0116470A/pt not_active IP Right Cessation
- 2001-12-06 JP JP2002547929A patent/JP2004515500A/ja not_active Withdrawn
- 2001-12-06 DK DK01987297T patent/DK1341791T3/da active
- 2001-12-06 BR BR0116026-5A patent/BR0116026A/pt not_active IP Right Cessation
- 2001-12-06 RU RU2003116649/04A patent/RU2351598C2/ru not_active IP Right Cessation
- 2001-12-06 KR KR10-2003-7007537A patent/KR20030070050A/ko not_active Application Discontinuation
- 2001-12-06 EE EEP200300268A patent/EE200300268A/xx unknown
- 2001-12-06 BR BRPI0116032-0A patent/BR0116032A/pt not_active IP Right Cessation
- 2001-12-06 BR BRPI0116464-3A patent/BR0116464A/pt not_active IP Right Cessation
- 2001-12-06 AT AT01992018T patent/ATE319711T1/de not_active IP Right Cessation
- 2001-12-06 EE EEP200300271A patent/EE200300271A/xx unknown
- 2001-12-06 NZ NZ526088A patent/NZ526088A/xx unknown
- 2001-12-06 KR KR10-2003-7007534A patent/KR20030070049A/ko active IP Right Grant
- 2001-12-06 KR KR10-2003-7007538A patent/KR20040028691A/ko not_active Application Discontinuation
- 2001-12-06 DK DK01987283T patent/DK1341790T3/da active
- 2001-12-06 HU HU0400704A patent/HUP0400704A2/hu unknown
- 2001-12-06 CN CNB01820161XA patent/CN1253452C/zh not_active Expired - Fee Related
- 2001-12-06 EP EP01992005A patent/EP1341792A2/en not_active Withdrawn
- 2001-12-06 EE EEP200300270A patent/EE200300270A/xx unknown
- 2001-12-06 HU HU0600605A patent/HUP0600605A2/hu unknown
- 2001-12-06 CZ CZ20031563A patent/CZ20031563A3/cs unknown
- 2001-12-06 PL PL392462A patent/PL392462A1/pl unknown
- 2001-12-06 US US10/012,599 patent/US6683088B2/en not_active Expired - Fee Related
- 2001-12-06 DE DE60117859T patent/DE60117859T2/de not_active Expired - Fee Related
- 2001-12-06 JP JP2002547930A patent/JP2004515501A/ja active Pending
- 2001-12-06 US US10/013,060 patent/US6656938B2/en not_active Expired - Fee Related
- 2001-12-06 NZ NZ526106A patent/NZ526106A/en not_active IP Right Cessation
- 2001-12-06 IL IL15604401A patent/IL156044A0/xx unknown
- 2001-12-06 IL IL15590301A patent/IL155903A0/xx unknown
- 2001-12-06 HU HU0600600A patent/HUP0600600A2/hu unknown
- 2001-12-06 EP EP01987283A patent/EP1341790B1/en not_active Expired - Lifetime
- 2001-12-06 AU AU2002239517A patent/AU2002239517B2/en not_active Ceased
- 2001-12-06 SK SK713-2003A patent/SK287732B6/sk not_active IP Right Cessation
- 2001-12-06 CA CA002431151A patent/CA2431151A1/en not_active Withdrawn
- 2001-12-06 CZ CZ20031562A patent/CZ20031562A3/cs unknown
- 2001-12-06 AU AU3951702A patent/AU3951702A/xx active Pending
- 2001-12-06 PL PL01366115A patent/PL366115A1/xx not_active Application Discontinuation
- 2001-12-06 AU AU2002232482A patent/AU2002232482B2/en not_active Ceased
- 2001-12-06 NZ NZ526089A patent/NZ526089A/en unknown
- 2001-12-06 CA CA002436983A patent/CA2436983A1/en not_active Abandoned
- 2001-12-06 DE DE60111076T patent/DE60111076T2/de not_active Expired - Lifetime
- 2001-12-06 AU AU3953002A patent/AU3953002A/xx active Pending
- 2001-12-06 AT AT01987297T patent/ATE296301T1/de active
- 2001-12-06 MX MXPA03005012A patent/MXPA03005012A/es active IP Right Grant
- 2001-12-06 AU AU2002232497A patent/AU2002232497B2/en not_active Ceased
- 2001-12-06 EP EP01990852A patent/EP1339715A2/en not_active Withdrawn
- 2001-12-06 PT PT01987297T patent/PT1341791E/pt unknown
- 2001-12-06 CA CA002430844A patent/CA2430844A1/en not_active Withdrawn
- 2001-12-06 RU RU2003116061/04A patent/RU2315049C2/ru not_active IP Right Cessation
- 2001-12-06 AU AU3951602A patent/AU3951602A/xx active Pending
- 2001-12-06 MX MXPA03004974A patent/MXPA03004974A/es active IP Right Grant
- 2001-12-06 IL IL15590401A patent/IL155904A0/xx unknown
- 2001-12-06 IL IL15595001A patent/IL155950A0/xx unknown
- 2001-12-06 MX MXPA03004975A patent/MXPA03004975A/es active IP Right Grant
- 2001-12-06 PL PL01365907A patent/PL365907A1/xx not_active Application Discontinuation
- 2001-12-06 PL PL366330A patent/PL207340B1/pl not_active IP Right Cessation
- 2001-12-06 JP JP2002547925A patent/JP4437189B2/ja not_active Expired - Fee Related
- 2001-12-06 CA CA2436846A patent/CA2436846C/en not_active Expired - Fee Related
- 2001-12-06 IL IL15588401A patent/IL155884A0/xx unknown
- 2001-12-06 SK SK710-2003A patent/SK287264B6/sk not_active IP Right Cessation
- 2001-12-06 JP JP2002547927A patent/JP2004529078A/ja active Pending
- 2001-12-06 NZ NZ526087A patent/NZ526087A/en unknown
- 2001-12-06 HU HU0600338A patent/HUP0600338A2/hu active IP Right Revival
- 2001-12-06 SI SI200130720T patent/SI1341790T1/sl unknown
- 2001-12-06 HU HU0700062A patent/HUP0700062A2/hu active IP Right Revival
- 2001-12-06 SK SK715-2003A patent/SK7152003A3/sk unknown
- 2001-12-06 KR KR10-2003-7007532A patent/KR20040023576A/ko not_active Application Discontinuation
- 2001-12-06 WO PCT/US2001/046581 patent/WO2002046189A2/en active IP Right Grant
- 2001-12-06 DE DE60126645T patent/DE60126645T2/de not_active Expired - Fee Related
- 2001-12-06 EP EP01992018A patent/EP1343784B1/en not_active Expired - Lifetime
- 2001-12-06 WO PCT/US2001/046359 patent/WO2002046188A2/en active IP Right Grant
- 2001-12-06 CN CNA018201687A patent/CN1479739A/zh active Pending
- 2001-12-06 WO PCT/US2001/046696 patent/WO2002046191A2/en active IP Right Grant
- 2001-12-06 CZ CZ20031591A patent/CZ20031591A3/cs unknown
- 2001-12-07 TW TW090130402A patent/TWI222972B/zh active
- 2001-12-07 TW TW090130404A patent/TWI293300B/zh active
- 2001-12-07 TW TW090130401A patent/TW584633B/zh not_active IP Right Cessation
- 2001-12-10 AR ARP010105727A patent/AR035665A1/es unknown
- 2001-12-10 AR ARP010105728A patent/AR035666A1/es unknown
- 2001-12-10 AR ARP010105729A patent/AR035667A1/es unknown
- 2001-12-10 AR ARP010105730A patent/AR035668A1/es unknown
- 2001-12-10 AR ARP010105726A patent/AR035664A1/es active IP Right Grant
- 2001-12-10 AR ARP010105731A patent/AR035669A1/es unknown
-
2003
- 2003-05-28 NO NO20032449A patent/NO20032449D0/no not_active Application Discontinuation
- 2003-05-28 NO NO20032451A patent/NO20032451L/no not_active Application Discontinuation
- 2003-05-28 NO NO20032452A patent/NO20032452L/no not_active Application Discontinuation
- 2003-05-30 NO NO20032473A patent/NO326159B1/no not_active IP Right Cessation
- 2003-06-06 HR HR20030463A patent/HRP20030463A2/xx not_active Application Discontinuation
- 2003-06-06 NO NO20032595A patent/NO20032595L/no not_active Application Discontinuation
- 2003-06-06 HR HR20030462A patent/HRP20030462A2/xx not_active Application Discontinuation
- 2003-06-06 HR HR20030461A patent/HRP20030461A2/hr not_active Application Discontinuation
- 2003-06-06 HR HR20030467A patent/HRP20030467B1/hr not_active IP Right Cessation
- 2003-06-06 HR HR20030466A patent/HRP20030466A2/hr not_active Application Discontinuation
- 2003-06-06 NO NO20032596A patent/NO20032596D0/no not_active Application Discontinuation
- 2003-06-06 HR HR20030464A patent/HRP20030464A2/hr not_active Application Discontinuation
- 2003-07-08 ZA ZA200305275A patent/ZA200305275B/en unknown
- 2003-07-08 ZA ZA200305270A patent/ZA200305270B/en unknown
- 2003-07-08 ZA ZA200305271A patent/ZA200305271B/en unknown
- 2003-07-08 ZA ZA200305273A patent/ZA200305273B/en unknown
- 2003-07-08 ZA ZA2003/05272A patent/ZA200305272B/en unknown
- 2003-07-08 ZA ZA200305274A patent/ZA200305274B/en unknown
- 2003-10-07 US US10/680,989 patent/US7049439B2/en not_active Expired - Fee Related
- 2003-10-29 US US10/696,476 patent/US20040092545A1/en not_active Abandoned
- 2003-10-29 US US10/696,753 patent/US6953804B2/en not_active Expired - Fee Related
-
2004
- 2004-09-20 HK HK04107230A patent/HK1064383A1/xx not_active IP Right Cessation
- 2004-11-11 HK HK04108904A patent/HK1066005A1/xx not_active IP Right Cessation
-
2005
- 2005-01-25 HK HK05100647A patent/HK1069166A1/xx not_active IP Right Cessation
- 2005-02-28 US US11/069,033 patent/US7132429B2/en not_active Expired - Fee Related
- 2005-05-19 US US11/132,900 patent/US7612083B2/en not_active Expired - Fee Related
- 2005-08-24 CY CY20051101024T patent/CY1105586T1/el unknown
-
2007
- 2007-05-09 CY CY20071100621T patent/CY1106569T1/el unknown
-
2009
- 2009-11-06 JP JP2009255040A patent/JP2010031040A/ja not_active Ceased
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6656938B2 (en) | Urea substituted imidazoquinoline ethers | |
US6660735B2 (en) | Urea substituted imidazoquinoline ethers | |
US6660747B2 (en) | Amido ether substituted imidazoquinolines | |
US6677347B2 (en) | Sulfonamido ether substituted imidazoquinolines | |
AU2002232497A1 (en) | Urea substituted imidazoquinoline ethers | |
AU2002239517A1 (en) | Sulfonamido ether substituted imidazoquinolines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20051121 Year of fee payment: 5 |
|
ODBI | Application refused |